Peptide library synthesis

Hot service products

No.Protein NameProtein Sequence

Peptide Librar

 Design

PurityApplicationCondition/Topic
1MoTif 001 M. tuberculosis (Ag85B)

MTDVSRKIRAWGRRLMIGTAAAVVLPGLVGLAGGAATAGAFSRPGLPVEYLQVPSPSMGRDIKVQ

FQSGGNNSPAVYLLDGLRAQDDYNGWDINTPAFEWYYQSGLSIVMPVGGQSSFYSDWYSPACG

KAGCQTYKWETFLTSELPQWLSANRAVKPTGSAAIGLSMAGSSAMILAAYHPQQFIYAGSLSALLD

PSQGMGPSLIGLAMGDAGGYKAADMWGPSSDPAWERNDPTQQIPKLVANNTRLWVYCGNGT

PNELGGANIPAEFLENFVRSSNLKFQDAYNAAGGHNAVFNFPPNGTHSWEYWGAQLNAMKGD

LQSSLGAG

Pool of 79 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
2MoTif 002 M. tuberculosis (ESAT-6)

MTEQQWNFAGIEAAASAIQGNVTSIHSLLDEGKQSLTKLAAAWGGSGSEAYQGVQQKWDATAT

ELNNALQNLARTISEAGQAMASTEGNVTGMFA

Pool of 21 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
3MoTif 003 Pan-T. cruzi Select (Trans-Sialidasen)see additional product documentationVirus-specific pool of 72 peptides (defined HLA class I & II-restricted T-cell epitopes)70%-90%T-cell immunityChagas disease, Fever, Infection, Sequence diversity
4MoTif 004 M. tuberculosis (TB10.4)

MSQIMYNYPAMLGHAGDMAGYAGTLQSLGAEIAVEQAALQSAWQGDTGITYQAWQAQWNQ

AMEDLVRAYHAMSSTHEANTMAMMARDTAEAAKWGG

Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
5MoTif 005 M. tuberculosis (Antitoxin VapB47)

MRATVGLVEAIGIRELRQHASRYLARVEAGEELGVTNKGRLVARLIPVQAAERSREALIESGVLIPAR

RPQNLLDVTAEPARGRKRTLSDVLNEMRDEQ

Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
6MoTif 006 SARS-CoV-2 (Spike Fusion-Peptide)KRSFIEDLLFNKVTLADPool of 28 peptides derived from a peptide scan (truncational scan (peptide length 11 to 17aa))70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
7MoTif 007 Collection EBV (2x1ug/peptide)

14 different PepMixes, 2 aliquots of 14 peptide pools each containin

1µg per peptide /tube

Collection of 14 peptide pools (overlapping peptide scans, 15mers with 11 aa overlap)70%-90%T-cell immunityAutoimmune disease, Burkitt's lymphoma, Cancer, Hodgkin's lymphoma, Infectious mononucleosis, Nasopharyngeal carcinoma
8MoTif 008 SARS-CoV-2 (VEMP)

MYSFVSEETGTLIVNSVLLFLAFVVFLLVTLAILTALRLCAYCCNIVNVSLVKPSFYVYSRVKNLNS

SRVPDLLV

Pool of 16 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
9MoTif 009 HCoV-OC43 (Spike Glycoprotein)

MFLILLISLPTAFAVIGDLKCTSDNINDKDTGPPPISTDTVDVTNGLGTYYVLDRVYLNTTLFLNGYY

PTSGSTYRNMALKGSVLLSRLWFKPPFLSDFINGIFAKVKNTKVIKDRVMYSEFPAITIGSTFVNTSY

SVVVQPRTINSTQDGDNKLQGLLEVSVCQYNMCEYPQTICHPNLGNHRKELWHLDTGVVSCLYK

RNFTYDVNADYLYFHFYQEGGTFYAYFTDTGVVTKFLFNVYLGMALSHYYVMPLTCNSKLTLEYWV

TPLTSRQYLLAFNQDGIIFNAEDCMSDFMSEIKCKTQSIAPPTGVYELNGYTVQPIADVYRRKPNLP

NCNIEAWLNDKSVPSPLNWERKTFSNCNFNMSSLMSFIQADSFTCNNIDAAKIYGMCFSSITIDK

FAIPNGRKVDLQLGNLGYLQSFNYRIDTTATSCQLYYNLPAANVSVSRFNPSTWNKRFGFIEDSVFK

PRPAGVLTNHDVVYAQHCFKAPKNFCPCKLNGSCVGSGPGKNNGIGTCPAGTNYLTCDNLCTPD

PITFTGTYKCPQTKSLVGIGEHCSGLAVKSDYCGGNSCTCRPQAFLGWSADSCLQGDKCNIFANFIL

HDVNSGLTCSTDLQKANTDIILGVCVNYDLYGILGQGIFVEVNATYYNSWQNLLYDSNGNLYGFR

DYIINRTFMIRSCYSGRVSAAFHANSSEPALLFRNIKCNYVFNNSLTRQLQPINYFDSYLGCVVNAY

NSTAISVQTCDLTVGSGYCVDYSKNRRSRGAITTGYRFTNFEPFTVNSVNDSLEPVGGLYEIQIPSEF

TIGNMVEFIQTSSPKVTIDCAAFVCGDYAACKSQLVEYGSFCDNINAILTEVNELLDTTQLQVANSL

MNGVTLSTKLKDGVNFNVDDINFSPVLGCLGSECSKASSRSAIEDLLFDKVKLSDVGFVEAYNNC

TGGAEIRDLICVQSYKGIKVLPPLLSENQISGYTLAATSASLFPPWTAAAGVPFYLNVQYRINGLGV

TMDVLSQNQKLIANAFNNALYAIQEGFDATNSALVKIQAVVNANAEALNNLLQQLSNRFGAISA

SLQEILSRLDALEAEAQIDRLINGRLTALNAYVSQQLSDSTLVKFSAAQAMEKVNECVKSQSSRINF

CGNGNHIISLVQNAPYGLYFIHFSYVPTKYVTARVSPGLCIAGDRGIAPKSGYFVNVNNTWMYTG

SGYYYPEPITENNVVVMSTCAVNYTKAPYVMLNTSIPNLPDFKEELDQWFKNQTSVAPDLSLDYI

NVTFLDLQVEMNRLQEAIKVLNQSYINLKDIGTYEYYVKWPWYVWLLICLAGVAMLVLLFFICCCT

GCGTSCFKKCGGCCDDYTGYQELVIKTSHDD

Pool of 336 (168+168) peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCommon cold, Covid-19, Infection, Respiratory infection
10MoTif 010 SARS-CoV-2 (Nsp4)

KIVNNWLKQLIKVTLVFLFVAAIFYLITPVHVMSKHTDFSSEIIGYKAIDGGVTRDIASTDTCFANKHA

DFDTWFSQRGGSYTNDKACPLIAAVITREVGFVVPGLPGTILRTTNGDFLHFLPRVFSAVGNICYTPS

KLIEYTDFATSACVLAAECTIFKDASGKPVPYCYDTNVLEGSVAYESLRPDTRYVLMDGSIIQFPNTYL

EGSVRVVTTFDSEYCRHGTCERSEAGVCVSTSGRWVLNNDYYRSLPGVFCGVDAVNLLTNMFTPL

IQPIGALDISASIVAGGIVAIVVTCLAYYFMRFRRAFGEYSHVVAFNTLLFLMSFTVLCLTPVYSFLPGV

YSVIYLYLTFYLTNDVSFLAHIQWMVMFTPLVPFWITIAYIICISTKHFYWFFSNYLKRRVVFNGVSFS

TFEEAALCTFLLNKEMYLKLRSDVLLPLTQYNRYLALYNKYKYFSGAMDTTSYREAACCHLAKALN

DFSNSGSDVLYQPPQTSITSAVLQ

Pool of 123 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
11MoTif 011SARS-CoV-2 (Nsp9)

NNELSPVALRQMSCAAGTTQTACTDDNALAYYNTTKGGRFVLALLSDLQDLKWARFPKSDGTG

TIYTELEPPCRFVTDTPKGPKVKYLYFIKGLNNLNRGMVLGSLAATVRLQ

Pool of 26 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
12MoTif 012SARS-CoV-2 (Nsp12)

SADAQSFLNRVCGVSAARLTPCGTGTSTDVVYRAFDIYNDKVAGFAKFLKTNCCRFQEKDEDDNLI

DSYFVVKRHTFSNYQHEETIYNLLKDCPAVAKHDFFKFRIDGDMVPHISRQRLTKYTMADLVYALRH

FDEGNCDTLKEILVTYNCCDDDYFNKKDWYDFVENPDILRVYANLGERVRQALLKTVQFCDAMRN

AGIVGVLTLDNQDLNGNWYDFGDFIQTTPGSGVPVVDSYYSLLMPILTLTRALTAESHVDTDLTKPYI

KWDLLKYDFTEERLKLFDRYFKYWDQTYHPNCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKI

FVDGVPFVVSTGYHFRELGVVHNQDVNLHSSRLSFKELLVYAADPAMHAASGNLLLDKRTTCFSVA

ALTNNVAFQTVKPGNFNKDFYDFAVSKGFFKEGSSVELKHFFFAQDGNAAISDYDYYRYNLPTMCD

IRQLLFVVEVVDKYFDCYDGGCINANQVIVNNLDKSAGFPFNKWGKARLYYDSMSYEDQDALFAY

TKRNVIPTITQMNLKYAISAKNRARTVAGVSICSTMTNRQFHQKLLKSIAATRGATVVIGTSKFYGGW

HNMLKTVYSDVENPHLMGWDYPKCDRAMPNMLRIMASLVLARKHTTCCSLSHRFYRLANECAQ

VLSEMVMCGGSLYVKPGGTSSGDATTAYANSVFNICQAVTANVNALLSTDGNKIADKYVRNLQHR

LYECLYRNRDVDTDFVNEFYAYLRKHFSMMILSDDAVVCFNSTYASQGLVASIKNFKSVLYYQNNVF

MSEAKCWTETDLTKGPHEFCSQHTMLVKQGDDYVYLPYPDPSRILGAGCFVDDIVKTDGTLMIERF

VSLAIDAYPLTKHPNQEYADVFHLYLQYIRKLHDELTGHMLDMYSVMLTNDNTSRYWEPEFYEAM

YTPHTVLQ

Pool of 231 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
13MoTif 013 SARS-CoV-2 (ORF10)MGYINVFAFPFTIYSLLLCRMNSRNYIAQVDVVNFNLTPool of 7 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
14MoTif 014 SARS-CoV-2 (VME1)

MADSNGTITVEELKKLLEQWNLVIGFLFLTWICLLQFAYANRNRFLYIIKLIFLWLLWPVTLACFVLA

AVYRINWITGGIAIAMACLVGLMWLSYFIASFRLFARTRSMWSFNPETNILLNVPLHGTILTRPLLES

ELVIGAVILRGHLRIAGHHLGRCDIKDLPKEITVATSRTLSYYKLGASQRVAGDSGFAAYSRYRIGNYK

LNTDHSSSSDNIALLVQ

Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
15MoTif 015 SARS-CoV-2 (C+NSP11)see additional product documentationPool of 16 peptides derived from a peptide scan (16mers + 1 x 13mer)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
16MoTif 016 SARS-CoV-2 (NS6)MFHLVDFQVTIAEILLIIMRTFKVSIWNLDYIINLIIKNLSKSLTENKYSQLDEEQPMEIDPool of 13 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
17MoTif 017 SARS-CoV-2 (NS7B)MIELSLIDFYLCFLAFLLFLVLIMLIIFWFSLELQDHNETCHAPool of 8 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
18MoTif 018 SARS-CoV-2 (Nsp5)

SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYEDLLIRKSNH

NFLVQAGNVQLRVIGHSMQNCVLKLKVDTANPKTPKYKFVRIQPGQTFSVLACYNGSPSGVYQCA

MRPNFTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELPTGVHAGTDLEGNFYGPFVDRQTAQA

AGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYEPLTQDHVDILGPLSAQTGI

AVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRQCSGVTFQ

Pool of 74 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
19MoTif 019 SARS-CoV-2 (Nsp6)

SAVKRTIKGTHHWLLLTILTSLLVLVQSTQWSLFFFLYENAFLPFAMGIIAMSAFAMMFVKHKHAFL

CLFLLPSLATVAYFNMVYMPASWVMRIMTWLDMVDTSLSGFKLKDCVMYASAVVLLILMTARTV

YDDGARRVWTLMNVLTLVYKVYYGNALDQAISMWALIISVTSNYSGVVTTVMFLARGIVFMCVE

YCPIFFITGNTLQCIMLVYCFLGYFCTCYFGLFCLLNRYFRLTLGVYDYLVSTQEFRYMNSQGLLPPKN

SIDAFKLNIKLLGVGGKPCIKVATVQ

Pool of 70 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
20MoTif 020 SARS-CoV-2 (Nsp8)

AIASEFSSLPSYAAFATAQEAYEQAVANGDSEVVLKKLKKSLNVAKSEFDRDAAMQRKLEKMADQ

AMTQMYKQARSEDKRAKVTSAMQTMLFTMLRKLDNDALNNIINNARDGCVPLNIIPLTTAAKLM

VVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPNLAWPLIVTALRANSAV

KLQ

Pool of 47 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
21MoTif 021 SARS-CoV-2 (Nsp10)

AGNATEVPANSTVLSFCAFAVDAAKAYKDYLASGGQPITNCVKMLCTHTGTGQAITVTPEANMD

QESFGGASCCLYCRCHIDHPNPKGFCDLKGKYVQIPTTCANDPVGFTLKNTVCTVCGMWKGYGC

SCDQLREPMLQ

Pool of 32 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
22MoTif 022 HCoV-HKU1 (Spike Glycoprotein)

MLLIIFILPTTLAVIGDFNCTNFAINDLNTTVPRISEYVVDVSYGLGTYYILDRVYLNTTILFTGYFPK

SGANFRDLSLKGTTYLSTLWYQKPFLSDFNNGIFSRVKNTKLYVNKTLYSEFSTIVIGSVFINNSYTIV

VQPHNGVLEITACQYTMCEYPHTICKSKGSSRNESWHFDKSEPLCLFKKNFTYNVSTDWLYFHFY

QERGTFYAYYADSGMPTTFLFSLYLGTLLSHYYVLPLTCNAISSNTDNETLQYWVTPLSKRQYLLKF

DNRGVITNAVDCSSSFFSEIQCKTKSLLPNTGVYDLSGFTVKPVATVHRRIPDLPDCDIDKWLNNF

NVPSPLNWERKIFSNCNFNLSTLLRLVHTDSFSCNNFDESKIYGSCFKSIVLDKFAIPNSRRSDLQL

GSSGFLQSSNYKIDTTSSSCQLYYSLPAINVTINNYNPSSWNRRYGFNNFNLSSHSVVYSRYCFSV

NNTFCPCAKPSFASSCKSHKPPSASCPIGTNYRSCESTTVLDHTDWCRCSCLPDPITAYDPRSCSQ

KKSLVGVGEHCAGFGVDEEKCGVLDGSYNVSCLCSTDAFLGWSYDTCVSNNRCNIFSNFILNGIN

SGTTCSNDLLQPNTEVFTDVCVDYDLYGITGQGIFKEVSAVYYNSWQNLLYDSNGNIIGFKDFVT

NKTYNIFPCYAGRVSAAFHQNASSLALLYRNLKCSYVLNNISLTTQPYFDSYLGCVFNADNLTDYS

VSSCALRMGSGFCVDYNSPSSSSSRRKRRSISASYRFVTFEPFNVSFVNDSIESVGGLYEIKIPTNFT

IVGQEEFIQTNSPKVTIDCSLFVCSNYAACHDLLSEYGTFCDNINSILDEVNGLLDTTQLHVADTLM

QGVTLSSNLNTNLHFDVDNINFKSLVGCLGPHCGSSSRSFFEDLLFDKVKLSDVGFVEAYNNCTG

GSEIRDLLCVQSFNGIKVLPPILSESQISGYTTAATVAAMFPPWSAAAGIPFSLNVQYRINGLGVTM

DVLNKNQKLIATAFNNALLSIQNGFSATNSALAKIQSVVNSNAQALNSLLQQLFNKFGAISSSLQ

EILSRLDALEAQVQIDRLINGRLTALNAYVSQQLSDISLVKFGAALAMEKVNECVKSQSPRINFCGN

GNHILSLVQNAPYGLLFMHFSYKPISFKTVLVSPGLCISGDVGIAPKQGYFIKHNDHWMFTGSSYY

YPEPISDKNVVFMNTCSVNFTKAPLVYLNHSVPKLSDFESELSHWFKNQTSIAPNLTLNLHTINATF

LDLYYEMNLIQESIKSLNNSYINLKDIGTYEMYVKWPWYVWLLISFSFIIFLVLLFFICCCTGCGSACFS

KCHNCCDEYGGHHDFVIKTSHDD

Pool of 337 (169+168) peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCommon cold, Covid-19, Infection, Respiratory infection
23MoTif 023 Collection EBV (25ug/peptide)

14 different PepMixes,1 aliquots of 14 peptide pools each containin

 15µg per peptide /tube

Collection of 14 peptide pools (overlapping peptide scans, 15mers with 11 aa overlap)70%-90%T-cell immunityAutoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infectious mononucleosis, Nasopharyngeal carcinoma
24MoTif 024 Collection HCMV (25ug/peptide)

19 different PepMixes,1 aliquot of 19 peptide pools in 20 vials each containin

 25µg per peptide /tube

Collection of 19 peptide pools (overlapping peptides scans, 15mers with 11 aa overlap)70%-90%T-cell immunityControl, Cytomegalovirus disease, Infectious mononucleosis, Opportunistic infections
25MoTif 025 Collection HCMV (2x1ug/peptide)

19 different PepMixes,2 aliquots of 19 peptide pools each containin

 1µg per peptide /tube

Collection of 19 peptide pools (overlapping peptides scans, 15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Control, Cytomegalovirus disease, Infectious mononucleosis, Opportunistic infections
26MoTif 026 SARS-CoV-2 (S-RBD BA.2.75)

RVQPTESIVRFPNITNLCPFHEVFNATRFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVS

PTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVS

GNYNYLYRLFRKSKLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLQSYGFRPTYGVGHQPYRV

VVLSFELLHAPATVCGPKKSTNLVKNKCVNF

Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap))70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
27MoTif 027 SARS-CoV-2 (Nsp13)

AVGACVLCNSQTSLRCGACIRRPFLCCKCCYDHVISTSHKLVLSVNPYVCNAPGCDVTDVTQL

YLGGMSYYCKSHKPPISFPLCANGQVFGLYKNTCVGSDNVTDFNAIATCDWTNAGDYILANT

CTERLKLFAAETLKATEETFKLSYGIATVREVLSDRELHLSWEVGKPRPPLNRNYVFTGYRVTKN

SKVQIGEYTFEKGDYGDAVVYRGTTTYKLNVGDYFVLTSHTVMPLSAPTLVPQEHYVRITGLYP

TLNISDEFSSNVANYQKVGMQKYSTLQGPPGTGKSHFAIGLALYYPSARIVYTACSHAAVDALC

EKALKYLPIDKCSRIIPARARVECFDKFKVNSTLEQYVFCTVNALPETTADIVVFDEISMATNYDL

SVVNARLRAKHYVYIGDPAQLPAPRTLLTKGTLEPEYFNSVCRLMKTIGPDMFLGTCRRCPAEIV

DTVSALVYDNKLKAHKDKSAQCFKMFYKGVITHDVSSAINRPQIGVVREFLTRNPAWRKAVFIS

PYNSQNAVASKILGLPTQTVDSSQGSEYDYVIFTQTTETAHSCNVNRFNVAITRAKVGILCIMSD

RDLYDKLQFTSLEIPRRNVATLQ

Pool of 148 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
28MoTif 028 SARS-CoV-2 (Nsp14)

AENVTGLFKDCSKVITGLHPTQAPTHLSVDTKFKTEGLCVDIPGIPKDMTYRRLISMMGFKMNY

QVNGYPNMFITREEAIRHVRAWIGFDVEGCHATREAVGTNLPLQLGFSTGVNLVAVPTGYVDTP

NNTDFSRVSAKPPPGDQFKHLIPLMYKGLPWNVVRIKIVQMLSDTLKNLSDRVVFVLWAHGFE

LTSMKYFVKIGPERTCCLCDRRATCFSTASDTYACWHHSIGFDYVYNPFMIDVQQWGFTGNLQS

NHDLYCQVHGNAHVASCDAIMTRCLAVHECFVKRVDWTIEYPIIGDELKINAACRKVQHMVVK

AALLADKFPVLHDIGNPKAIKCVPQADVEWKFYDAQPCSDKAYKIEELFYSYATHSDKFTDGVCL

FWNCNVDRYPANSIVCRFDTRVLSNLNLPGCDGGSLYVNKHAFHTPAFDKSAFVNLKQLPFFYY

SDSPCESHGKQVVSDIDYVPLKSATCITRCNLGGAVCRHHANEYRLYLDAYNMMISAGFSLWVY

KQFDTYNLWNTFTRLQ

Pool of 129 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
29MoTif 029 SARS-CoV-2 (ORF9B)

MDPKISEMHPALRLVDPQIQLAVTRMENAVGRDQNNVGPKVYPIILRLGSPLSLNMARKTLNSL

EDKAFQLTPIAVQMTKLATTEELPDEFVVVTVK

Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
30MoTif 030 SARS-CoV-2 (NS7A)

MKIILFLALITLATCELYHYQECVRGTTVLLKEPCSSGTYEGNSPFHPLADNKFALTCFSTQFAFACP

DGVKHVYQLRARSVSPKLFIRQEEVQELYSPIFLIVAAIVFITLCFTLKRKTE

Pool of 28 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
31MoTif 031 SARS-CoV-2 (Nsp1)

MESLVPGFNEKTHVQLSLPVLQVRDVLVRGFGDSVEEVLSEARQHLKDGTCGLVEVEKGVLPQLE

QPYVFIKRSDARTAPHGHVMVELVAELEGIQYGRSGETLGVLVPHVGEIPVAYRKVLLRKNGNKGA

GGHSYGADLKSFDLGDELGTDPYEDFQENWNTKHSSGVTRELMRELNGG

Pool of 43 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
32MoTif 032 SARS-CoV-2 (Nsp2)

AYTRYVDNNFCGPDGYPLECIKDLLARAGKASCTLSEQLDFIDTKRGVYCCREHEHEIAWYTERSE

KSYELQTPFEIKLAKKFDTFNGECPNFVFPLNSIIKTIQPRVEKKKLDGFMGRIRSVYPVASPNECNQ

MCLSTLMKCDHCGETSWQTGDFVKATCEFCGTENLTKEGATTCGYLPQNAVVKIYCPACHNSEVG

PEHSLAEYHNESGLKTILRKGGRTIAFGGCVFSYVGCHNKCAYWVPRASANIGCNHTGVVGEGSE

GLNDNLLEILQKEKVNINIVGDFKLNEEIAIILASFSASTSAFVETVKGLDYKAFKQIVESCGNFKVTK

GKAKKGAWNIGEQKSILSPLYAFASEAARVVRSIFSRTLETAQNSVRVLQKAAITILDGISQYSLRLID

AMMFTSDLATNNLVVMAYITGGVVQLTSQWLTNIFGTVYEKLKPVLDWLEEKFKEGVEFLRDGW

EIVKFISTCACEIVGGQIVTCAKEIKESVQTFFKLVNKFLALCADSIIIGGAKLKALNLGETFVTHSKGLY

RKCVKSREETGLLMPLKAPKEIIFLEGETLPTEVLTEEVVLKTGDLQPLEQPTSEAVEAPLVGTPVCING

LMLLEIKDTEKYCALAPNMMVTNNTFTLKGG

Pool of 157 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
33MoTif 033 SARS-CoV-2 (Nsp15)

SLENVAFNVVNKGHFDGQQGEVPVSIINNTVYTKVDGVDVELFENKTTLPVNVAFELWAKRNIKPVPE

VKILNNLGVDIAANTVIWDYKRDAPAHISTIGVCSMTDIAKKPTETICAPLTVFFDGRVDGQVDLFRNAR

NGVLITEGSVKGLQPSVGPKQASLNGVTLIGEAVKTQFNYYKKVDGVVQQLPETYFTQSRNLQEFKPRSQ

MEIDFLELAMDEFIERYKLEGYAFEHIVYGDFSHSQLGGLHLLIGLAKRFKESPFELEDFIPMDSTVKNYFIT

DAQTGSSKCVCSVIDLLLDDFVEIIKSQDLSVVSKVVKVTIDYTEISFMLWCKDGHVETFYPKLQ

Pool of 84 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
34MoTif 034 SARS-CoV-2 (AP3A)

MDLFMRIFTIGTVTLKQGEIKDATPSDFVRATATIPIQASLPFGWLIVGVALLAVFQSASKIITLKKRWQLA

LSKGVHFVCNLLLLFVTVYSHLLLVAAGLEAPFLYLYALVYFLQSINFVRIIMRLWLCWKCRSKNPLLYDAN

YFLCWHTNCYDYCIPYNSVTSSIVITSGDGTTSPISEHDYQIGGYTEKWESGVKDCVVLHSYFTSDYYQLY

STQLSTDTGVEHVTFFIYNKIVDEPEEHVQIHTIDGSSGVVNPVMEPIYDEPTTTTSVPL

Pool of 66 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
35MoTif 035 SARS-CoV-2 (NS8)

MKFLVFLGIITTVAAFHQECSLQSCTQHQPYVVDDPCPIHFYSKWYIRVGARKSAPLIELCVDEAGSKSPI

QYIDIGNYTVSCLPFTINCQEPKLGSLVVRCSFYEDFLEYHDVRVVLDFI

Pool of 28 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
36MoTif 036 SARS-CoV-2 (Nsp3)

APTKVTFGDDTVIEVQGYKSVNITFELDERIDKVLNEKCSAYTVELGTEVNEFACVVADAVIKTLQPVSEL

LTPLGIDLDEWSMATYYLFDESGEFKLASHMYCSFYPPDEDEEEGDCEEEEFEPSTQYEYGTEDDYQGKP

LEFGATSAALQPEEEQEEDWLDDDSQQTVGQQDGSEDNQTTTIQTIVEVQPQLEMELTPVVQTIEVNS

FSGYLKLTDNVYIKNADIVEEAKKVKPTVVVNAANVYLKHGGGVAGALNKATNNAMQVESDDYIATN

GPLKVGGSCVLSGHNLAKHCLHVVGPNVNKGEDIQLLKSAYENFNQHEVLLAPLLSAGIFGADPIHSL

RVCVDTVRTNVYLAVFDKNLYDKLVSSFLEMKSEKQVEQKIAEIPKEEVKPFITESKPSVEQRKQDDKKIK

ACVEEVTTTLEETKFLTENLLLYIDINGNLHPDSATLVSDIDITFLKKDAPYIVGDVVQEGVLTAVVIPTKKA

GGTTEMLAKALRKVPTDNYITTYPGQGLNGYTVEEAKTVLKKCKSAFYILPSIISNEKQEILGTVSWNLRE

MLAHAEETRKLMPVCVETKAIVSTIQRKYKGIKIQEGVVDYGARFYFYTSKTTVASLINTLNDLNETLVTM

PLGYVTHGLNLEEAARYMRSLKVPATVSVSSPDAVTAYNGYLTSSSKTPEEHFIETISLAGSYKDWSYSGQ

STQLGIEFLKRGDKSVYYTSNPTTFHLDGEVITFDNLKTLLSLREVRTIKVFTTVDNINLHTQVVDMSMTY

GQQFGPTYLDGADVTKIKPHNSHEGKTFYVLPNDDTLRVEAFEYYHTTDPSFLGRYMSALNHTKKWKY

PQVNGLTSIKWADNNCYLATALLTLQQIELKFNPPALQDAYYRARAGEAANFCALILAYCNKTVGELGDV

RETMSYLFQHANLDSCKRVLNVVCKTCGQQQTTLKGVEAVMYMGTLSYEQFKKGVQIPCTCGKQATKY

LVQQESPFVMMSAPPAQYELKHGTFTCASEYTGNYQCGHYKHITSKETLYCIDGALLTKSSEYKGPITDVF

YKENSYTTTIKPVTYKLDGVVCTEIDPKLDNYYKKDNSYFTEQPIDLVPNQPYPNASFDNFKFVCDNIKFA

DDLNQLTGYKKPASRELKVTFFPDLNGDVVAIDYKHYTPSFKKGAKLLHKPIVWHVNNATNKATYKPNT

WCIRCLWSTKPVETSNSFDVLKSEDAQGMDNLACEDLKPVSEEVVENPTIQKDVLECNVKTTEVVGDIIL

KPANNSLKITEEVGHTDLMAAYVDNSSLTIKKPNELSRVLGLKTLATHGLAAVNSVPWDTIANYAKPFLN

KVVSTTTNIVTRCLNRVCTNYMPYFFTLLLQLCTFTRSTNSRIKASMPTTIAKNTVKSVGKFCLEASFNYLK

SPNFSKLINIIIWFLLLSVCLGSLIYSTAALGVLMSNLGMPSYCTGYREGYLNSTNVTIATYCTGSIPCSVCLS

GLDSLDTYPSLETIQITISSFKWDLTAFGLVAEWFLAYILFTRFFYVLGLAAIMQLFFSYFAVHFISNSWLMW

LIINLVQMAPISAMVRMYIFFASFYYVWKSYVHVVDGCNSSTCMMCYKRNRATRVECTTIVNGVRRSFY

VYANGGKGFCKLHNWNCVNCDTFCAGSTFISDEVARDLSLQFKRPINPTDQSSYIVDSVTVKNGSIHLYF

DKAGQKTYERHSLSHFVNLDNLRANNTKGSLPINVIVFDGKSKCEESSAKSASVYYSQLMCQPILLLDQA

LVSDVGDSAEVAVKMFDAYVNTFSSTFNVPMEKLKTLVATAEAELAKNVSLDNVLSTFISAARQGFVDSD

VETKDVVECLKLSHQSDIEVTGDSCNNYMLTYNKVENMTPRDLGACIDCSARHINAQVAKSHNIALIWN

VKDFMSLSEQLRKQIRSAAKKNNLPFKLTCATTRQVVNVVTTKIALKGG

Pool of 484 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
37MoTif 037 HCoV-229E (Spike Glycoprotein)

MFVLLVAYALLHIAGCQTTNGLNTSYSVCNGCVGYSENVFAVESGGYIPSDFAFNNWFLLTNTSSVVDGV

VRSFQPLLLNCLWSVSGLRFTTGFVYFNGTGRGDCKGFSSDVLSDVIRYNLNFEENLRRGTILFKTSYGVVV

FYCTNNTLVSGDAHIPFGTVLGNFYCFVNTTIGNETTSAFVGALPKTVREFVISRTGHFYINGYRYFTLGNV

EAVNFNVTTAETTDFCTVALASYADVLVNVSQTSIANIIYCNSVINRLRCDQLSFDVPDGFYSTSPIQSVELP

VSIVSLPVYHKHTFIVLYVDFKPQSGGGKCFNCYPAGVNITLANFNETKGPLCVDTSHFTTKYVAVYANVGR

WSASINTGNCPFSFGKVNNFVKFGSVCFSLKDIPGGCAMPIVANWAYSKYYTIGSLYVSWSDGDGITGVP

QPVEGVSSFMNVTLDKCTKYNIYDVSGVGVIRVSNDTFLNGITYTSTSGNLLGFKDVTKGTIYSITPCNPPD

QLVVYQQAVVGAMLSENFTSYGFSNVVELPKFFYASNGTYNCTDAVLTYSSFGVCADGSIIAVQPRNVSYD

SVSAIVTANLSIPSNWTTSVQVEYLQITSTPIVVDCSTYVCNGNVRCVELLKQYTSACKTIEDALRNSARLES

ADVSEMLTFDKKAFTLANVSSFGDYNLSSVIPSLPTSGSRVAGRSAIEDILFSKLVTSGLGTVDADYKKCTKG

LSIADLACAQYYNGIMVLPGVADAERMAMYTGSLIGGIALGGLTSAVSIPFSLAIQARLNYVALQTDVLQEN

QKILAASFNKAMTNIVDAFTGVNDAITQTSQALQTVATALNKIQDVVNQQGNSLNHLTSQLRQNFQAISS

SIQAIYDRLDTIQADQQVDRLITGRLAALNVFVSHTLTKYTEVRASRQLAQQKVNECVKSQSKRYGFCGNG

THIFSIVNAAPEGLVFLHTVLLPTQYKDVEAWSGLCVDGTNGYVLRQPNLALYKEGNYYRITSRIMFEPRIPT

MADFVQIENCNVTFVNISRSELQTIVPEYIDVNKTLQELSYKLPNYTVPDLVVEQYNQTILNLTSEISTLENKS

AELNYTVQKLQTLIDNINSTLVDLKWLNRVETYIKWPWWVWLCISVVLIFVVSMLLLCCCSTGCCGFFSCFA

SSIRGCCESTKLPYYDVEKIHIQ

Pool of 291 (146+145) peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCommon cold, Covid-19, Infection, Respiratory infection
38MoTif 038 SARS-CoV-2 (S-RBD B.1.617.2 / Delta)

RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDL

CFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSN

LKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTN

LVKNKCVNF

Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap))70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
39MoTif 039 SARS-CoV-2 (S-RBD B.1.1.529 / BA.1 / Omicron)

RVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDL

CFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNL

KPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLV

KNKCVNF

Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap))70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
40MoTif 040 SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)

MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHVISGTN

GTKRFDNPVLPFNDGVYFASIEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDHKNN

KSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIIVREPEDLPQG

FSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCA

LDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADY

SVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWN

SNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYR

VVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLKGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQ

TLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EYVNNSYECDIPIGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILP

VSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGF

NFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFKGLTVLPPLLTDEMIAQYT

SALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASAL

GKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDIFSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAE

IRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK

AHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFK

NHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVM

VTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
41MoTif 041 SARS-CoV-2 (S-RBD B.1.1.529 / BA.2 / Omicron)

RVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPTKLNDL

CFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVGGNYNYLYRLFRKSN

LKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTN

LVKNKCVNF

Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap))70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
42MoTif 042 SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)

MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAISGTNGT

KRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYYHK

NNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLGRDLP

QGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAV

DCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNC

VADYSVLYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGC

VIAWNSNKLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGVNCYFPLQSYGFRPTYG

VGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTT

DAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ

TRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTN

FTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYK

TPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPL

LTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQ

DSLSSTASALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYV

TQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTA

PAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFK

EELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIA

GLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
43MoTif 043 SARS-CoV-2 (S-RBD B.1.617.2 / Delta)

RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLC

FTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLK

PFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVK

NKCVNF

Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap))70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
44MoTif 044SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron)

MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNG

TKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYYHKN

NKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLGRDLPQG

FSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCAL

DPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSV

LYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN

KLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYGFRPTYGVGHQPYRVV

VLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEI

LDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYV

NNSYECDIPIGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSM

TKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQI

LPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLA

GTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQD

VVNHNAQALNTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL

AATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGV

FVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDL

GDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSC

CSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
45MoTif 045 SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron)

MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGT

KRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYYHKNN

KSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLGRDLPQGFS

ALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDP

LSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYN

FAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDS

KVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYGFRPTYGVGHQPYRVVVLSFE

LLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPC

SFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYEC

DIPIGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDC

TMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPS

KRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTF

GAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQAL

NTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLG

QSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQ

RNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQ

KEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCK

FDEDDSEPVLKGVKLHYT

Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
46MoTif 046 SARS-CoV-2 (Nsp13)

AVGACVLCNSQTSLRCGACIRRPFLCCKCCYDHVISTSHKLVLSVNPYVCNAPGCDVTDVTQLYLGGMSYYC

KSHKPPISFPLCANGQVFGLYKNTCVGSDNVTDFNAIATCDWTNAGDYILANTCTERLKLFAAETLKATEETFK

LSYGIATVREVLSDRELHLSWEVGKPRPPLNRNYVFTGYRVTKNSKVQIGEYTFEKGDYGDAVVYRGTTTYKLN

VGDYFVLTSHTVMPLSAPTLVPQEHYVRITGLYPTLNISDEFSSNVANYQKVGMQKYSTLQGPPGTGKSHFAIG

LALYYPSARIVYTACSHAAVDALCEKALKYLPIDKCSRIIPARARVECFDKFKVNSTLEQYVFCTVNALPETTADIV

VFDEISMATNYDLSVVNARLRAKHYVYIGDPAQLPAPRTLLTKGTLEPEYFNSVCRLMKTIGPDMFLGTCRRCP

AEIVDTVSALVYDNKLKAHKDKSAQCFKMFYKGVITHDVSSAINRPQIGVVREFLTRNPAWRKAVFISPYNSQ

NAVASKILGLPTQTVDSSQGSEYDYVIFTQTTETAHSCNVNRFNVAITRAKVGILCIMSDRDLYDKLQFTSLEIPR

RNVATLQ

Pool of 148 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
47MoTif 047 SARS-CoV-2 (Nsp2)

AYTRYVDNNFCGPDGYPLECIKDLLARAGKASCTLSEQLDFIDTKRGVYCCREHEHEIAWYTERSEKSYELQT

PFEIKLAKKFDTFNGECPNFVFPLNSIIKTIQPRVEKKKLDGFMGRIRSVYPVASPNECNQMCLSTLMKCDHCG

ETSWQTGDFVKATCEFCGTENLTKEGATTCGYLPQNAVVKIYCPACHNSEVGPEHSLAEYHNESGLKTILRKGG

RTIAFGGCVFSYVGCHNKCAYWVPRASANIGCNHTGVVGEGSEGLNDNLLEILQKEKVNINIVGDFKLNEEIAI

ILASFSASTSAFVETVKGLDYKAFKQIVESCGNFKVTKGKAKKGAWNIGEQKSILSPLYAFASEAARVVRSIFSRT

LETAQNSVRVLQKAAITILDGISQYSLRLIDAMMFTSDLATNNLVVMAYITGGVVQLTSQWLTNIFGTVYEKLK

PVLDWLEEKFKEGVEFLRDGWEIVKFISTCACEIVGGQIVTCAKEIKESVQTFFKLVNKFLALCADSIIIGGAKLKA

LNLGETFVTHSKGLYRKCVKSREETGLLMPLKAPKEIIFLEGETLPTEVLTEEVVLKTGDLQPLEQPTSEAVEAPLVG

TPVCINGLMLLEIKDTEKYCALAPNMMVTNNTFTLKGG

Pool of 157 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
48MoTif 048 SARS-CoV-2 (Nsp14)

AENVTGLFKDCSKVITGLHPTQAPTHLSVDTKFKTEGLCVDIPGIPKDMTYRRLISMMGFKMNYQVNGYPN

MFITREEAIRHVRAWIGFDVEGCHATREAVGTNLPLQLGFSTGVNLVAVPTGYVDTPNNTDFSRVSAKPPPGD

QFKHLIPLMYKGLPWNVVRIKIVQMLSDTLKNLSDRVVFVLWAHGFELTSMKYFVKIGPERTCCLCDRRATCFS

TASDTYACWHHSIGFDYVYNPFMIDVQQWGFTGNLQSNHDLYCQVHGNAHVASCDAIMTRCLAVHECFVK

RVDWTIEYPIIGDELKINAACRKVQHMVVKAALLADKFPVLHDIGNPKAIKCVPQADVEWKFYDAQPCSDKAYKIEELFYSYATHSDKFTDGVCLFWNCNVDRYPANSIVCRFDTRVLSNLNLPGCDGGSLYVNKHAFHTPAFDKSAFVNLKQLPFFYYSDSPCESHGKQVVSDIDYVPLKSATCITRCNLGGAVCRHHANEYRLYLDAYNMMISAGFSLWVYKQFDTYNLWNTFTRLQ

Pool of 129 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
49MoTif 049 HCoV-229E (Spike Glycoprotein)

MFVLLVAYALLHIAGCQTTNGLNTSYSVCNGCVGYSENVFAVESGGYIPSDFAFNNWFLLTNTSSVVDGVVRS

FQPLLLNCLWSVSGLRFTTGFVYFNGTGRGDCKGFSSDVLSDVIRYNLNFEENLRRGTILFKTSYGVVVFYCTNN

TLVSGDAHIPFGTVLGNFYCFVNTTIGNETTSAFVGALPKTVREFVISRTGHFYINGYRYFTLGNVEAVNFNVTTAETTDFCTVALASYADVLVNVSQTSIANIIYCNSVINRLRCDQLSFDVPDGFYSTSPIQSVELPVSIVSLPVYHKHTFIVLYVDFKPQSGGGKCFNCYPAGVNITLANFNETKGPLCVDTSHFTTKYVAVYANVGRWSASINTGNCPFSFGKVNNFVKFGSVCFSLKDIPGGCAMPIVANWAYSKYYTIGSLYVSWSDGDGITGVPQPVEGVSSFMNVTLDKCTKYNIYDVSGVGVIRVSNDTFLNGITYTSTSGNLLGFKDVTKGTIYSITPCNPPDQLVVYQQAVVGAMLSENFTSYGFSNVVELPKFFYASNGTYNCTDAVLTYSSFGVCADGSIIAVQPRNVSYDSVSAIVTANLSIPSNWTTSVQVEYLQITSTPIVVDCSTYVCNGNVRCVELLKQYTSACKTIEDALRNSARLESADVSEMLTFDKKAFTLANVSSFGDYNLSSVIPSLPTSGSRVAGRSAIEDILFSKLVTSGLGTVDADYKKCTKGLSIADLACAQYYNGIMVLPGVADAERMAMYTGSLIGGIALGGLTSAVSIPFSLAIQARLNYVALQTDVLQENQKILAASFNKAMTNIVDAFTGVNDAITQTSQALQTVATALNKIQDVVNQQGNSLNHLTSQLRQNFQAISSSIQAIYDRLDTIQADQQVDRLITGRLAALNVFVSHTLTKYTEVRASRQLAQQKVNECVKSQSKRYGFCGNGTHIFSIVNAAPEGLVFLHTVLLPTQYKDVEAWSGLCVDGTNGYVLRQPNLALYKEGNYYRITSRIMFEPRIPTMADFVQIENCNVTFVNISRSELQTIVPEYIDVNKTLQELSYKLPNYTVPDLVVEQYNQTILNLTSEISTLENKSAELNYTVQKLQTLIDNINSTLVDLKWLNRVETYIKWPWWVWLCISVVLIFVVSMLLLCCCSTGCCGFFSCFASSIRGCCESTKLPYYDVEKIHIQ

Pool of 291 (146+145) peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCommon cold, Covid-19, Infection, Respiratory infection
50MoTif 050 SARS-CoV-2 (S-RBD B.1.351 / Beta)

RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLND

LCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRK

SNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKK

STNLVKNKCVNF

Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
51MoTif 051 SARS-CoV-2 (S-RBD B.1.1.529 / BA.4 & BA.5 / Omicron)

RVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPTKLND

LCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVGGNYNYRYRLFRK

SNLKPFERDISTEIYQAGNKPCNGVAGVNCYFPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPK

KSTNLVKNKCVNF

Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap))70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
52MoTif 052 Collection EBV (25ug/peptide)14 different PepMixes,1 aliquots of 14 peptide pools each containing 15µg per peptide /tubeCollection of 14 peptide pools (overlapping peptide scans, 15mers with 11 aa overlap)70%-90%T-cell immunityAutoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infectious mononucleosis, Nasopharyngeal carcinoma
53MoTif 053 Collection HCMV (25ug/peptide)

19 different PepMixes,1 aliquot of 19 peptide pools in 20 vials each containing

 25µg per peptide /tube

Collection of 19 peptide pools (overlapping peptides scans, 15mers with 11 aa overlap)70%-90%T-cell immunityControl, Cytomegalovirus disease, Infectious mononucleosis, Opportunistic infections
54MoTif 054 Collection HCMV (2x1ug/peptide)

19 different PepMixes,2 aliquots of 19 peptide pools each containing 

1µg per peptide /tube

Collection of 19 peptide pools (overlapping peptides scans, 15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Control, Cytomegalovirus disease, Infectious mononucleosis, Opportunistic infections
55MoTif 055 Arabidopsis (WRKY47)

MEEHIQDRREIAFLHSGEFLHGDSDSKDHQPNESPVERHHESSIKEVDFFAAKSQPFDLGHVRTTTIVG

SSGFNDGLGLVNSCHGTSSNDGDDKTKTQISRLKLELERLHEENHKLKHLLDEVSESYNDLQRRVLLAR

QTQVEGLHHKQHEDVPQAGSSQALENRRPKDMNHETPATTLKRRSPDDVDGRDMHRGSPKTPRID

QNKSTNHEEQQNPHDQLPYRKARVSVRARSDATTVNDGCQWRKYGQKMAKGNPCPRAYYRCTMA

VGCPVRKQVQRCAEDTTILTTTYEGNHNHPLPPSATAMAATTSAAAAMLLSGSSSSNLHQTLSSPSAT

SSSSFYHNFPYTSTIATLSASAPFPTITLDLTNPPRPLQPPPQFLSQYGPAAFLPNANQIRSMNNNNQQ

LLIPNLFGPQAPPREMVDSVRAAIAMDPNFTAALAAAISNIIGGGNNDNNNNTDINDNKVDAKSGG

SSNGDSPQLPQSCTTFSTN

Pool of 120 peptides derived from a peptide scan through Transcription factors/activators (Swiss-Prot ID: Q9ZSI7) of .70%-90%Cancer biomarker research, T-cell immunityCancer
56MoTif 056 Collection SARS-CoV-2 Wuhan Structural Proteins

8 different SARS-CoV-2 PepMixes: SARS-CoV-2 (Spike Glycoprotein) SARS-CoV-

2 (S-RBD) SARS-CoV-2 (NCAP) SARS-CoV-2 (VEMP) SARS-CoV-2 (VME1) SARS-

CoV-2 (AP3A) SARS-CoV-2 (ORF9B) SARS-CoV-2 (Y14)

Collection of 8 peptide pools (overlapping peptides scans, 15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19
57MoTif 057 HCoV-NL63 (NCAP)

MASVNWADDRAARKKFPPPSFYMPLLVSSDKAPYRVIPRNLVPIGKGNKDEQIGYWNVQERWRMR

RGQRVDLPPKVHFYYLGTGPHKDLKFRQRSDGVVWVAKEGAKTVNTSLGNRKRNQKPLEPKFSIALP

PELSVVEFEDRSNNSSRASSRSSTRNNSRDSSRSTSRQQSRTRSDSNQSSSDLVAAVTLALKNLGFDN

QSKSPSSSGTSTPKKPNKPLSQPRADKPSQLKKPRWKRVPTREENVIQCFGPRDFNHNMGDSDLVQ

NGVDAKGFPQLAELIPNQAALFFDSEVSTDEVGDNVQITYTYKMLVAKDNKNLPKFIEQISAFTKPSSI

KEMQSQSSHVAQNTVLNASIPESKPLADDDSAIIEIVNEVLH

Pool of 92 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCommon cold, Covid-19, Infection, Respiratory infection
58MoTif 058 Collection SARS-CoV-2 Wuhan Non-Structural Proteins

20 different SARS-CoV-2 PepMixes: SARS-CoV-2 (NSP1) SARS-CoV-2 (NSP2) SARS-CoV-2

(NSP3)SARS-CoV-2 (NSP4) SARS-CoV-2 (NSP5) SARS-CoV-2 (NSP6) SARS-CoV-2 (NSP7) 

SARS-CoV-2(NSP8) SARS-CoV-2 (NSP9) SARS-CoV-2 (NSP10) SARS-CoV-2 (C+NSP11) 

SARS-CoV-2 (NSP12) SARS-CoV-2 (NSP13) SARS-CoV-2 (NSP14) SARS-CoV-2 (NSP15) 

SARS-CoV-2 (NSP16) SARS-CoV-2 (NS6) SARS-CoV-2 (NS7A) SARS-CoV-2 (NS7B) 

SARS-CoV-2 (NS8)

Collection of 20 peptide pools (overlapping peptides scans, 15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19
59MoTif 059 Pan-Psoriasis Selectsee additional product documentationVirus-specific pool of 79 peptides (defined HLA class I & II-restricted T-cell epitopes) from selected proteins of Human for T cell assays (e.g. ELISPOT).70%-90%T-cell immunityAutoimmune disease
60MoTif 060 Pan-Hepatitis C Virus Selectsee additional product documentationVirus-specific pool of 150 peptides (defined HLA class I & II-restricted T-cell epitopes)70%-90%/Hepatitis, Infection
61MoTif 061 SARS-CoV (Spike Glycoprotein)

MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNVTGF

HTINHTFGNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNP

FFAVSKPMGTQTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGYQPID

VVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQDIWGTSAAAYFVGYLKPTTFMLKYDENGTITD

AVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWER

KKISNCVADYSVLYNSTFFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNY

KLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPALNCYW

PLNDYGFYTTTGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRF

QPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVSTAIHAD

QLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGAGICASYHTVSLLRSTSQKSIVAYTMSLG

ADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMYICGDSTECANLLLQYGSFCTQLNRALSG

IAAEQDRNTREVFAQVKQMYKTPTLKYFGGFNFSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQY

GECLGDINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAY

RFNGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFG

AISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVD

FCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTSWFITQRN

FFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVV

NIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGFIAGLIAIVMVTILLCCMTSCCSCLKG

ACSCGSCCKFDEDDSEPVLKGVKLHYT

Pool of 311 (156+155) peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
62MoTif 062 SARS-CoV-2 (Spike Fusion-Peptide)KRSFIEDLLFNKVTLADPool of 28 peptides derived from a peptide scan (truncational scan (peptide length 11 to 17aa))70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
63MoTif 063 Pan-Yellow Fever Virus Selectsee additional product documentationVirus-specific pool of 150 peptides (defined HLA class I & II-restricted T-cell epitopes)70%-90%/Infection, Yellow Fever
64MoTif 064 Collection EBV (2x1ug/peptide)Collection of 14 peptide pools (overlapping peptide scans, 15mers with 11 aa overlap)14 different PepMixes, 2 aliquots of 14 peptide pools each containing 1µg per peptide /tube70%-90%T-cell immunityAutoimmune disease, Burkitt's lymphoma, Cancer, Hodgkin's lymphoma, Infectious mononucleosis, Nasopharyngeal carcinoma
65MoTif 065 SARS-CoV-2 (NCPMUT)

MSDNGPQNQRNALRITFGGPSDSTGSN (MUT_NCAP_SARS2_0013P/L) + QASSRSSSRSRNISR

NSTPGSSRGTSP (MUT_NCAP_SARS2_0193S/I) + QASSRSSSRSRNSLRNSTPGSSRGTSP (MUT_

NCAP_SARS2_0194S/L) + RSSSRSRNSSRNLTPGSSRGTSPARMA (MUT_NCAP_SARS2_0197S/L) 

+ RSRNSSRNSTPGSSKGTSPARMAGNGG (MUT_NCAP_SARS2_0203R/K) + SSRNSTPGSSRRTSP

ARMAGNGG (MUT_NCAP_SARS2_0204G/R)

Pool of 23 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
66MoTif 066 HCoV-HKU1 (NCAP)

MSYTPGHYAGSRSSSGNRSGILKKTSWADQSERNYQTFNRGRKTQPKFTVSTQPQGNTIPHYSWFSG

ITQFQKGRDFKFSDGQGVPIAFGVPPSEAKGYWYRHSRRSFKTADGQQKQLLPRWYFYYLGTGPYANA

SYGESLEGVFWVANHQADTSTPSDVSSRDPTTQEAIPTRFPPGTILPQGYYVEGSGRSASNSRPGSRSQ

SRGPNNRSLSRSNSNFRHSDSIVKPDMADEIANLVLAKLGKDSKPQQVTKQNAKEIRHKILTKPRQKRT

PNKHCNVQQCFGKRGPSQNFGNAEMLKLGTNDPQFPILAELAPTPGAFFFGSKLDLVKRDSEADSPV

KDVFELHYSGSIRFDSTLPGFETIMKVLEENLNAYVNSNQNTDSDSLSSKPQRKRGVKQLPEQFDSLNL

SAGTQHISNDFTPEDHSLLATLDDPYVEDSVA

Pool of 108 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCommon cold, Covid-19, Infection, Respiratory infection
67MoTif 067 HCoV-NL63 (Spike Glycoprotein)

MKLFLILLVLPLASCFFTCNSNANLSMLQLGVPDNSSTIVTGLLPTHWFCANQSTSVYSANGFFYIDVG

NHRSAFALHTGYYDANQYYIYVTNEIGLNASVTLKICKFSRNTTFDFLSNASSSFDCIVNLLFTEQLGAP

LGITISGETVRLHLYNVTRTFYVPAAYKLTKLSVKCYFNYSCVFSVVNATVTVNVTTHNGRVVNYTVCD

DCNGYTDNIFSVQQDGRIPNGFPFNNWFLLTNGSTLVDGVSRLYQPLRLTCLWPVPGLKSSTGFVYFN

ATGSDVNCNGYQHNSVVDVMRYNLNFSANSLDNLKSGVIVFKTLQYDVLFYCSNSSSGVLDTTIPFG

PSSQPYYCFINSTINTTHVSTFVGILPPTVREIVVARTGQFYINGFKYFDLGFIEAVNFNVTTASATDFWT

VAFATFVDVLVNVSATNIQNLLYCDSPFEKLQCEHLQFGLQDGFYSANFLDDNVLPETYVALPIYYQHT

DINFTATASFGGSCYVCKPHQVNISLNGNTSVCVRTSHFSIRYIYNRVKSGSPGDSSWHIYLKSGTCPFS

FSKLNNFQKFKTICFSTVEVPGSCNFPLEATWHYTSYTIVGALYVTWSEGNSITGVPYPVSGIREFSNLVL

NNCTKYNIYDYVGTGIIRSSNQSLAGGITYVSNSGNLLGFKNVSTGNIFIVTPCNQPDQVAVYQQSIIGA

MTAVNESRYGLQNLLQLPNFYYVSNGGNNCTTAVMTYSNFGICADGSLIPVRPRNSSDNGISAIITANL

SIPSNWTTSVQVEYLQITSTPIVVDCATYVCNGNPRCKNLLKQYTSACKTIEDALRLSAHLETNDVSSML

TFDSNAFSLANVTSFGDYNLSSVLPQRNIRSSRIAGRSALEDLLFSKVVTSGLGTVDVDYKSCTKGLSIAD

LACAQYYNGIMVLPGVADAERMAMYTGSLIGGMVLGGLTSAAAIPFSLALQARLNYVALQTDVLQENQ

KILAASFNKAINNIVASFSSVNDAITQTAEAIHTVTIALNKIQDVVNQQGSALNHLTSQLRHNFQAISNSI

QAIYDRLDSIQADQQVDRLITGRLAALNAFVSQVLNKYTEVRGSRRLAQQKINECVKSQSNRYGFCGN

GTHIFSIVNSAPDGLLFLHTVLLPTDYKNVKAWSGICVDGIYGYVLRQPNLVLYSDNGVFRVTSRVMFQP

RLPVLSDFVQIYNCNVTFVNISRVELHTVIPDYVDVNKTLQEFAQNLPKYVKPNFDLTPFNLTYLNLSSELK

QLEAKTASLFQTTVELQGLIDQINSTYVDLKLLNRFENYIKWPWWVWLIISVVFVVLLSLLVFCCLSTGCCG

CCNCLTSSMRGCCDCGSTKLPYYEFEKVHVQ

Pool of 337 (169+168) peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCommon cold, Covid-19, Infection, Respiratory infection
68MoTif 068 Influenza B (M1) Ultrasee additional product documentationPool of 67 peptides derived from a peptide scan (15mers)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Sequence diversity
69MoTif 069 SARS-CoV-2 (Spike BF.7)

MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAISGTN

GTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDV

YYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPI

NLGRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYN

ENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATTFASVY

AWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIA

DYNYKLPDDFTGCVIAWNSNKLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGV

NCYFPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTE

SNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVA

IHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTKSHRRARSVASQS

IIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQ

LKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGF

IKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQM

AYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQALNTLVKQLSSKF

GAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRV

DFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQ

RNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS

VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLK

GCCSCGSCCKFDEDDSEPVLKGVKLHYT

Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
70MoTif 070 Pan-Human Rhinovirus Selectsee additional product documentationVirus-specific pool of 169 peptides (defined HLA class I & II-restricted T-cell epitopes) from selected proteins of for T cell assays (e.g. ELISPOT).70%-90%T-cell immunityCommon cold, Infection, Respiratory infection
71MoTif 071 SARS-CoV-2 (Spike BQ.1.1)

MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAISGT

NGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFL

DVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSK

HTPINLGRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTF

LLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNAT

TFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPG

QTGNIADYNYKLPDDFTGCVIAWNSNKLDSTVGGNYNYRYRLFRKSKLKPFERDISTEIYQAGNKPC

NGVAGVNCYFPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGL

TGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQG

VNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTKSH

RRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECS

NLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIED

LLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTF

GAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNH

NAQALNTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL

AATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFP

REGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKN

HTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIV

MVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
72MoTif 072 Human (TERT)

MPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPP

AAPSFRQVSCLKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGS

GAWGLLLRRVGDDVLVHLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPHASGPRRRLGCER

AWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSWAHPGRTRGPSD

RGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSS

GDKEQLRPSFLLSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQC

PYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRRLVQLLRQHSSPWQVYGFVRACLR

RLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGVGCVPAAEHRLR

EEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVR

QHREARPALLTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLG

ASVLGLDDIHRAWRTFVLRVRAQDPPPELYFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVV

QKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFDVFLRFMCH

HAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRT

LVRGVPEYGCVVNLRKTVVNFPVEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSYARTSIR

ASLTFNRGFKAGRNMRRKLFGVLRLKCHSLFLDLQVNSLQTVCTNIYKILLLQAYRFHACVLQLPFHQQ

VWKNPTFFLRVISDTASLCYSILKAKNAGMSLGAKGAAGPLPSEAVQWLCHQAFLLKLTRHRVTYVPLL

GSLRTAQTQLSRKLPGTTLTALEAAANPALPSDFKTILD

Pool of 281 peptides derived from a peptide scan through Telomerase reverse transcriptase (Swiss-Prot ID: O14746) of Human.70%-90%Cancer biomarker research, T-cell immunityBreast cancer, Burkitt's lymphoma, Cancer, Gastric cancer, Malignant genital cancers, Melanoma, Prostate cancer
73MoTif 073 Human (TYMS)

MPVAGSELPRRPLPPAAQERDAEPRPPHGELQYLGQIQHILRCGVRKDDRTGTGTLSVFGMQARYSLR

DEFPLLTTKRVFWKGVLEELLWFIKGSTNAKELSSKGVKIWDANGSRDFLDSLGFSTREEGDLGPVYGFQ

WRHFGAEYRDMESDYSGQGVDQLQRVIDTIKTNPDDRRIIMCAWNPRDLPLMALPPCHALCQFYVV

NSELSCQLYQRSGDMGLGVPFNIASYALLTYMIAHITGLKPGDFIHTLGDAHIYLNHIEPLKIQLQREPRP

FPKLRILRKVEKIDDFKAEDFQIEGYNPHPTIKMEMAV

Pool of 76 peptides derived from a peptide scan through Thymidylate synthase (Swiss-Prot ID: P04818) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer
74MoTif 074 VZV (gE)

MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHTDEDKLDTNSVYEPYYHSDHAESSWVNR

GESSRKAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGI

HVIPTLNGDDRHKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETW

SFLPSLTCTGDAAPAIQHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTS

TLFDELELDPPEIEPGVLKVLRTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRG

AEFHMWNYHSHVFSVGDTFSLAMHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCL

SHMNSGCTFTSPHLAQRVASTVYQNCEHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGL

YVFVVYFNGHVEAVAYTVVSTVDHFVNAIEERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGL

AAVVLLCLVIFLICTAKRMRVKAYRVDKSPYNQSMYYAGLPVDDFEDSESTDTEEEFGNAIGGSHGGSSY

TVYIDKTR

Pool of 153 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityChicken Pox, Herpes zoster, Infection, Shingles
75MoTif 075 Human (PAP)

MRAAPLLLARAASLSLGFLFLLFFWLDRSVLAKELKFVTLVFRHGDRSPIDTFPTDPIKESSWPQGFGQL

TQLGMEQHYELGEYIRKRYRKFLNESYKHEQVYIRSTDVDRTLMSAMTNLAALFPPEGVSIWNPILLW

QPIPVHTVPLSEDQLLYLPFRNCPRFQELESETLKSEEFQKRLHPYKDFIATLGKLSGLHGQDLFGIWSKV

YDPLYCESVHNFTLPSWATEDTMTKLRELSELSLLSLYGIHKQKEKSRLQGGVLVNEILNHMKRATQIPSY

KKLIMYSAHDTTVSGLQMALDVYNGLLPPYASCHLTELYFEKGEYFVEMYYRNETQHEPYPLMLPGCSP

SCPLERFAELVGPVIPQDWSTECMTTNSHQGTEDSTD

Pool of 94 peptides derived from a peptide scan through Prostatic acid phosphatase (PAP) (Swiss-Prot ID: P15309) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer, Phosphatase, Prostate cancer
76MoTif 076 Human (AFP)

MKWVESIFLIFLLNFTESRTLHRNEYGIASILDSYQCTAEISLADLATIFFAQFVQEATYKEVSKMVKDALT

AIEKPTGDEQSSGCLENQLPAFLEELCHEKEILEKYGHSDCCSQSEEGRHNCFLAHKKPTPASIPLFQVPE

PVTSCEAYEEDRETFMNKFIYEIARRHPFLYAPTILLWAARYDKIIPSCCKAENAVECFQTKAATVTKELRE

SSLLNQHACAVMKNFGTRTFQAITVTKLSQKFTKVNFTEIQKLVLDVAHVHEHCCRGDVLDCLQDGEK

IMSYICSQQDTLSNKITECCKLTTLERGQCIIHAENDEKPEGLSPNLNRFLGDRDFNQFSSGEKNIFLASF

VHEYSRRHPQLAVSVILRVAKGYQELLEKCFQTENPLECQDKGEEELQKYIQESQALAKRSCGLFQKLGE

YYLQNAFLVAYTKKAPQLTSSELMAITRKMAATAATCCQLSEDKLLACGEGAADIIIGHLCIRHEMTPVN

PGVGQCCTSSYANRRPCFSSLVVDETYVPPAFSDDKFIFHKDLCQAQGVALQTMKQEFLINLVKQKPQI

TEEQLEAVIADFSGLLEKCCQGQEQEVCFAEEGQKLISKTRAALGV

Pool of 150 peptides derived from a peptide scan through Alpha-fetoprotein (Swiss-Prot ID: P02771) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer
77MoTif 077 Dengue 1 (E) Ultrasee additional product documentationPool of 150 peptides derived from a peptide scan through Envelope Protein of Dengue Virus - type 1 (DENV1).70%-90%T-cell immunityDengue fever, Infection, Sequence diversity
78MoTif 078 HIV-1 (GAG) Ultrasee additional product documentationPool of 150 peptides derived from a peptide scan (Selected immunogenic peptides (15mers))70%-90%T-cell immunityAIDS (HIV), HIV, Infection, Sequence diversity
79MoTif 079 HIV-1 (POL) Ultrasee additional product documentationPool of 150 peptides derived from a peptide scan (Selected immunogenic peptides (15mers))70%-90%T-cell immunityAIDS (HIV), HIV, Infection, Sequence diversity
80MoTif 080 HPIV-3 (Matrix Protein)

MSITNSAIYTFPESSFSENGHIEPLPLKVNEQRKAVPHIRVAKIGNPPKHGSRYLDVFLLGFFEMERIKDKYGSVNDLDSDPGYKVCGSGSLPIGLAKYTGNDQELLQAATKLDIEVRRTVKAKEMIVYTVQNIKPELYPWSSRLRKGMLFDANKVALAPQCLPLDRSIKFRVIFVNCTAIGSITLFKIPKSMASLSLPSTISINLQVHIKTGVQTDSKGIVQILDEKGEKSLNFMVHLGLIKRKVGRMYSVEYCKQKIEKMRLIFSLGLVGGISLHVNATGSISKTLASQLVFKREICYPLMDLNPHLNLVIWASSVEITRVDAIFQPSLPGEFRYYPNIIAKGVGKIKQWN

Pool of 86 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityBronchitis, Infection, Respiratory infection
81MoTif 081 Human (TERT)

MPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPSFRQVSCLKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSWAHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFLLSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRRLVQLLRQHSSPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGVGCVPAAEHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPALLTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRAWRTFVLRVRAQDPPPELYFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRTLVRGVPEYGCVVNLRKTVVNFPVEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSYARTSIRASLTFNRGFKAGRNMRRKLFGVLRLKCHSLFLDLQVNSLQTVCTNIYKILLLQAYRFHACVLQLPFHQQVWKNPTFFLRVISDTASLCYSILKAKNAGMSLGAKGAAGPLPSEAVQWLCHQAFLLKLTRHRVTYVPLLGSLRTAQTQLSRKLPGTTLTALEAAANPALPSDFKTILD

Pool of 281 peptides derived from a peptide scan through Telomerase reverse transcriptase (Swiss-Prot ID: O14746) of Human.70%-90%Cancer biomarker research, T-cell immunityBreast cancer, Burkitt's lymphoma, Cancer, Gastric cancer, Malignant genital cancers, Melanoma, Prostate cancer
82MoTif 082 Human (TYMS)

MPVAGSELPRRPLPPAAQERDAEPRPPHGELQYLGQIQHILRCGVRKDDRTGTGTLSVFGMQARYSLRDEFPLLTTKRVFWKGVLEELLWFIKGSTNAKELSSKGVKIWDANGSRDFLDSLGFSTREEGDLGPVYGFQWRHFGAEYRDMESDYSGQGVDQLQRVIDTIKTNPDDRRIIMCAWNPRDLPLMALPPCHALCQFYVVNSELSCQLYQRSGDMGLGVPFNIASYALLTYMIAHITGLKPGDFIHTLGDAHIYLNHIEPLKIQLQREPRPFPKLRILRKVEKIDDFKAEDFQIEGYNPHPTIKMEMAV

Pool of 76 peptides derived from a peptide scan through Thymidylate synthase (Swiss-Prot ID: P04818) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer
83MoTif 083 Human (AFP)

MKWVESIFLIFLLNFTESRTLHRNEYGIASILDSYQCTAEISLADLATIFFAQFVQEATYKEVSKMVKDALTAIEKPTGDEQSSGCLENQLPAFLEELCHEKEILEKYGHSDCCSQSEEGRHNCFLAHKKPTPASIPLFQVPEPVTSCEAYEEDRETFMNKFIYEIARRHPFLYAPTILLWAARYDKIIPSCCKAENAVECFQTKAATVTKELRESSLLNQHACAVMKNFGTRTFQAITVTKLSQKFTKVNFTEIQKLVLDVAHVHEHCCRGDVLDCLQDGEKIMSYICSQQDTLSNKITECCKLTTLERGQCIIHAENDEKPEGLSPNLNRFLGDRDFNQFSSGEKNIFLASFVHEYSRRHPQLAVSVILRVAKGYQELLEKCFQTENPLECQDKGEEELQKYIQESQALAKRSCGLFQKLGEYYLQNAFLVAYTKKAPQLTSSELMAITRKMAATAATCCQLSEDKLLACGEGAADIIIGHLCIRHEMTPVNPGVGQCCTSSYANRRPCFSSLVVDETYVPPAFSDDKFIFHKDLCQAQGVALQTMKQEFLINLVKQKPQITEEQLEAVIADFSGLLEKCCQGQEQEVCFAEEGQKLISKTRAALGV

Pool of 150 peptides derived from a peptide scan through Alpha-fetoprotein (Swiss-Prot ID: P02771) of Human.70%-90%CancerCancer biomarker research, T-cell immunity
84MoTif 084 Human (HMMR)

MSFPKAPLKRFNDPSGCAPSPGAYDVKTLEVLKGPVSFQKSQRFKQQKESKQNLNVDKDTTLPASARKVKSSESKESQKNDKDLKILEKEIRVLLQERGAQDRRIQDLETELEKMEARLNAALREKTSLSANNATLEKQLIELTRTNELLKSKFSENGNQKNLRILSLELMKLRNKRETKMRGMMAKQEGMEMKLQVTQRSLEESQGKIAQLEGKLVSIEKEKIDEKSETEKLLEYIEEISCASDQVEKYKLDIAQLEENLKEKNDEILSLKQSLEENIVILSKQVEDLNVKCQLLEKEKEDHVNRNREHNENLNAEMQNLKQKFILEQQEREKLQQKELQIDSLLQQEKELSSSLHQKLCSFQEEMVKEKNLFEEELKQTLDELDKLQQKEEQAERLVKQLEEEAKSRAEELKLLEEKLKGKEAELEKSSAAHTQATLLLQEKYDSMVQSLEDVTAQFESYKALTASEIEDLKLENSSLQEKAAKAGKNAEDVQHQILATESSNQEYVRMLLDLQTKSALKETEIKEITVSFLQKITDLQNQLKQQEEDFRKQLEDEEGRKAEKENTTAELTEEINKWRLLYEELYNKTKPFQLQLDAFEVEKQALLNEHGAAQEQLNKIRDSYAKLLGHQNLKQKIKHVVKLKDENSQLKSEVSKLRCQLAKKKQSETKLQEELNKVLGIKHFDPSKAFHHESKENFALKTPLKEGNTNCYRAPMECQESWK

Pool of 179 peptides derived from a peptide scan through Hyaluronan mediated motility receptor (Swiss-Prot ID: O75330) of Human.70%-90%Cancer biomarker research, T-cell immunityBreast cancer, Cancer, Cell motility
85MoTif 085 Human (BRAF)

MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH

Pool of 189 peptides derived from a peptide scan (15mers with 11 aa overlap) through Serine/threonine-protein kinase B-raf (Swiss-Prot ID: P15056) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer
86MoTif 086 Dengue 1 (E) Ultrasee additional product documentationPool of 150 peptides derived from a peptide scan through Envelope Protein of Dengue Virus - type 1 (DENV1).70%-90%T-cell immunityDengue fever, Infection, Sequence diversity
87MoTif 087 HIV-1 (GAG) Ultrasee additional product documentationPool of 150 peptides derived from a peptide scan (Selected immunogenic peptides (15mers)) through Gag polyprotein (gag) of Human Immunodeficiency Virus (HIV).70%-90%T-cell immunityAIDS (HIV), HIV, Infection, Sequence diversity
88MoTif 088 HIV-1 (POL) Ultrasee additional product documentationPool of 150 peptides derived from a peptide scan (Selected immunogenic peptides (15mers)) through Pol polyprotein (POL) of Human Immunodeficiency Virus (HIV).70%-90%T-cell immunityAIDS (HIV), HIV, Infection, Sequence diversity
89MoTif 089 HPIV-3 (Matrix Protein)

MSITNSAIYTFPESSFSENGHIEPLPLKVNEQRKAVPHIRVAKIGNPPKHGSRYLDVFLLGFFEMERIKDKYGSVNDLDSDPGYKVCGSGSLPIGLAKYTGNDQELLQAATKLDIEVRRTVKAKEMIVYTVQNIKPELYPWSSRLRKGMLFDANKVALAPQCLPLDRSIKFRVIFVNCTAIGSITLFKIPKSMASLSLPSTISINLQVHIKTGVQTDSKGIVQILDEKGEKSLNFMVHLGLIKRKVGRMYSVEYCKQKIEKMRLIFSLGLVGGISLHVNATGSISKTLASQLVFKREICYPLMDLNPHLNLVIWASSVEITRVDAIFQPSLPGEFRYYPNIIAKGVGKIKQWN

Pool of 86 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityBronchitis, Infection, Respiratory infection
90MoTif 090 Human (WT1/WT33)

MGSDVRDLNALLPAVPSLGGGGGCALPVSGAAQWAPVLDFAPPGASAYGSLGGPAPPPAPPPPPPPPPHSFIKQEPSWGGAEPHEEQCLSAFTVHFSGQFTGTAGACRYGPFGPPPPSQASSGQARMFPNAPYLPSCLESQPAIRNQGYSTVTFDGTPSYGHTPSHHAAQFPNHSFKHEDPMGQQGSLGEQQYSVPPPVYGCHTPTDSCTGSQALLLRTPYSSDNLYQMTSQLECMTWNQMNLGATLKGVAAGSSSSVKWTEGQSNHSTGYESDNHTTPILCGAQYRIHTHGVFRGIQDVRRVPGVAPTLVRSASETSEKRPFMCAYPGCNKRYFKLSHLQMHSRKHTGEKPYQCDFKDCERRFSRSDQLKRHQRRHTGVKPFQCKTCQRKFSRSDHLKTHTRTHTGKTSEKPFSCRWPSCQKKFARSDELVRHHNMHQRNMTKLQLAL

Pool of 110 peptides derived from a peptide scan through Wilms tumor protein (Swiss-Prot ID: P19544) of Human.70%-90%T-cell Immunity, Cancer biomarker researchCancer, Wilms tumor 1
91MoTif 091 SARS-CoV-2 (Y14)MLQSCYNFLKEQHCQKASTQKGAEAAVKPLLVPHHVVATVQEIQLQAAVGELLLLEWLAMAVMLLLLCCCLTDPool of 16 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
92MoTif 092 Influenza A (HA/H1N1/Wisconsin/2019)

MKAILVVMLYTFTTANADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECESLSTARSWSYIVETSNSDNGTCYPGDFINYEELREQLSSVSSFERFEIFPKTSSWPNHDSDNGVTAACPHAGAKSFYKNLIWLVKKGKSYPKINQTYINDKGKEVLVLWGIHHPPTIADQQSLYQNADAYVFVGTSRYSKKFKPEIATRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVAPRYAFTMERDAGSGIIISDTPVHDCNTTCQTPEGAINTSLPFQNVHPITIGKCPKYVKSTKLRLATGLRNVPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQNAIDKITNKVNSVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRNQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNREKIDGVKLDSTRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQCRICI

Pool of 139 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza
93MoTif 093 Human (NY-ESO-2)

MQAEGRGTGGSTGDADGPGGPGIPDGPGGNAGGPGEAGATGGRGPRGAGAARASGPRGGAPRGPHGGAASAQDGRCPCGARRPDSRLLELHITMPFSSPMEAELVRRILSRDAAPLPRPGAVLKDFTVSGNLLFMSVRDQDREGAGRMRVVGWGLGSASPEGQKARDLRTPKHKVSEQRPGTPGPPPPEGAQGDGCRGVAFNVMFSAPHI

Pool of 50 peptides derived from a peptide scan (Peptide Scan (15mers with 11aa overlap))70%-90%Cancer biomarker research, T-cell immunityCancer, Malignant genital cancers
94MoTif 094 Human (Prame/OIP4)

MERRRLWGSIQSRYISMSVWTSPRRLVELAGQSLLKDEALAIAALELLPRELFPPLFMAAFDGRHSQTLKAMVQAWPFTCLPLGVLMKGQHLHLETFKAVLDGLDVLLAQEVRPRRWKLQVLDLRKNSHQDFWTVWSGNRASLYSFPEPEAAQPMTKKRKVDGLSTEAEQPFIPVEVLVDLFLKEGACDELFSYLIEKVKRKKNVLRLCCKKLKIFAMPMQDIKMILKMVQLDSIEDLEVTCTWKLPTLAKFSPYLGQMINLRRLLLSHIHASSYISPEKEEQYIAQFTSQFLSLQCLQALYVDSLFFLRGRLDQLLRHVMNPLETLSITNCRLSEGDVMHLSQSPSVSQLSVLSLSGVMLTDVSPEPLQALLERASATLQDLVFDECGITDDQLLALLPSLSHCSQLTTLSFYGNSISISALQSLLQHLIGLSNLTHVLYPVPLESYEDIHGTLHLERLAYLHARLRELLCELGRPSMVWLSANPCPHCGDRTFYDPEPILCPCFMPN

Pool of 125 peptides derived from a peptide scan through Melanoma antigen preferentially expressed in tumors (PRAME/OIP4) (Swiss-Prot ID: P78395) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer, Melanoma
95MoTif 095 Human (Matrilysin, MMP7)

MRLTVLCAVCLLPGSLALPLPQEAGGMSELQWEQAQDYLKRFYLYDSETKNANSLEAKLKEMQKFFGLPITGMLNSRVIEIMQKPRCGVPDVAEYSLFPNSPKWTSKVVTYRIVSYTRDLPHITVDRLVSKALNMWGKEIPLHFRKVVWGTADIMIGFARGAHGDSYPFDGPGNTLAHAFAPGTGLGGDAHFDEDERWTDGSSLGINFLYAATHELGHSLGMGHSSDPNAVMYPTYGNGDPQNFKLSQDDIKGIQKLYGKRSNSRKK

Pool of 64 peptides derived from a peptide scan through Matrilysin (Swiss-Prot ID: P09237) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer
96MoTif 096 HSV2 (E3 ICP0)

MEPRPGTSSRADPGPERPPRQTPGTQPAAPHAWGMLNDMQWLASSDSEEETEVGISDDDLHRDSTSEAGSTDTEMFEAGLMDAATPPARPPAERQGSPTPADAQGSCGGGPVGEEEAEAGGGGDVCAVCTDEIAPPLRCQSFPCLHPFCIPCMKTWIPLRNTCPLCNTPVAYLIVGVTASGSFSTIPIVNDPRTRVEAEAAVRAGTAVDFIWTGNPRTAPRSLSLGGHTVRALSPTPPWPGTDDEDDDLADVDYVPPAPRRAPRRGGGGAGATRGTSQPAATRPAPPGAPRSSSSGGAPLRAGVGSGSGGGPAVAAVVPRVASLPPAAGGGRAQARRVGEDAAAAEGRTPPARQPRAAQEPPIVISDSPPPSPRRPAGPGPLSFVSSSSAQVSSGPGGGGLPQSSGRAARPRAAVAPRVRSPPRAAAAPVVSASADAAGPAPPAVPVDAHRAPRSRMTQAQTDTQAQSLGRAGATDARGSGGPGAEGGPGVPRGTNTPGAAPHAAEGAAARPRKRRGSDSGPAASSSASSSAAPRSPLAPQGVGAKRAAPRRAPDSDSGDRGHGPLAPASAGAAPPSASPSSQAAVAAASSSSASSSSASSSSASSSSASSSSASSSSASSSSASSSAGGAGGSVASASGAGERRETSLGPRAAAPRGPRKCARKTRHAEGGPEPGARDPAPGLTRYLPIAGVSSVVALAPYVNKTVTGDCLPVLDMETGHIGAYVVLVDQTGNVADLLRAAAPAWSRRTLLPEHARNCVRPPDYPTPPASEWNSLWMTPVGNMLFDQGTLVGALDFHGLRSRHPWSREQGAPAPAGDAPAGHGE

Pool of 204 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Encephalitis, Genital herpes, Infection, Oral Herpes
97MoTif 097Human (RGS5)

MCKGLAALPHSCLERAKEIKIKLGILLQKPDSVGDLVIPYNEKPEKPAKTQKTSLDEALQWRDSLDKLLQNNYGLASFKSFLKSEFSEENLEFWIACEDYKKIKSPAKMAEKAKQIYEEFIQTEAPKEVNIDHFTKDITMKNLVEPSLSSFDMAQKRIHALMEKDSLPRFVRSEFYQELIK

Pool of 43 peptides derived from a peptide scan through Regulator of G-protein signaling 5 (Swiss-Prot ID: O15539) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer
98MoTif 098 Measles virus (Hemagglutinin glycoprotein)

MSPQRDRINAFYKDNPHPKGSRIVINREHLMIDRPYVLLAVLFVMFLSLIGLLAIAGIRLHRAAIYTAEIHKSLSTNLDVTNSIEHQVKDVLTPLFKIIGDEVGLRTPQRFTDLVKLISDKIKFLNPDREYDFRDLTWCINPPERIKLDYDQYCADVAAEELMNALVNSTLLETRTTNQFLAVSKGNCSGPTTIRGQFSNMSLSLLDLYLGRGYNVSSIVTMTSQGMYGGTYLVEKPNLSSKRSELSQLSMYRVFEVGVIRNPGLGAPVFHMTNYLEQPVSNDLSNCMVALGELKLAALCHGEDSITIPYQGSGKGVSFQLVKLGVWKSPTDMQSWVPLSTDDPVIDRLYLSSHRGVIADNQAKWAVPTTRTDDKLRMETCFQQACKGKIQALCENPEWAPLKDNRIPSYGVLSVDLSLTVELKIKIASGFGPLITHGSGMDLYKSNHNNVYWLTIPPMKNLALGVINTLEWIPRFKVSPYLFTVPIKEAGEDCHAPTYLPAEVDGDVKLSSNLVILPGQDLQYVLATYDTSRVEHAVVYYVYSPSRSFSYFYPFRLPIKGVPIELQVECFTWDQKLWCRHFCVLADSESGGHITHSGMVGMGVSCTVTREDGTNRR

Pool of 152 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Measles
99MoTif 099 Influenza A (HA/H1N1/Wisconsin/2019)

MKAILVVMLYTFTTANADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECESLSTARSWSYIVETSNSDNGTCYPGDFINYEELREQLSSVSSFERFEIFPKTSSWPNHDSDNGVTAACPHAGAKSFYKNLIWLVKKGKSYPKINQTYINDKGKEVLVLWGIHHPPTIADQQSLYQNADAYVFVGTSRYSKKFKPEIATRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVAPRYAFTMERDAGSGIIISDTPVHDCNTTCQTPEGAINTSLPFQNVHPITIGKCPKYVKSTKLRLATGLRNVPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQNAIDKITNKVNSVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRNQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNREKIDGVKLDSTRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQCRICI

Pool of 139 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza
100MoTif 100 Human (WT1/WT33)

MGSDVRDLNALLPAVPSLGGGGGCALPVSGAAQWAPVLDFAPPGASAYGSLGGPAPPPAPPPPPPPPPHSFIKQEPSWGGAEPHEEQCLSAFTVHFSGQFTGTAGACRYGPFGPPPPSQASSGQARMFPNAPYLPSCLESQPAIRNQGYSTVTFDGTPSYGHTPSHHAAQFPNHSFKHEDPMGQQGSLGEQQYSVPPPVYGCHTPTDSCTGSQALLLRTPYSSDNLYQMTSQLECMTWNQMNLGATLKGVAAGSSSSVKWTEGQSNHSTGYESDNHTTPILCGAQYRIHTHGVFRGIQDVRRVPGVAPTLVRSASETSEKRPFMCAYPGCNKRYFKLSHLQMHSRKHTGEKPYQCDFKDCERRFSRSDQLKRHQRRHTGVKPFQCKTCQRKFSRSDHLKTHTRTHTGKTSEKPFSCRWPSCQKKFARSDELVRHHNMHQRNMTKLQLAL

Pool of 110 peptides derived from a peptide scan through Wilms tumor protein (Swiss-Prot ID: P19544) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer, Wilms tumor 1
101MoTif 101 SARS-CoV-2 (Y14)MLQSCYNFLKEQHCQKASTQKGAEAAVKPLLVPHHVVATVQEIQLQAAVGELLLLEWLAMAVMLLLLCCCLTDPool of 16 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
102MoTif 102 Human (Prame/OIP4)

MERRRLWGSIQSRYISMSVWTSPRRLVELAGQSLLKDEALAIAALELLPRELFPPLFMAAFDGRHSQTLKAMVQAWPFTCLPLGVLMKGQHLHLETFKAVLDGLDVLLAQEVRPRRWKLQVLDLRKNSHQDFWTVWSGNRASLYSFPEPEAAQPMTKKRKVDGLSTEAEQPFIPVEVLVDLFLKEGACDELFSYLIEKVKRKKNVLRLCCKKLKIFAMPMQDIKMILKMVQLDSIEDLEVTCTWKLPTLAKFSPYLGQMINLRRLLLSHIHASSYISPEKEEQYIAQFTSQFLSLQCLQALYVDSLFFLRGRLDQLLRHVMNPLETLSITNCRLSEGDVMHLSQSPSVSQLSVLSLSGVMLTDVSPEPLQALLERASATLQDLVFDECGITDDQLLALLPSLSHCSQLTTLSFYGNSISISALQSLLQHLIGLSNLTHVLYPVPLESYEDIHGTLHLERLAYLHARLRELLCELGRPSMVWLSANPCPHCGDRTFYDPEPILCPCFMPN

Pool of 125 peptides derived from a peptide scan through Melanoma antigen preferentially expressed in tumors (PRAME/OIP4) (Swiss-Prot ID: P78395) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer, Melanoma
103MoTif 103 Human (Matrilysin, MMP7)

MRLTVLCAVCLLPGSLALPLPQEAGGMSELQWEQAQDYLKRFYLYDSETKNANSLEAKLKEMQKFFGLPITGMLNSRVIEIMQKPRCGVPDVAEYSLFPNSPKWTSKVVTYRIVSYTRDLPHITVDRLVSKALNMWGKEIPLHFRKVVWGTADIMIGFARGAHGDSYPFDGPGNTLAHAFAPGTGLGGDAHFDEDERWTDGSSLGINFLYAATHELGHSLGMGHSSDPNAVMYPTYGNGDPQNFKLSQDDIKGIQKLYGKRSNSRKK

Pool of 64 peptides derived from a peptide scan through Matrilysin (Swiss-Prot ID: P09237) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer
104MoTif 104 Human (NY-ESO-2)

MQAEGRGTGGSTGDADGPGGPGIPDGPGGNAGGPGEAGATGGRGPRGAGAARASGPRGGAPRGPHGGAASAQDGRCPCGARRPDSRLLELHITMPFSSPMEAELVRRILSRDAAPLPRPGAVLKDFTVSGNLLFMSVRDQDREGAGRMRVVGWGLGSASPEGQKARDLRTPKHKVSEQRPGTPGPPPPEGAQGDGCRGVAFNVMFSAPHI

Pool of 50 peptides derived from a peptide scan (Peptide Scan (15mers with 11aa overlap))70%-90%Cancer biomarker research, T-cell immunityCancer, Malignant genital cancers
105MoTif 105 HSV2 (E3 ICP0)

MEPRPGTSSRADPGPERPPRQTPGTQPAAPHAWGMLNDMQWLASSDSEEETEVGISDDDLHRDSTSEAGSTDTEMFEAGLMDAATPPARPPAERQGSPTPADAQGSCGGGPVGEEEAEAGGGGDVCAVCTDEIAPPLRCQSFPCLHPFCIPCMKTWIPLRNTCPLCNTPVAYLIVGVTASGSFSTIPIVNDPRTRVEAEAAVRAGTAVDFIWTGNPRTAPRSLSLGGHTVRALSPTPPWPGTDDEDDDLADVDYVPPAPRRAPRRGGGGAGATRGTSQPAATRPAPPGAPRSSSSGGAPLRAGVGSGSGGGPAVAAVVPRVASLPPAAGGGRAQARRVGEDAAAAEGRTPPARQPRAAQEPPIVISDSPPPSPRRPAGPGPLSFVSSSSAQVSSGPGGGGLPQSSGRAARPRAAVAPRVRSPPRAAAAPVVSASADAAGPAPPAVPVDAHRAPRSRMTQAQTDTQAQSLGRAGATDARGSGGPGAEGGPGVPRGTNTPGAAPHAAEGAAARPRKRRGSDSGPAASSSASSSAAPRSPLAPQGVGAKRAAPRRAPDSDSGDRGHGPLAPASAGAAPPSASPSSQAAVAAASSSSASSSSASSSSASSSSASSSSASSSSASSSSASSSAGGAGGSVASASGAGERRETSLGPRAAAPRGPRKCARKTRHAEGGPEPGARDPAPGLTRYLPIAGVSSVVALAPYVNKTVTGDCLPVLDMETGH

IGAYVVLVDQTGNVADLLRAAAPAWSRRTLLPEHARNCVRPPDYPTPPASEWNSLWMTPVGNMLFDQGTLVGALDFHGLRSRHPWSREQGAPAPAGDAPAGHGE

Pool of 204 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Encephalitis, Genital herpes, Infection, Oral Herpes
106MoTif 106 Human (Actin)

MCDEDETTALVCDNGSGLVKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQSKRGILTLKYPIEHGIITNWDDMEKIWHHTFYNELRVAPEEHPTLLTEAPLNPKANREKMTQIMFETFNVPAMYVAIQAVLSLYASGRTTGIVLDSGDGVTHNVPIYEGYALPHAIMRLDLAGRDLTDYLMKILTERGYSFVTTAEREIVRDIKEKLCYVALDFENEMATAASSSSLEKSYELPDGQVITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDIDIRKDLYANNVMSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWITKQEYDEAGPSIVHRKCF

Control Pool of 92 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityControl
107MoTif 107 Human (MOG)

GQFRVIGPRHPIRALVGDEVELPCRISPGKNATGMEVGWYRPPFSRVVHLYRNGKDQDGDQAPEYRGRTELLKDAIGEGKVTLRIRNVRFSDEGGFTCFFRDHSYQEEAAMELKVEDPFYWVSPG

Control Pool of 29 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityControl
108MoTif 108 Human (CEA)

MESPSAPPHRWCIPWQRLLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLVHNLPQHLFGYSWYKGERVDGNRQIIGYVIGTQQATPGPAYSGREIIYPNASLLIQNIIQNDTGFYTLHVIKSDLVNEEATGQFRVYPELPKPSISSNNSKPVEDKDAVAFTCEPETQDATYLWWVNNQSLPVSPRLQLSNGNRTLTLFNVTRNDTASYKCETQNPVSARRSDSVILNVLYGPDAPTISPLNTSYRSGENLNLSCHAASNPPAQYSWFVNGTFQQSTQELFIPNITVNNSGSYTCQAHNSDTGLNRTTVTTITVYAEPPKPFITSNNSNPVEDEDAVALTCEPEIQNTTYLWWVNNQSLPVSPRLQLSNDNRTLTLLSVTRNDVGPYECGIQNKLSVDHSDPVILNVLYGPDDPTISPSYTYYRPGVNLSLSCHAASNPPAQYSWLIDGNIQQHTQELFISNITEKNSGLYTCQANNSASGHSRTTVKTITVSAELPKPSISSNNSKPVEDKDAVAFTCEPEAQNTTYLWWVNGQSLPVSPRLQLSNGNRTLTLFNVTRNDARAYVCGIQNSVSANRSDPVTLDVLYGPDTPIISPPDSSYLSGANLNLSCHSASNPSPQYSWRINGIPQQHTQVLFIAKITPNNNGTYACFVSNLATGRNNSIVKSITVSASGTSPGLSAGATVGIMIGVLVGVALI

Pool of 173 peptides derived from a peptide scan through Carcinoembryonic antigen-related cell adhesion molecule 5 (Swiss-Prot ID: P06731) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer, Epithelium
109MoTif 109 Human (PSMA)

MWNLLHETDSAVATARRPRWLCAGALVLAGGFFLLGFLFGWFIKSSNEATNITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAAETLSEVA

Pool of 185 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap))70%-90%Cancer biomarker research, T-cell immunityAlzheimer's disease, Breast cancer, Cancer, Epithelium, Gastric cancer, Malignant genital cancers, Melanoma, Neurodegeneration, Prostate cancer
110MoTif 110 Human (PSMA)

MWNLLHETDSAVATARRPRWLCAGALVLAGGFFLLGFLFGWFIKSSNEATNITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAAETLSEVA

Pool of 185 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap))70%-90%Cancer biomarker research, T-cell immunityAlzheimer's disease, Breast cancer, Cancer, Epithelium, Gastric cancer, Malignant genital cancers, Melanoma, Neurodegeneration, Prostate cancer
111MoTif 111 Mouse (Tyrosinase)

MFLAVLYCLLWSFQISDGHFPRACASSKNLLAKECCPPWMGDGSPCGQLSGRGSCQDILLSSAPSGPQFPFKGVDDRESWPSVFYNRTCQCSGNFMGFNCGNCKFGFGGPNCTEKRVLIRRNIFDLSVSEKNKFFSYLTLAKHTISSVYVIPTGTYGQMNNGSTPMFNDINIYDLFVWMHYYVSRDTLLGGSEIWRDIDFAHEAPGFLPWHRLFLLLWEQEIRELTGDENFTVPYWDWRDAENCDICTDEYLGGRHPENPNLLSPASFFSSWQIICSRSEEYNSHQVLCDGTPEGPLLRNPGNHDKAKTPRLPSSADVEFCLSLTQYESGSMDRTANFSFRNTLEGFASPLTGIADPSQSSMHNALHIFMNGTMSQVQGSANDPIFLLHHAFVDSIFEQWLRRHRPLLEVYPEANAPIGHNRDSYMVPFIPLYRNGDFFITSKDLGYDYSYLQESDPGFYRNYIEPYLEQASRIWPW

Pool of 117 peptides derived from a peptide scan through Tyrosinase (Swiss-Prot ID: P11344, region: 1-447) of Mouse.70%-90%Cancer biomarker research, T-cell immunityAlbinism, Cancer, Melanoma
112MoTif 112 Human (Tyrosinase)

MLLAVLYCLLWSFQTSAGHFPRACVSSKNLMEKECCPPWSGDRSPCGQLSGRGSCQNILLSNAPLGPQFPFTGVDDRESWPSVFYNRTCQCSGNFMGFNCGNCKFGFWGPNCTERRLLVRRNIFDLSAPEKDKFFAYLTLAKHTISSDYVIPIGTYGQMKNGSTPMFNDINIYDLFVWMHYYVSMDALLGGSEIWRDIDFAHEAPAFLPWHRLFLLRWEQEIQKLTGDENFTIPYWDWRDAEKCDICTDEYMGGQHPTNPNLLSPASFFSSWQIVCSRLEEYNSHQSLCNGTPEGPLRRNPGNHDKSRTPRLPSSADVEFCLSLTQYESGSMDKAANFSFRNTLEGFASPLTGIADASQSSMHNALHIYMNGTMSQVQGSANDPIFLLHHAFVDSIFEQWLRRHRPLQEVYPEANAPIGHNRESYMVPFIPLYRNGDFFISSKDLGYDYSYLQDSDPDSFQDYIKSYLEQASRIWSWLLGAAMVGAVLTALLAGLVSLLCRHKRKQLPEEKQPLLMEKEDYHSLYQSHL

Pool of 130 peptides derived from a peptide scan (Peptide Scan (15mers with 11aa overlap))70%-90%Cancer biomarker research, T-cell immunityAlbinism, Cancer, Melanoma
113MoTif 113 Mouse (Survivin)

MGAPALPQIWQLYLKNYRIATFKNWPFLEDCACTPERMAEAGFIHCPTENEPDLAQCFFCFKELEGWEPDDNPIEEHRKHSPGCAFLTVKKQMEELTVSEFLKLDRQRAKNKIAKETNNKQKEFEETAKTTRQSIEQLAA

Pool of 33 peptides derived from a peptide scan through Baculoviral IAP repeat-containing protein 5 (Survivin) (Swiss-Prot ID: O70201) of Mouse.70%-90%Cancer biomarker research, T-cell immunityCancer
114MoTif 114 Human (TPTE)

MNESPDPTDLAGVIIELGPNDSPQTSEFKGATEEAPAKESPHTSEFKGAARVSPISESVLARLSKFEVEDAENVASYDSKIKKIVHSIVSSFAFGLFGVFLVLLDVTLILADLIFTDSKLYIPLEYRSISLAIALFFLMDVLLRVFVERRQQYFSDLFNILDTAIIVILLLVDVVYIFFDIKLLRNIPRWTHLLRLLRLIILLRIFHLFHQKRQLEKLIRRRVSENKRRYTRDGFDLDLTYVTERIIAMSFPSSGRQSFYRNPIKEVVRFLDKKHRNHYRVYNLCSERAYDPKHFHNRVVRIMIDDHNVPTLHQMVVFTKEVNEWMAQDLENIVAIHCKGGTDRTGTMVCAFLIASEICSTAKESLYYFGERRTDKTHSEKFQGVKTPSQKRYVAYFAQVKHLYNWNLPPRRILFIKHFIIYSIPRYVRDLKIQIEMEKKVVFSTISLGKCSVLDNITTDKILIDVFDGLPLYDDVKVQFFYSNLPTYYDNCSFYFWLHTSFIENNRLYLPKNELDNLHKQKARRIYPSDFAVEILFGEKMTSSDVVAGSD

Pool of 135 peptides derived from a peptide scan through Putative tyrosine-protein phosphatase TPTE (Swiss-Prot ID: P56180) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer
115MoTif 115 Human (Brachyury)

MSSPGTESAGKSLQYRVDHLLSAVENELQAGSEKGDPTERELRVGLEESELWLRFKELTNEMIVTKNGRRMFPVLKVNVSGLDPNAMYSFLLDFVAADNHRWKYVNGEWVPGGKPEPQAPSCVYIHPDSPNFGAHWMKAPVSFSKVKLTNKLNGGGQIMLNSLHKYEPRIHIVRVGGPQRMITSHCFPETQFIAVTAYQNEEITALKIKYNPFAKAFLDAKERSDHKEMMEEPGDSQQPGYSQWGWLLPGTSTLCPPANPHPQFGGALSLPSTHSCDRYPTLRSHRSSPYPSPYAHRNNSPTYSDNSPACLSMLQSHDNWSSLGMPAHPSMLPVSHNASPPTSSSQYPSLWSVSNGAVTPGSQAAAVSNGLGAQFFRGSPAHYTPLTHPVSAPSSSGSPLYEGAAAATDIVDSQYDAAAQGRLIASWTPVSPPSM

Pool of 106 peptides derived from a peptide scan through Transcription factors/activators (Swiss-Prot ID: O15178) of Human.70%-90%Cancer biomarker research, T-cell immunityBrachyury Mutation, Cancer
116MoTif 116 HBV (Capsid Protein) Ultrasee additional product documentationPool of 155 peptides derived from a peptide scan (selected 15mers) through Capsid protein of Hepatitis B Virus (HBV).70%-90%T-cell immunityHepatitis, Infection, Sequence diversity
117MoTif 117 Measles virus (Hemagglutinin glycoprotein)

MSPQRDRINAFYKDNPHPKGSRIVINREHLMIDRPYVLLAVLFVMFLSLIGLLAIAGIRLHRAAIYTAEIHKSLSTNLDVTNSIEHQVKDVLTPLFKIIGDEVGLRTPQRFTDLVKLISDKIKFLNPDREYDFRDLTWCINPPERIKLDYDQYCADVAAEELMNALVNSTLLETRTTNQFLAVSKGNCSGPTTIRGQFSNMSLSLLDLYLGRGYNVSSIVTMTSQGMYGGTYLVEKPNLSSKRSELSQLSMYRVFEVGVIRNPGLGAPVFHMTNYLEQPVSNDLSNCMVALGELKLAALCHGEDSITIPYQGSGKGVSFQLVKLGVWKSPTDMQSWVPLSTDDPVIDRLYLSSHRGVIADNQAKWAVPTTRTDDKLRMETCFQQACKGKIQALCENPEWAPLKDNRIPSYGVLSVDLSLTVELKIKIASGFGPLITHGSGMDLYKSNHNNVYWLTIPPMKNLALGVINTLEWIPRFKVSPYLFTVPIKEAGEDCHAPTYLPAEVDGDVKLSSNLVILPGQDLQYVLATYDTSRVEHAVVYYVYSPSRSFSYFYPFRLPIKGVPIELQVECFTWDQKLWCRHFCVLADSESGGHITHSGMVGMGVSCTVTREDGTNRR

Pool of 152 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Measles
118MoTif 118 VZV (IE62)_2 subpools

MDTPPMQRSTPQRAGSPDTLELMDLLDAAAAAAEHRARVVTSSQPDDLLFGENGVMVGREHEIVSIPSVSGLQPEPRTEDVGEELTQDDYVCEDGQDLMGSPVIPLAEVFHTRFSEAGAREPTGADRSLETVSLGTKLARSPKPPMNDGETGRGTTPPFPQAFSPVSPASPVGDAAGNDQREDQRSIPRQTTRGNSPGLPSVVHRDRQTQSISGKKPGDEQAGHAHASGDGVVLQKTQRPAQGKSPKKKTLKVKVPLPARKPGGPVPGPVEQLYHVLSDSVPAKGAKADLPFETDDTRPRKHDARGITPRVPGRSSGGKPRAFLALPGRSHAPDPIEDDSPVEKKPKSREFVSSSSSSSSWGSSSEDEDDEPRRVSVGSETTGSRSGREHAPSPSNSDDSDSNDGGSTKQNIQPGYRSISGPDPRIRKTKRLAGEPGRQRQKSFSLPRSRTPIIPPVSGPLMMPDGSPWPGSAPLPSNRVRFGPSGETREGHWEDEAVRAARARYEASTEPVPLYVPELGDPARQYRALINLIYCPDRDPIAWLQNPKLTGVNSALNQFYQKLLPPGRAGTAVTGSVASPVPHVGEAMATGEALWALPHAAAAVAMSRRYDRAQKHFILQSLRRAFASMAYPEATGSSPAARISRGHPSPTTPATQTPDPQPSAAARSLSVCPPDDRLRTPRKRKSQPVESRSLLDKIRETPVADARVADDHVVSKAKRRVSEPVTITSGPVVDPPAVITMPLDGPAPNGGFRRIPRGALHTPVPSDQARKAYCTPETIARLVDDPLFPTAWRPALSFDPGALAEIAARRPGGGDRRFGPPSGVEALRRRCAWMRQIPDPEDVRLLIIYDPLPGEDINGPLESTLATDPGPSWSPSRGGLSVVLAALSNRLCLPSTHAWAGNWTGPPDVSALNARGVLLLSTRDLAFAGAVEYLGSRLASARRRLLVLDAVALERWPRDGPALSQYHVYVRAPARPDAQAVVRWPDSAVTEGLARAVFASSRTFGPASFARIETAFANLYPGEQPLCLCRGGNVAYTVCTRAGPKTRVPLSPREYRQYVLPGFDGCKDLARQSRGLGLGAADFVDEAAHSHRAANRWGLGAALRPVFLPEGRRPGAAGPEAGDVPTWARVFCRHALLEPDPAAEPLVLPPVAGRSVALYASADEARNALPPIPRVMWPPGFGAAETVLEGSDGTRFVFGHHGGSERPAETQAGRQRRTADDREHALEPDDWEVGCEDAWDSEEGGGDDGDAPGSSFGVSIVSVAPGVLRDRRVGLRPAVKVELLSSSSSSEDEDDVWGGRGGRSPPQSRG

Pool of 325 (163 + 162) peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityChicken Pox, Herpes zoster, Infection, Shingles
119MoTif 119 Human (P53)

MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPRVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD

Pool of 96 peptides derived from a peptide scan through Cellular tumor antigen p53 (Swiss-Prot ID: P04637) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer
120MoTif 120 Vaccinia virus (MVA018L)

MGIQHEFDIIINGDIALRNLQLHKGDNYGCKLKIISNDYKKLKFRFIIRPDWSEIDEVKGLTVFANNYAVKVNKVDDTFYYVIYEAVIHLYNKKTEILIYSDDENELFKHYYPYISLNMISKKYKVKEENYSSPYIEHPLIPYRDYESMD

Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Small Pox, Small Pox Vaccine
121MoTif 121 Vaccinia virus (MVA121L)

MMPIKSIVTLDQLEDSEYLFRIVSTVLPHLCLDYKVCDQLKTTFVHPFDILLNNSLGSVTKQDELQAAISKLGINYLIDTTSRELKLFNVTLNAGNIDIINTPINISSETNPIINTHSFYDLPPFTQHLLNIRLTDTEYRARFIGGYIKPDGSDSMDVLAEKKYPDLNFDNTYLFNILYKDVINAPIKEFKAKIVNGVLSRQDFDNLIGVRQYITAQDRPRFDNAYNIADAARHYGVNLNTLPLPNVDLTTMPTYKHLIMFEQYFIYTYDRVDIYYNGNKMLLDDEIMNFCISMRYQSLIPRLVEFFPDIPVNNNIVLHTRDPQNAAVNVTVALPNVQFVDIGRNHKFFINFFNLLAKEQRSTAIKVTKSMFWDGMDYEEYKSKNLQDMMFINSTCYVFGLYNHNNTTYCSILSDIISAEKTPIRVCLLPRVVGGKTVTNLISETLKSISSMTIREFPRKDKSIMHIGLSETGFMRFFQLLRLMADKPHETAIKEVVMAYVGIKLGDKGSPYYIRKESYQDFIYLLFASMGFKVTTRRSIMGSNNISIISIRPRVTKQYIVTTLMKTSCSKNEAEKLITSAFDLLNFMVSVSDFRDYQSYRQYRNYCPRYFYAGSPEGEETIICDSEPISILDRIDTRGIFSAYTINEMMDTDIFSPENKAFKNNLSRFIESGNITGEDIFCAMPYNILDRIITNAGTCTVSIGDMLDNITTQSDCNMTNEITDMINASLKNTISKDNNMLVSQALDSVANRSKQTIGDLRQSSCKMALLFKNLATSIYTIERIFNAKVGDDVKASMLEKYKVFTDISMSLYKDLIAMENLKAMLYIIRRSGCRIDDAQITTDDLVKSYSLIRPKILSMINYYNEMSRGYFEHMKKNLNMTDGDSVSFDDE

Pool of 220 (110 + 110 (in 2 vials)) peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Small Pox, Small Pox Vaccine
122MoTif 122 Vaccinia virus (MVA074R)

MGIKNLKSLLLENKSLTILDDNLYKVYNGIFVDTMSIYIAVANCVRNLEELTTVFIKYVNGWVKKGGHVTLFIDRGSIKIKQDVRDKRRKYSKLTKDRKMLELEKCTSEIQNVTGFMEEEIKAEMQLKIDKLTFQIYLSDSDNIKISLNEILTHFNNNENVTLFYCDERDAEFVMCLEAKTHFSTTGEWPLIISTDQDTMLFASTDNHPKMIKNLTQLFKFVPSAEDNYLAKLTALVNGCDFFPGLYGASITPTNLNKIQLFSDFTIDNIVTSLAIKNYYRKTNSTVDVRNIVTFINDYANLDDVYSYVPPCQCTVQEFIFSALDEKWNNFKSSYLETVPLPCQLMYALEPRKEIDVSEVKTLSSYIDFENTKSDIDVIKSISSIFGYSNENCNTIVFGIYKDNLLLSINSSFYFNDSLLITNTKSDNIINIGY

Pool of 106 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Small Pox, Small Pox Vaccine
123MoTif 123 Human Adenovirus 26 (Hexon Protein)

MATPSMMPQWAYMHIAGQDASEYLSPGLVQFARATDTYFSLGNKFRNPTVAPTHDVTTDRSQRLTLRFVPVDREDTTYSYKARFTLAVGDNRVLDMASTYFDIRGVLDRGPSFKPYSGTAYNSLAPKGAPNPSQWETKEKQGTTGGVQQEKDVTKTFGVAATGGINITNQGLLLGTDETAENGKKDIYADKTFQPEPQVGEENWQENEAFYGGRALKKDTKMKPCYGSFARPTNEKGGQAKFKPVNEGEQPKDLDIDFAYFDVPGGSPPAGGSGEEYKADIILYTENVNLETPDTHVVYKPGTSDNSSEINLVQQSMPNRPNYIGFRDNFVGLMYYNSTGNMGVLAGQASQLNAVVDLQDRNTELSYQLLLDSLGDRTRYFSMWNSAVDSYDPDVRIIENHGVEDELPNYCFPLNGTGTNSTYQGVKITNGNDGAEESEWEKDDAISRQNQICKGNVYAMEINLQANLWKSFLYSNVALYLPDSYKYTPANVKLPANTNTYEYMNGRVVAPSLVDAYIHIGARWSLDPMDNVNPFNHHRNAGLRYRSMLLGNGRYVPFHIQVPQKFFAIKNLLLLPGSYTYEWNFRKDVNMILQSSLGNDLRVDGASVRFDSVNLYATFFPMAHNTASTLEAMLRNDTNDQSFNDYLSAANMLYPIPAKATNVPISIPSRNWAAFRGWSFTRLKTKETPSLGSGFDPYFVYSGSIPYLDGTFYLNHTFKKVSIMFDSSVSWPGNDRLLTPNEFEIKRSVDGEGYNVAQCNMTKDWFLVQMLSHYNIGYQGFHVPEGYKDRMYSFFRNFQPMSRQVVDEINYKDYKAVTLPFQHNNSGFTGYLAPTMRQGQPYPANFPYPLIGQTAVPSVTQKKFLCDRVMWRIPFSSNFMSMGALTDLGQNMLYANSAHALDMTFEVDPMDEPTLLYLLFEVFDVVRVHQPHRGVIEAVYLRTPFSAGNATT

Pool of 236 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Gene therapy, Infection
124MoTif 124 Human Adenovirus 5 (Hexon Protein)

MATPSMMPQWSYMHISGQDASEYLSPGLVQFARATETYFSLNNKFRNPTVAPTHDVTTDRSQRLTLRFIPVDREDTAYSYKARFTLAVGDNRVLDMASTYFDIRGVLDRGPTFKPYSGTAYNALAPKGAPNPCEWDEAATALEINLEEEDDDNEDEVDEQAEQQKTHVFGQAPYSGINITKEGIQIGVEGQTPKYADKTFQPEPQIGESQWYETEINHAAGRVLKKTTPMKPCYGSYAKPTNENGGQGILVKQQNGKLESQVEMQFFSTTEATAGNGDNLTPKVVLYSEDVDIETPDTHISYMPTIKEGNSRELMGQQSMPNRPNYIAFRDNFIGLMYYNSTGNMGVLAGQASQLNAVVDLQDRNTELSYQLLLDSIGDRTRYFSMWNQAVDSYDPDVRIIENHGTEDELPNYCFPLGGVINTETLTKVKPKTGQENGWEKDATEFSDKNEIRVGNNFAMEINLNANLWRNFLYSNIALYLPDKLKYSPSNVKISDNPNTYDYMNKRVVAPGLVDCYINLGARWSLDYMDNVNPFNHHRNAGLRYRSMLLGNGRYVPFHIQVPQKFFAIKNLLLLPGSYTYEWNFRKDVNMVLQSSLGNDLRVDGASIKFDSICLYATFFPMAHNTASTLEAMLRNDTNDQSFNDYLSAANMLYPIPANATNVPISIPSRNWAAFRGWAFTRLKTKETPSLGSGYDPYYTYSGSIPYLDGTFYLNHTFKKVAITFDSSVSWPGNDRLLTPNEFEIKRSVDGEGYNVAQCNMTKDWFLVQMLANYNIGYQGFYIPESYKDRMYSFFRNFQPMSRQVVDDTKYKDYQQVGILHQHNNSGFVGYLAPTMREGQAYPANFPYPLIGKTAVDSITQKKFLCDRTLWRIPFSSNFMSMGALTDLGQNLLYANSAHALDMTFEVDPMDEPTLLYVLFEVFDVVRVHRPHRGVIETVYLRTPFSAGNATT

Pool of 236 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Gene therapy, Infection, Respiratory infection
125MoTif 125 HPV 18 (E7)

MHGPKATLQDIVLHLEPQNEIPVDLLCHEQLSDSEEENDEIDGVNHQHLPARRAEPQRHTMLCMCCKCEARIKLVVESSADDLRAFQQLFLNTLSFVCPWCASQQ

Pool of 24 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
126MoTif 126 HPV35 (E6)

MFQDPAERPYKLHDLCNEVEESIHEICLNCVYCKQELQRSEVYDFACYDLCIVYREGQPYGVCMKCLKFYSKISEYRWYRYSVYGETLEKQCNKQLCHLLIRCITCQKPLCPVEKQRHLEEKKRFHNIGGRWTGRCMSCWKPTRRETEV

Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
127MoTif 127 HPV58 (E7)

MRGNNPTLREYILDLHPEPTDLFCYEQLCDSSDEDEIGLDGPDGQAQPATANYYIVTCCYTCGTTVRLCINSTTTDVRTLQQLLMGTCTIVCPSCAQQ

Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
128MoTif 128 HPV16 (E4)

MADPAAATKYPLLKLLGSTWPTTPPRPIPKPSPWAPKKHRRLSSDQDQSQTPETPATPLSCCTETQWTVLQSSLHLTAHTKDGLTVIVTLHP

Pool of 21 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
129MoTif 129 HPV18 (E5)MLSLIFLFCFCVCMYVCCHVPLLPSVCMCAYAWVLVFVYIVVITSPATAFTVYVFCFLLPMLLLHIHAILSLQPool of 16 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
130MoTif 130 HPV 06 (E7)

MHGRHVTLKDIVLDLQPPDPVGLHCYEQLVDSSEDEVDEVDGQDSQPLKQHYQIVTCCCGCDSNVRLVVQCTETDIREVQQLLLGTLNIVCPICAPKT

Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%Cancer biomarker research, T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
131MoTif 131 HPV 31 (E6)

MFKNPAERPRKLHELSSALEIPYDELRLNCVYCKGQLTETEVLDFAFTDLTIVYRDDTPHGVCTKCLRFYSKVSEFRWYRYSVYGTTLEKLTNKGICDLLIRCITCQRPLCPEEKQRHLDKKKRFHNIGGRWTGRCIACWRRPRTETQV

Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
132MoTif 132 HPV33 (E7)

MRGHKPTLKEYVLDLYPEPTDLYCYEQLSDSSDEDEGLDRPDGQAQPATADYYIVTCCHTCNTTVRLCVNSTASDLRTIQQLLMGTVNIVCPTCAQQ

Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
133MoTif 133 HCoV-OC43 (NCAP)

MSFTPGKQSSSRASSGNRSGNGILKWADQSDQVRNVQTRGRRAQPKQTATSQQPSGGNVVPYYSWFSGITQFQKGKEFEFVEGQGPPIAPGVPATEAKGYWYRHNRGSFKTADGNQRQLLPRWYFYYLGTGPHAKDQYGTDIDGVYWVASNQADVNTPADIVDRDPSSDEAIPTRFPPGTVLPQGYYIEGSGRSAPNSRSTSRTSSRASSAGSRSRANSGNRTPTSGVTPDMADQIASLVLAKLGKDATKPQQVTKHTAKEVRQKILNKPRQKRSPNKQCTVQQCFGKRGPNQNFGGGEMLKLGTSDPQFPILAELAPTAGAFFFGSRLELAKVQNLSGNPDEPQKDVYELRYNGAIRFDSTLSGFETIMKVLNENLNAYQQQDGMMNMSPKPQRQRGHKNGQGENDNISVAVPKSRVQQNKSRELTAEDISLLKKMDEPYTEDTSEI

Pool of 110 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCommon cold, Covid-19, Infection, Respiratory infection
134MoTif 134 Influenza A (HA /California (H1N1))

MKAILVVLLYTFATANADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETPSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADAYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCNTTCQTPKGAINTSLPFQNIHPITIGKCPKYVKSTKLRLATGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQNAIDEITNKVNSVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRSQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNREEIDGVKLESTRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQCRICI

Pool of 139 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
135MoTif 135 Influenza A (Neuroamidase /California (H1N1)

MNPNQKIITIGSVCMTIGMANLILQIGNIISIWISHSIQLGNQNQIETCNQSVITYENNTWVNQTYVNISNTNFAAGQSVVSVKLAGNSSLCPVSGWAIYSKDNSVRIGSKGDVFVIREPFISCSPLECRTFFLTQGALLNDKHSNGTIKDRSPYRTLMSCPIGEVPSPYNSRFESVAWSASACHDGINWLTIGISGPDNGAVAVLKYNGIITDTIKSWRNNILRTQESECACVNGSCFTVMTDGPSNGQASYKIFRIEKGKIVKSVEMNAPNYHYEECSCYPDSSEITCVCRDNWHGSNRPWVSFNQNLEYQIGYICSGIFGDNPRPNDKTGSCGPVSSNGANGVKGFSFKYGNGVWIGRTKSISSRNGFEMIWDPNGWTGTDNNFSIKQDIVGINEWSGYSGSFVQHPELTGLDCIRPCFWVELIRGRPKENTIWTSGSSISFCGVNSDTVGWSWPDGAELPFTIDK

Pool of 115 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
136MoTif 136 Influenza A (HA/Indonesia (H5N1))

MEKIVLLLAIVSLVKSDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILEKTHNGKLCDLDGVKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKANPTNDLCYPGSFNDYEELKHLLSRINHFEKIQIIPKSSWSDHEASSGVSSACPYLGSPSFFRNVVWLIKKNSTYPTIKKSYNNTNQEDLLVLWGIHHPNDAAEQTRLYQNPTTYISIGTSTLNQRLVPKIATRSKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKGDSAIMKSELEYGNCNTKCQTPMGAINSSMPFHNIHPLTIGECPKYVKSNRLVLATGLRNSPQRESRRKKRGLFGAIAGFIEGGWQGMVDGWYGYHHSNEQGSGYAADKESTQKAIDGVTNKVNSIIDKMNTQFEAVGREFNNLERRIENLNKKMEDGFLDVWTYNAELLVLMENERTLDFHDSNVKNLYDKVRLQLRDNAKELGNGCFEFYHKCDNECMESIRNGTYNYPQYSEEARLKREEISGVKLESIGTYQILSIYSTVASSLALAIMIAGLSLWMCSNGSLQCRICI

Pool of 140 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
137MoTif 137 Human (Tyrosinase-related protein 2)

MSPLWWGFLLSCLGCKILPGAQGQFPRVCMTVDSLVNKECCPRLGAESANVCGSQQGRGQCTEVRADTRPWSGPYILRNQDDRELWPRKFFHRTCKCTGNFAGYNCGDCKFGWTGPNCERKKPPVIRQNIHSLSPQEREQFLGALDLAKKRVHPDYVITTQHWLGLLGPNGTQPQFANCSVYDFFVWLHYYSVRDTLLGPGRPYRAIDFSHQGPAFVTWHRYHLLCLERDLQRLIGNESFALPYWNFATGRNECDVCTDQLFGAARPDDPTLISRNSRFSSWETVCDSLDDYNHLVTLCNGTYEGLLRRNQMGRNSMKLPTLKDIRDCLSLQKFDNPPFFQNSTFSFRNALEGFDKADGTLDSQVMSLHNLVHSFLNGTNALPHSAANDPIFVVLHSFTDAIFDEWMKRFNPPADAWPQELAPIGHNRMYNMVPFFPPVTNEELFLTSDQLGYSYAIDLPVSVEETPGWPTTLLVVMGTLVALVGLFVLLAFLQYRRLRKGYTPLMETHLSSKRYTEEA

Pool of 127 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap))70%-90%Cancer biomarker research, T-cell immunityCancer
138MoTif 138 HIV-1 (Con B gag motif)See Sequences under Product DocumentationPool of 123 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityAIDS (HIV), HIV, Infection
139MoTif 139 Zaire Ebola (GP/Kikwit-95)

MGVTGILQLPRDRFKRTSFFLWVIILFQRTFSIPLGVIHNSTLQVSDVDKLVCRDKLSSTNQLRSVGLNLEGNGVATDVPSATKRWGFRSGVPPKVVNYEAGEWAENCYNLEIKKPDGSECLPAAPDGIRGFPRCRYVHKVSGTGPCAGDFAFHKEGAFFLYDRLASTVIYRGTTFAEGVVAFLILPQAKKDFFSSHPLREPVNATEDPSSGYYSTTIRYQATGFGTNETEYLFEVDNLTYVQLESRFTPQFLLQLNETIYTSGKRSNTTGKLIWKVNPEIDTTIGEWAFWETKKNLTRKIRSEELSFTAVSNRAKNISGQSPARTSSDPGTNTTTEDHKIMASENSSAMVQVHSQGREAAVSHLTTLATISTSPQPPTTKPGPDNSTHNTPVYKLDISEATQVEQHHRRTDNDSTASDTPPATTAAGPLKAENTNTSKGTDLLDPATTTSPQNHSETAGNNNTHHQDTGEESASSGKLGLITNTIAGVAGLITGGRRARREAIVNAQPKCNPNLHYWTTQDEGAAIGLAWIPYFGPAAEGIYTEGLMHNQDGLICGLRQLANETTQALQLFLRATTELRTFSILNRKAIDFLLQRWGGTCHILGPDCCIEPHDWTKNITDKIDQIIHDFVDKTLPDQGDNDNWWTGWRQWIPAGIGVTGVIIAVIALFCICKFVF

Pool of 167 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityEbola, Ebola fever, Infection
140MoTif 140 Human (Tyrosinase-related protein 1)

MSAPKLLSLGCIFFPLLLFQQARAQFPRQCATVEALRSGMCCPDLSPVSGPGTDRCGSSSGRGRCEAVTADSRPHSPQYPHDGRDDREVWPLRFFNRTCHCNGNFSGHNCGTCRPGWRGAACDQRVLIVRRNLLDLSKEEKNHFVRALDMAKRTTHPLFVIATRRSEEILGPDGNTPQFENISIYNYFVWTHYYSVKKTFLGVGQESFGEVDFSHEGPAFLTWHRYHLLRLEKDMQEMLQEPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPNSVFSQWRVVCDSLEDYDTLGTLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSNSTNSFRNTVEGYSDPTGKYDPAVRSLHNLAHLFLNGTGGQTHLSPNDPIFVLLHTFTDAVFDEWLRRYNADISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYTYEIQWPSREFSVPEIIAIAVVGALLLVALIFGTASYLIRARRSMDEANQPLLTDQYQCYAEEYEKLQNPNQSVV

Pool of 132 peptides derived from a peptide scan (Peptide Scan (15mers with 11aa overlap))70%-90%Cancer biomarker research, T-cell immunityCancer
141MoTif 141 SARS-CoV-2 (S-RBD BF.7)/Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap))70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
142MoTif 142 Human (PLAC1)

MKVFKFIGLMILLTSAFSAGSGQSPMTVLCSIDWFMVTVHPFMLNNDVCVHFHELHLGLGCPPNHVQPHAYQFTYRVTECGIRAKAVSQDMVIYSTEIHYSSKGTPSKFVIPVSCAAPQKSPWLTKPCSMRVASKSRATAQKDEKCYEVFSLSQSSQRPNCDCPPCVFSEEEHTQVPCHQAGAQEAQPLQPSHFLDISEDWSLHTDDMIGSM

Pool of 51 peptides derived from a peptide scan through Placenta-specific protein 1 (Swiss-Prot ID: Q9HBJ0) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer
143MoTif 143 EBV (BRLF1)

MRPKKDGLEDFLRLTPEIKKQLGSLVSDYCNVLNKEFTAGSVEITLRSYKICKAFINEAKAHGREWGGLMATLNICNFWAILRNNRVRRRAENAGNDACSIACPIVMRYVLDHLIVVTDRFFIQAPSNRVMIPATIGTAMYKLLKHSRVRAYTYSKVLGVDRAAIMASGKQVVEHLNRMEKEGLLSSKFKAFCKWVFTYPVLEEMFQTMVSSKTGHLTDDVKDVRALIKTLPRASYSSHAGQRSYVSGVLPACLLSTKSKAVETPILVSGADRMDEELMGNDGGASHTEARYSESGQFHAFTDELESLPSPTMPLKPGAQSADCGDSSSSSSDSGNSDTEQSEREEARAEAPRLRAPKSRRTSRPNRGQTPCPSNAAEPEQPWIAAVHQESDERPIFPHPSKPTFLPPVKRKKGLRDSREGMFLPKPEAGSAISDVFEGREVCQPKRIRPFHPPGSPWANRPLPASLAPTPTGPVHEPVGSLTPAPVPQPLDPAPAVTPEASHLLEDPDEETSQAVKALREMADTVIPQKEEAAICGQMDLSHPPPRGHLDELTTTLESMTEDLNLDSPLTPELNEILDTFLNDECLLHAMHISTGLSIFDTSLF

Pool of 149 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityAutoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma
144MoTif 144 EBV (EBNA1)

MSDEGPGTGPGNGLGEKGDTSGPEGSGGSGPQRRGGDNHGRGRGRGRGRGGGRPGAPGGSGSGPRHRDGVRRPQKRPSCIGCKGTHGGTGAGAGAGGAGAGGAGAGGGAGAGGGAGGAGGAGGAGAGGGAGAGGGAGGAGGAGAGGGAGAGGGAGGAGAGGGAGGAGGAGAGGGAGAGGGAGGAGAGGGAGGAGGAGAGGGAGAGGAGGAGGAGAGGAGAGGGAGGAGGAGAGGAGAGGAGAGGAGAGGAGGAGAGGAGGAGAGGAGGAGAGGGAGGAGAGGGAGGAGAGGAGGAGAGGAGGAGAGGAGGAGAGGGAGAGGAGAGGGGRGRGGSGGRGRGGSGGRGRGGSGGRRGRGRERARGGSRERARGRGRGRGEKRPRSPSSQSSSSGSPPRRPPPGRRPFFHPVGEADYFEYHQEGGPDGEPDVPPGAIEQGPADDPGEGPSTGPRGQGDGGRRKKGGWFGKHRGQGGSNPKFENIAEGLRALLARSHVERTTDEGTWVAGVFVYGGSKTSLYNLRRGTALAIPQCRLTPLSRLPFGMAPGPGPQPGPLRESIVCYFMVFLQTHIFAEVLKDAIKDLVMTKPAPTCNIRVTVCSFDDGVDLPPWFPPMVEGAAAEGDDGDDGDEGGDGDEGEEGQE

Pool of 158 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityAutoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma
145MoTif 145 EBV (EBNA2)

MPTFYLALHGGQTYHLIVDTDSLGNPSLSVIPSNPYQEQLSDTPLIPLTIFVGENTGVPPPLPPPPPPPPPPPPPPPPPPPPPPPPPPSPPPPPPPPPPPQRRDAWTQEPSPLDRDPLGYDVGHGPLASAMRMLWMANYIVRQSRGDRGLILPQGPQTAPQARLVQPHVPPLRPTAPTILSPLSQPRLTPPQPLMMPPRPTPPTPLPPATLTVPPRPTRPTTLPPTPLLTVLQRPTELQPTPSPPRMHLPVLHVPDQSMHPLTHQSTPNDPDSPEPRSPTVFYNIPPMPLPPSQLPPPAAPAQPPPGVINDQQLHHLPSGPPWWPPICDPPQPSKTQGQSRGQSRGRGRGRGRGRGKGKSRDKQRKPGGPWRPEPNTSSPSMPELSPVLGLHQGQGAGDSPTPGPSNAAPVCRNSHTATPNVSPIHEPESHNSPEAPILFPDDWYPPSIDPADLDESWDYIFETTESPSSDEDYVEGPSKRPRPSIQ

Pool of 119 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityAutoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma
146MoTif 146 HCMVA (IE-1)

MESSAKRKMDPDNPDEGPSSKVPRPETPVTKATTFLQTMLRKEVNSQLSLGDPLFPELAEESLKTFEQVTEDCNENPEKDVLAELVKQIKVRVDMVRHRIKEHMLKKYTQTEEKFTGAFNMMGGCLQNALDILDKVHEPFEEMKCIGLTMQSMYENYIVPEDKREMWMACIKELHDVSKGAANKLGGALQAKARAKKDELRRKMMYMCYRNIEFFTKNSAFPKTTNGCSQAMAALQNLPQCSPDEIMAYAQKIFKILDEERDKVLTHIDHIFMDILTTCVETMCNEYKVTSDACMMTMYGGISLLSEFCRVLCCYVLEETSVMLAKRPLITKPEVISVMKRRIEEICMKVFAQYILGADPLRVCSPSVDDLRAIAEESDEEEAIVAYTLATAGVSSSDSLVSPPESPVPATIPLSSVIVAENSDQEESEQSDEEEEEGAQEEREDTVSVKSEPVSEIEEVAPEEEEDGAEEPTASGGKSTHPMVTRSKADQ

Pool of 120 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityControl, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections
147MoTif 147 HCMVA (UL82)

MSQASSSPGEGPSSEAAAISEAEAASGSFGRLHCQVLRLITNVEGGSLEAGRLRLLDLRTNIEVSRPSVLCCFQENKSPHDTVDLTDLNIKGRCVVGEQDRLLVDLNNFGPRRLTPGSENNTVSVLAFALPLDRVPVSGLHLFQSQRRGGEENRPRMEARAIIRRTAHHWAVRLTVTPNWRRRTDSSLEAGQIFVSQFAFRAGAIPLTLVDALEQLACSDPNTYIHKTETDERGQWIMLFLHHDSPHPPTSVFLHFSVYTHRAEVVARHNPYPHLRRLPDNGFQLLIPKSFTLTRIHPEYIVQIQNAFETNQTHDTIFFPENIPGVSIEAGPLPDRVRITLRVTLTGDQAVHLEHRQPLGRIHFFRRGFWTLTPGKPDKIKRPQVQLRAGLFPRSNVMRGAVSEFLPQSPGLPPTEEEEEEEEEDDEDDLSSTPTPTPLSEAMFAGFEEASGDEDSDTQAGLSPALILTGQRRRSGNNGALTLVIPSWHVFASLDDLVPLTVSVQHAALRPTSYLRSDMDGDVRTAADISSTLRSVPAPRPSPISTASTSSTPRSRPRI

Pool of 137 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections
148MoTif 148 HCMVA (UL99)

MGAELCKRICCEFGTTPGEPLKDALGRQVSLRSYDNIPPTSSSDEGEDDDDGEDDDNEERQQKLRLCGSGCGGNDSSSGSHREATHDGSKKNAVRSTFREDKAPKPSKQSKKKKKPSKHHHHQQSSIMQETDDLDEEDTSIYLSPPPVPPVQVVAKRLPRPDTPRTPRQKKISQRPPTPGTKKPAASLPF

Pool of 45 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections
149MoTif 149 EBV (BARF1)

MARFIAQLLLLASCVAAGQAVTAFLGERVTLTSYWRRVSLGPEIEVSWFKLGPGEEQVLIGRMHHDVIFIEWPFRGFFDIHRSANTFFLVVTAANISHDGNYLCRMKLGETEVTKQEHLSVVKPLTLSVHSERSQFPDFSVLTVTCTVNAFPHPHVQWLMPEGVEPAPTAANGGVMKEKDGSLSVAVDLSLPKPWHLPVTCVGKNDKEEAHGVYVSGYLSQ

Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityAutoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma
150MoTif 150 Human (MAGEA3)

MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQEAASSSSTLVEVTLGEVPAAESPDPPQSPQGASSLPTTMNYPLWSQSYEDSSNQEEEGPSTFPDLESEFQAALSRKVAELVHFLLLKYRAREPVTKAEMLGSVVGNWQYFFPVIFSKASSSLQLVFGIELMEVDPIGHLYIFATCLGLSYDGLLGDNQIMPKAGLLIIVLAIIAREGDCAPEEKIWEELSVLEVFEGREDSILGDPKKLLTQHFVQENYLEYRQVPGSDPACYEFLWGPRALVETSYVKVLHHMVKISGGPHISYPPLHEWVLREGEE

Pool of 76 peptides derived from a peptide scan through Melanoma-associated antigen (MAGE) (Swiss-Prot ID: P43357) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer, Melanoma
151MoTif 151 Human (MAGEA10)

MPRAPKRQRCMPEEDLQSQSETQGLEGAQAPLAVEEDASSSTSTSSSFPSSFPSSSSSSSSSCYPLIPSTPEEVSADDETPNPPQSAQIACSSPSVVASLPLDQSDEGSSSQKEESPSTLQVLPDSESLPRSEIDEKVTDLVQFLLFKYQMKEPITKAEILESVIRNYEDHFPLLFSEASECMLLVFGIDVKEVDPTGHSFVLVTSLGLTYDGMLSDVQSMPKTGILILILSIVFIEGYCTPEEVIWEALNMMGLYDGMEHLIYGEPRKLLTQDWVQENYLEYRQVPGSDPARYEFLWGPRAHAEIRKMSLLKFLAKVNGSDPRSFPLWYEEALKDEEERAQDRIATTDDTTAMASASSSATGSFSYPE

Pool of 90 peptides derived from a peptide scan through Melanoma-associated antigen 10 (Swiss-Prot ID: P43363) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer, Melanoma, Prostate cancer
152MoTif 152 Human (MAGEA9)

MSLEQRSPHCKPDEDLEAQGEDLGLMGAQEPTGEEEETTSSSDSKEEEVSAAGSSSPPQSPQGGASSSISVYYTLWSQFDEGSSSQEEEEPSSSVDPAQLEFMFQEALKLKVAELVHFLLHKYRVKEPVTKAEMLESVIKNYKRYFPVIFGKASEFMQVIFGTDVKEVDPAGHSYILVTALGLSCDSMLGDGHSMPKAALLIIVLGVILTKDNCAPEEVIWEALSVMGVYVGKEHMFYGEPRKLLTQDWVQENYLEYRQVPGSDPAHYEFLWGSKAHAETSYEKVINYLVMLNAREPICYPSLYEEVLGEEQEGV

Pool of 76 peptides derived from a peptide scan through Melanoma-associated antigen (MAGE) (Swiss-Prot ID: P43362) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer, Melanoma
153MoTif 153 Human (ACTL8)

MAARTVIIDHGSGFLKAGTAGWNEPQMVFPNIVNYLPCKENPGPSYARRRVSLGIDICHPDTFSYPIERGRILNWEGVQYLWSFVLENHRREQEVPPVIITETPLREPADRKKMLEILFELLHVPSVLLADQLQMSLYASGLLTGVVVDSGYGLTRVQPFHQGRPLPASGKTLEFAGQDLSAYLLKSLFKEDCDRRCLFQLETVAVTQMNKCYVPQNLGEALDFRERQQSALDESNTYQLPDGSRVELTPMQRVAPEMFFSPQVFEQPGPSIPRAIVESVESCEISLRPLLVSHVMACGGNTLYPGFTKRLFRELMGDHVSSTKATVWEGSNRNFSVWLGASVVAHLSTYQSEWMSREEYGEHMRM

Pool of 89 peptides derived from a peptide scan through Actin-like protein 8 (Swiss-Prot ID: Q9H568) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer, Epithelium
154MoTif 154 Human (MAGEC2)

MPPVPGVPFRNVDNDSPTSVELEDWVDAQHPTDEEEEEASSASSTLYLVFSPSSFSTSSSLILGGPEEEEVPSGVIPNLTESIPSSPPQGPPQGPSQSPLSSCCSSFSWSSFSEESSSQKGEDTGTCQGLPDSESSFTYTLDEKVAELVEFLLLKYEAEEPVTEAEMLMIVIKYKDYFPVILKRAREFMELLFGLALIEVGPDHFCVFANTVGLTDEGSDDEGMPENSLLIIILSVIFIKGNCASEEVIWEVLNAVGVYAGREHFVYGEPRELLTKVWVQGHYLEYREVPHSSPPYYEFLWGPRAHSESIKKKVLEFLAKLNNTVPSSFPSWYKDALKDVEERVQATIDTADDATVMASESLSVMSSNVSFSE

Pool of 91 peptides derived from a peptide scan (Peptide Scan (15mers with 11aa overlap))70%-90%Cancer biomarker research, T-cell immunityCancer, Melanoma
155MoTif 155 HCoV-229E (NCAP)

MATVKWADASEPQRGRQGRIPYSLYSPLLVDSEQPWKVIPRNLVPINKKDKNKLIGYWNVQKRFRTRKGKRVDLSPKLHFYYLGTGPHKDAKFRERVEGVVWVAVDGAKTEPTGYGVRRKNSEPEIPHFNQKLPNGVTVVEEPDSRAPSRSQSRSQSRGRGESKPQSRNPSSDRNHNSQDDIMKAVAAALKSLGFDKPQEKDKKSAKTGTPKPSRNQSPASSQTSAKSLARSQSSETKEQKHEMQKPRWKRQPNDDVTSNVTQCFGPRDLDHNFGSAGVVANGVKAKGYPQFAELVPSTAAMLFDSHIVSKESGNTVVLTFTTRVTVPKDHPHLGKFLEELNAFTREMQQHPLLNPSALEFNPSQTSPATAEPVRDEVSIETDIIDEVN

Pool of 95 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCommon cold, Covid-19, Infection, Respiratory infection
156MoTif 156 Influenza A (MP2 /California (H1N1))

MSLLTEVETPTRSEWECRCSDSSDPLVIAANIIGILHLILWITDRLFFKCIYRRFKYGLKRGPSTEGVPESMREEYQQEQQSAVDVDDGHFVNIELE

Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
157MoTif 157 EBV (EBNA-LP)

MGDRSEGPGPTRPGPPGIGPEGPLGQLLRRHRSPSPTRGGQEPRRVRRRVLVQQEEEVVSGSPSGPRGDRSEGPGPTRPGPPGIGPEGPLGQLLRRHRSPSPTRGGQEPRRVRRRVLVQQEEEVVSGSPSGPRGDRSEGPGPTRPGPPGIGPEGPLGQLLRRHRSPSPTRGGQEPRRVRRRVLVQQEEEVVSGSPSGPRGDRSEGPGPTRPGPPGIGPEGPLGQLLRRHRSPSPTRGGQEPRRVRRRVLVQQEEEVVSGSPSGPRGDRSEGPGPTRPGPPGIGPEGPLGQLLRRHRSPSPTRGGQEPRRVRRRVLVQQEEEVVSGSPSGPRGDRSEGPGPTRPGPPGIGPEGPLGQLLRRHRSPSPTRGGQEPRRVRRRVLVQQEEEVVSGSPSGPRGDRSEGPGPTRPGPPGIGPEGPLGQLLRRHRSPSPTRGGQEPRRVRRRVLVQQEEEVVSGSPSGPLRPRPRPPARSLREWLLRIRDHFEPPTVTTQRQSVYIEEEEDED

Pool of 124 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityAutoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma
158MoTif 158 ZIKV (E) Ultra

Envelope protein E based on the following polyprotein sequences:  AMC33116.1 (Martinique); AMC13913. (Guatemala); AMC13912.1 (Guatemala); AMC13911.1 (Puerto Rico); AMB37295.1 (Haiti); AMA12087.1 (Brazil); AMA12086.1 (Brazil); AMA12085.1 (Brazil); AMA12084.1 (Brazil); ALX35659.1 (Suriname); AHL37808.1 (Canada); AHZ13508.1 (French Polynesia); AFD30972.1 (Cambodia); ACD75819.1 (Micronesia); ALU33341.1 (Brazil) Country of sample origin is given in parentheses if available. All sequences are completely covered.

Pool of 146 peptides derived from a peptide scan (15mers) through Envelope protein of ZIKA virus (ZIKV).70%-90%T-cell immunityInfection, Microcephaly, Sequence diversity, ZIKA fever, Zika virus disease
159MoTif 159 HBV (LEP) Ultrasee additional product documentationPool of 121 peptides derived from a peptide scan (selected 15mers) through Large envelope protein of Hepatitis B Virus (HBV).70%-90%T-cell immunityHepatitis, Infection, Sequence diversity
160MoTif 160 HRSVA (Matrix Protein)

METYVNKLHEGSTYTAAVQYNVLEKDDDPASLTIWVPMFQSSMPADLLIKELANVNILVKQISTPKGPSLRVMINSRSAVLA

QMPSKFTICANVSLDERSKLAYDVTTPCEIKACSLTCLKSKNMLTTVKDLTMKTLNPTHDIIALCEFENIVTSKKVIIPTYLRSISV

RNKDLNTLENITTTEFKNAITNAKIIPYSGLLLVITVTDNKGAFKYIKPQSQFIVDLGAYLEKESIYYVTTNWKHTATRFAIKPMED

Pool of 62 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Opportunistic infections, Respiratory infection
161MoTif 161 Human (FJX1)

MGRRMRGAAATAGLWLLALGSLLALWGGLLPPRTELPASRPPEDRLPRRPARSGGPAPAPRFPLPPPLAWDARGGSLKTFR

ALLTLAAGADGPPRQSRSEPRWHVSARQPRPEESAAVHGGVFWSRGLEEQVPPGFSEAQAAAWLEAARGARMVALERGG

CGRSSNRLARFADGTRACVRYGINPEQIQGEALSYYLARLLGLQRHVPPLALARVEARGAQWAQVQEELRAAHWTEGSVVS

LTRWLPNLTDVVVPAPWRSEDGRLRPLRDAGGELANLSQAELVDLVQWTDLILFDYLTANFDRLVSNLFSLQWDPRVMQRA

TSNLHRGPGGALVFLDNEAGLVHGYRVAGMWDKYNEPLLQSVCVFRERTARRVLELHRGQDAAARLLRLYRRHEPRFPELAA

LADPHAQLLQRRLDFLAKHILHCKAKYGRRSGT

Pool of 107 peptides derived from a peptide scan through Four-jointed box protein 1 (Swiss-Prot ID: Q86VR8) of Human.70%-90%Cancer biomarker research, T-cell immunityFreeze-dried in glass vial
162MoTif 162 SARS-CoV-2 (Spike P.1 / Gamma)

MFVFLVLLPLVSSQCVNFTNRTQLPSAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNYPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLSEFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGTIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAAIKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASFVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

Peptide scan through the entire Spike glycoprotein of SARS-CoV-2 P.1, (Severe Acute Respiratory Syndrome-related coronavirus 2, Lineage P.1, Brazil) covering the following mutations: L0018F, T0020N, P0026S, D0138Y, R0190S, K0417T, E0484K, N0501Y, D0614G, H0655Y, T1027I, V1176F.70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
163MoTif 163 SARS-CoV-2 (Spike BA.2.75.2)

MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSS

VLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFN

DGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKV

CEFQFCNDPFLDVYYHENNKSRMESELRVYSSANNCTFEYV

SQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPVNLG

RDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSS

WTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSET

KCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFHEVFN

ATTFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPT

KLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPD

DFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSKLKPFERDIS

TEIYQAGNKPCNGVAGSNCYFPLQSYGFRPTYGVGHQPYRV

VVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVL

TESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGV

SVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVY

STGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTK

SHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVT

TEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRA

LTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPS

KPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQK

FNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPF

AMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSS

TASALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDILSR

LDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATK

MSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPA

QEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP

QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFK

NHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLINLQ

ELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLK

GCCSCGSCCKFDEDDSEPVLKGVKLHYT

Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
164MoTif 164 CyCMV (TP-UL83)

MALSQRYRLDYVSELGPIAGKVIQSVFDEAREPVKPHETKIVKT

GLRVQVHRPSIIFLTQFARNLKPDPRYEHNTLQIKHTTFEDQEL

KDVYLHVHNPTDKPITPADEPMSFFLYALPLRHLVLADLTLHPG

GTYNPELPTYDAAVQAFAQGYHTRFNAYHLQWTQRYNRWM

PHGVHHTASFYVNTSPMPLWSINVANELVCSLRNTHVRKVQL

VDKVKGLVRIFLESFQEETPDDKVFVHLAWEQSNGVITMNRNP

KPFLTPQQRNGYTILNPKRLHLKPREHANVMIDTYFESDKYIGFI

CPKSVPGCSISCNPIMPTQCIFIEIRSLHDSVYIEAFQAIASLHFFD

RSLFFTYKKTDHSIFKDQYRVTTSFEYHQGKGVPIVQDSSEDDD

SSSSESEDMDVFEVASTTPHAGTSSSSSASKKREKLYKPLVQRKR

FTEDDGARKSSSDDDNDDFFPTLFWGVWQFGVRASELTPMIA

SVCGDQLPHQEFSWEGDDDLRIFSGLSGSWHMYQTPKRRHYS

PSEQLPSTSGESVSKRPCE

Pool of 133 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Infectious mononucleosis
165MoTif 165 Human (Cyclin-B1)

MALRVTRNSKINAENKAKINMAGAKRVPTAPAATSKPGLRPRT

ALGDIGNKVSEQLQAKMPMKKEAKPSATGKVIDKKLPKPLEKV

PMLVPVPVSEPVPEPEPEPEPEPVKEEKLSPEPILVDTASPSPMET

SGCAPAEEDLCQAFSDVILAVNDVDAEDGADPNLCSEYVKDIY

AYLRQLEEEQAVRPKYLLGREVTGNMRAILIDWLVQVQMKFRL

LQETMYMTVSIIDRFMQNNCVPKKMLQLVGVTAMFIASKYEE

MYPPEIGDFAFVTDNTYTKHQIRQMEMKILRALNFGLGRPLPL

HFLRRASKIGEVDVEQHTLAKYLMELTMLDYDMVHFPPSQIAA

GAFCLALKILDNGEWTPTLQHYLSYTEESLLPVMQHLAKNVVM

VNQGLTKHMTVKNKYATSKHAKISTLPQLNS

ALVQDLAKAVAKV

Pool of 106 peptides derived from a peptide scan through G2/mitotic-specific cyclin-B1 (Swiss-Prot ID: P14635) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer
166MoTif 166 Human (NKX3-1)

MLRVPEPRPGEAKAEGAAPPTPSKPLTSFLIQDILRDGAQRQGG

RTSSQRQRDPEPEPEPEPEGGRSRAGAQNDQLSTGPRAAPEEA

ETLAETEPERHLGSYLLDSENTSGALPRLPQTPKQPQKRSRAAFS

HTQVIELERKFSHQKYLSAPERAHLAKNLKLTETQVKIWFQNRR

YKTKRKQLSSELGDLEKHSSLPALKEEAFSRASLVSVYNSYPYYPY

LYCVGSWSPAFW

Pool of 56 peptides derived from a peptide scan through Homeobox protein Nkx-3.1 (Swiss-Prot ID: Q99801) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer, Prostate cancer
167MoTif 167 Human (PD-L1)

MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPV

EKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARL

LKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKV

NAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQ

VLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEEN

HTAELVIPELPLAHPPNERTHLVILGAILLCLGVALTFIFRLRKGRM

MDVKKCGIQDTNSKKQSDTHLEET

Pool of 70 peptides derived from a peptide scan through Programmed cell death 1 ligand (Swiss-Prot ID: Q9NZQ7) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer, Immune checkpoint
168MoTif 168 Human (ErbB2_ICD)

LVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPN

QAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKV

LRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQL

MPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLV

HRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIK

WMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREI

PDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFS

RMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDAE

EYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEP

SEEEAPRSPLAPSEGAGSDVFDGDLGMGAAKGLQSLPTHDPSPLQ

RYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDVRPQPPSPREG

PLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ

GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAE

NPEYLGLDVPV

Pool of 146 peptides derived from a peptide scan through ErbB-2 receptor tyrosin-protein kinase (Swiss-Prot ID: P04626, region: 663-1255) of Human.70%-90%Cancer biomarker research, T-cell immunityBreast cancer, Cancer, Gastric cancer, Glioma, Malignant genital cancers
169MoTif 169 HIV-1 (NEF) Ultrasee additional product documentationPool of 150 peptides derived from a peptide scan (Selected immunogenic peptides (15mers)) through Nef protein (NEF) of Human Immunodeficiency Virus (HIV).70%-90%AIDS (HIV), HIV, Infection, Sequence diversityT-cell immunity
170MoTif 170 HAdV-5 (penton protein)

MRRAAMYEEGPPPSYESVVSAAPVAAALGSPFDAPLDPPFVP

PRYLRPTGGRNSIRYSELAPLFDTTRVYLVDNKSTDVASLNYQN

DHSNFLTTVIQNNDYSPGEASTQTINLDDRSHWGGDLKTILHT

NMPNVNEFMFTNKFKARVMVSRLPTKDNQVELKYEWVEFTL

PEGNYSETMTIDLMNNAIVEHYLKVGRQNGVLESDIGVKFDTR

NFRLGFDPVTGLVMPGVYTNEAFHPDIILLPGCGVDFTHSRLSN

LLGIRKRQPFQEGFRITYDDLEGGNIPALLDVDAYQASLKDDTE

QGGGGAGGSNSSGSGAEENSNAAAAAMQPVEDMNDHAIR

GDTFATRAEEKRAEAEAAAEAAAPAAQPEVEKPQKKPVIKPLTE

DSKKRSYNLISNDSTFTQYRSWYLAYNYGDPQTGIRSWTLLCTP

DVTCGSEQVYWSLPDMMQDPVTFRSTRQISNFPVVGAELLPV

HSKSFYNDQAVYSQLIRQFTSLTHVFNRFPENQILARPPAPTITT

VSENVPALTDHGTLPLRNSIGGVQRVTITDARRRTCPYVYKALG

IVSPRVLSSRTF

Pool of 140 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Gene therapy, Infection, Respiratory infection
171MoTif 171 HCMVA (UL151)

MVFVSGTALGTGFHRAEGSFCGCEGRSFFRTLGTGLGDGGCA

GRRWXRXVAGTGITLGTGTRGPGLRDGGDGGVCGEDGGLLR

RGRGLAGPAVAGVCGDGGLLQRRGLRGQECAXPGGFAGGH

GTGGGGDSTNHTHTQLTSAVALSEPPLFFINVLIPPAYTRNAAC

SYAHTLSLHSDMLLRLCTAAADTSGHRHLPPHMAHVLRRPAS

YVVCSQHGAFFPARHLHRTPSAAFAVASTREQYATACAVAAAT

WPPRLPHLFRTPNLWLPTTDVQGSRTRRPIPPILQRPRPPSQTS

WKPTQTQHSIDARPRCCATSSSPATPNAALPTEPHPRGLP

Pool of 82 peptides derived from a peptide scan (15mers with 11 aa overlap - X = synthesized as A)70%-90%T-cell immunityCancer, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections
172MoTif 172 HSV2 (gD)

MGRLTSGVGTAALLVVAVGLRVVCAKYALADPSLKMADPNRF

RGKNLPVLDQLTDPPGVKRVYHIQPSLEDPFQPPSIPITVYYAV

LERACRSVLLHAPSEAPQIVRGASDEARKHTYNLTIAWYRMG

DNCAIPITVMEYTECPYNKSLGVCPIRTQPRWSYYDSFSAVSED

NLGFLMHAPAFETAGTYLRLVKINDWTEITQFILEHRARASCKY

ALPLRIPPAACLTSKAYQQGVTVDSIGMLPRFIPENQRTVALYS

LKIAGWHGPKPPYTSTLLPPELSDTTNATQPELVPEDPEDSALL

EDPAGTVSSQIPPNWHIPSIQDVAPHHAPAAPSNPGLIIGALA

GSTLAVLVIGGIAFWVRRRAQMAPKRLRLPHIRDDDAPPSHQ

PLFY

Pool of 96 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Encephalitis, Genital herpes, Infection, Oral Herpes
173MoTif 173 Influenza A (NP (H3N2))

MASQGTKRSYEQMETDGERQNATEIRASVGKMIDGIGRFYIQ

MCTELKLSDYEGRLIQNSLTIERMVLSAFDERRNRYLEEHPSAG

KDPKKTGGPIYKRVDGRWMRELVLYDKEEIRRIWRQANNGDD

ATAGLTHMMIWHSNLNDTTYQRTRALVRTGMDPRMCSLMQ

GSTLPRRSGAAGAAVKGIGTMVMELIRMIKRGINDRNFWRGE

NGRKTRSAYERMCNILKGKFQTAAQRAMMDQVRESRNPGN

AEIEDLIFSARSALILRGSVAHKSCLPACVYGPAVSSGYNFEKEGY

SLVGIDPFKLLQNSQVYSLIRPNENPAHKSQLVWMACHSAAFE

DLRLLSFIRGTKVSPRGKLSTRGVQIASNENMDNMESSTLELRS

RYWAIRTRSGGNTNQQRASAGQISVQPTFSVQRNLPFEKSTV

MAAFTGNTEGRTSDMRAEIIRMMEGAKPEEVSFRGRGVFELSD

EKATNPIVPSFDMSNEGSYFFGDNAEEYDN

Pool of 122 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
174MoTif 174 HPV 18 (L1)

MCLYTRVLILHYHLLPLYGPLYHPRPLPLHSILVYMVHIIICGHYIIL

FLRNVNVFPIFLQMALWRPSDNTVYLPPPSVARVVNTDDYVTP

TSIFYHAGSSRLLTVGNPYFRVPAGGGNKQDIPKVSAYQYRVFR

VQLPDPNKFGLPDTSIYNPETQRLVWACAGVEIGRGQPLGVGL

SGHPFYNKLDDTESSHAATSNVSEDVRDNVSVDYKQTQLCILG

CAPAIGEHWAKGTACKSRPLSQGDCPPLELKNTVLEDGDMVDT

GYGAMDFSTLQDTKCEVPLDICQSICKYPDYLQMSADPYGDSM

FFCLRREQLFARHFWNRAGTMGDTVPQSLYIKGTGMPASPGSC

VYSPSPSGSIVTSDSQLFNKPYWLHKAQGHNNGVCWHNQLFV

TVVDTTPSTNLTICASTQSPVPGQYDATKFKQYSRHVEEYDLQFI

FQLCTITLTADVMSYIHSMNSSILEDWNFGVPPPPTTSLVDTYRF

VQSVAITCQKDAAPAENKDPYDKLKFWNVDLKEKFSLDLDQYP

LGRKFLVQAGLRRKPTIGPRKRSAPSATTSSKPAKRVRVRARK

Pool of 140 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
175MoTif 175 HPV 06 (E6)

MESANASTSATTIDQLCKTFNLSMHTLQINCVFCKNALTTAEIYS

YAYKQLKVLFRGGYPYAACACCLEFHGKINQYRHFDYAGYATTV

EEETKQDILDVLIRCYLCHKPLCEVEKVKHILTKARFIKLNCTWKG

RCLHCWTTCMEDMLP

Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%Cancer biomarker research, T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
176MoTif 176 HPV 18 (E6)

MARFEDPTRRPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEF

AFKDLFVVYRDSIPHAACHKCIDFYSRIRELRHYSDSVYGDTLEKL

TNTGLYNLLIRCLRCQKPLNPAEKLRHLNEKRRFHNIAGHYRGQ

CHSCCNRARQERLQRRRETQV

Pool of 37 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
177MoTif 177 HPV 11 (E6)

MESKDASTSATSIDQLCKTFNLSLHTLQIQCVFCRNALTTAEIYAY

AYKNLKVVWRDNFPFAACACCLELQGKINQYRHFNYAAYAPTV

EEETNEDILKVLIRCYLCHKPLCEIEKLKHILGKARFIKLNNQWKGR

CLHCWTTCMEDLLP

Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap) through Protein E6 (Swiss-Prot ID: P04019) of Human Papillomavirus (HPV).70%-90%Cancer biomarker research, T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
178MoTif 178 HCMVA (UL151)

MVFVSGTALGTGFHRAEGSFCGCEGRSFFRTLGTGLGDGGCAGR

RWXRXVAGTGITLGTGTRGPGLRDGGDGGVCGEDGGLLRRGRG

LAGPAVAGVCGDGGLLQRRGLRGQECAXPGGFAGGHGTGGGG

DSTNHTHTQLTSAVALSEPPLFFINVLIPPAYTRNAACSYAHTLSL

HSDMLLRLCTAAADTSGHRHLPPHMAHVLRRPASYVVCSQHG

AFFPARHLHRTPSAAFAVASTREQYATACAVAAATWPPRLPHLFR

TPNLWLPTTDVQGSRTRRPIPPILQRPRPPSQTSWKPTQTQHSID

ARPRCCATSSSPATPNAALPTEPHPRGLP

Pool of 82 peptides derived from a peptide scan (15mers with 11 aa overlap - X = synthesized as A)70%-90%T-cell immunityCancer, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections
179MoTif 179 BKV (capsid protein VP2)

MGAALALLGDLVASVSEAAAATGFSVAEIAAGEAAAAIEVQIASLA

TVEGITSTSEAIAAIGLTPQTYAVIAGAPGAIAGFAALIQTVSGISSLA

QVGYRFFSDWDHKVSTVGLYQQSGMALELFNPDEYYDILFPGVN

TFVNNIQYLDPRHWGPSLFATISQALWHVIRDDIPSITSQELQRRT

ERFFRDSLARFLEETTWTIVNAPINFYNYIQQYYSDLSPIRPSMVRQ

VAEREGTRVHFGHTYSIDDADSIEEVTQRMDLRNQQSVHSGEFIE

KTIAPGGANQRTAPQWMLPLLLGLYGTVTPALEAYEDGPNQKKRR

VSRGSSQKAKGTRASAKTTNKRRSRSSRS

Pool of 85 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Merkel cell carcinoma, Nephritis, interstitial
180MoTif 180 Influenza B (HA/H0N0/Austria/2021)

MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP

LTTTPTKSHFANLKGTETRGKLCPKCLNCTDLDVALGRPKCTGKIPS

ARVSILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEHVRLSTHNV

INTEDAPGGPYEIGTSGSCLNITNGKGFFATMAWAVPKNKTATNPL

TIEVPYICTEEEDQITVWGFHSDDETQMARLYGDSKPQKFTSSANG

VTTHYVSQIGGFPNQTEDGGLPQSGRIVVDYMVQKSGKTGTITYQ

RGILLPQKVWCASGKSKVIKGSLPLIGEADCLHEKYGGLNKSKPYYT

GEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIAGFLE

GGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSL

SELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAVLLS

NEGIINSEDEHLLALERKLKKMLGPSAVEIGNGCFETKHKCNQTCLD

RIAAGTFDAGEFSLPTFDSLNITAASLNDDGLDNHTILLYYSTAASSL

AVTLMIAIFVVYMVSRDNVSCSICL

Pool of 143 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
181MoTif 181 HSV2 (gD)

MGRLTSGVGTAALLVVAVGLRVVCAKYALADPSLKMADPNRFRG

KNLPVLDQLTDPPGVKRVYHIQPSLEDPFQPPSIPITVYYAVLERAC

RSVLLHAPSEAPQIVRGASDEARKHTYNLTIAWYRMGDNCAIPITV

MEYTECPYNKSLGVCPIRTQPRWSYYDSFSAVSEDNLGFLMHAPA

FETAGTYLRLVKINDWTEITQFILEHRARASCKYALPLRIPPAACLTSK

AYQQGVTVDSIGMLPRFIPENQRTVALYSLKIAGWHGPKPPYTSTL

LPPELSDTTNATQPELVPEDPEDSALLEDPAGTVSSQIPPNWHIPSI

QDVAPHHAPAAPSNPGLIIGALAGSTLAVLVIGGIAFWVRRRAQM

APKRLRLPHIRDDDAPPSHQPLFY

Pool of 96 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Encephalitis, Genital herpes, Infection, Oral Herpes
182MoTif 182 SARS-CoV-2 (Spike HK.3)

MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLH

STHDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPALPFNDGVYFAS

TEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFL

DVYQKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKEGN

FKNLREFVFKNIDGYFKIYSKHTPINLERDLPQGFSALEPLVDLPIGI

NITRFQTLLALHRSYLTPVDSSSGWTAGAAAYYVGYLQPRTFLLKY

NENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTES

IVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNF

APFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTG

NIADYNYKLPDDFTGCVIAWNSNKLDSKPSGNYNYLYRFLRKSK

LKPFERDISTEIYQAGNKPCNGVAGPNCYSPLQSYGFRPTYGVGH

QPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTG

VLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVS

VITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGS

NVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTKSHRRAR

SVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMT

KTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKN

TQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFN

KVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEM

IAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQ

NVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQ

ALNTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSL

QTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH

LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPRE

GVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNT

VYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK

EIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAI

VMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLH

YT

Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
183MoTif 183 SARS-CoV-2 (Spike JG.3)

MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHS

THDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPALPFNDGVYFASTE

KSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVY

QKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKEGNFKNL

REFVFKNIDGYFKIYSKHTPINLERDLPQGFSALEPLVDLPIGINITRFQ

TLLALHRSYLTPVDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTIT

DAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNL

CPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAPFFAFKCYGV

SPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDF

TGCVIAWNSNKLDSKPSGNYNYLYRFLRKSKLKPFERDISTEIYQAGN

KPCNGVAGPNCYSPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPAT

VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIA

DTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCT

EVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIP

IGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENLVAYSNNSIAI

PTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQL

KRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKP

SKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVL

PPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNG

IGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHN

AQALNTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQ

TYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSF

PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNG

THWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDS

FKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES

LIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLK

GCCSCGSCCKFDEDDSEPVLKGVKLHYT

Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
184MoTif 184 SARS-CoV-2 (Spike JN.1)

MFVFLVLLPLVSSQCVMPLFNLITTTQSYTNSFTRGVYYPDKVFRSSV

LHLTQDLFLPFFSNVTWFHAISGTNGTKRFDNPVLPFNDGVYFASTE

KSNIIRGWIFGTTLDSKTQSLLIVNNATNVFIKVCEFQFCNDPFLDVYH

KNNKSWMESESGVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLRE

FVFKNIDGYFKIYSKHTPIIGRDFPQGFSALEPLVDLPIGINITRFQTLLA

LNRSYLTPGDSSSGWTAGAADYYVGYLQPRTFLLKYNENGTITDAVD

CALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNVTNLCPFH

EVFNATRFASVYAWNRTRISNCVADYSVLYNFAPFFAFKCYGVSPTKL

NDLCFTNVYADSFVIKGNEVRQIAPGQTGNIADYNYKLPDDFTGCVI

AWNSNKLDSKHSGNYDYWYRSFRKSKLKPFERDISTEIYQAGNKPC

KGKGPNCYFPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPK

KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIVDTTDA

VRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVSVA

IHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGV

CASYQTQTKSRRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNF

TISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRAL

TGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRS

FIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLL

TDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGV

TQNVLYENQKLIANQFNSAIGKIQDSLFSTASALGKLQDVVNHNAQ

ALNTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQT

YVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSF

PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSN

GTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQLEL

DSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNL

NESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCC

SCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
185MoTif 185 HPV 18 (L1)

MCLYTRVLILHYHLLPLYGPLYHPRPLPLHSILVYMVHIIICGHYIILFLRN

VNVFPIFLQMALWRPSDNTVYLPPPSVARVVNTDDYVTPTSIFYHAG

SSRLLTVGNPYFRVPAGGGNKQDIPKVSAYQYRVFRVQLPDPNKFGLP

DTSIYNPETQRLVWACAGVEIGRGQPLGVGLSGHPFYNKLDDTESSHA

ATSNVSEDVRDNVSVDYKQTQLCILGCAPAIGEHWAKGTACKSRPLSQ

GDCPPLELKNTVLEDGDMVDTGYGAMDFSTLQDTKCEVPLDICQSICK

YPDYLQMSADPYGDSMFFCLRREQLFARHFWNRAGTMGDTVPQSLY

IKGTGMPASPGSCVYSPSPSGSIVTSDSQLFNKPYWLHKAQGHNNGV

CWHNQLFVTVVDTTPSTNLTICASTQSPVPGQYDATKFKQYSRHVEEY

DLQFIFQLCTITLTADVMSYIHSMNSSILEDWNFGVPPPPTTSLVDTYRF

VQSVAITCQKDAAPAENKDPYDKLKFWNVDLKEKFSLDLDQYPLGRKF

LVQAGLRRKPTIGPRKRSAPSATTSSKPAKRVRVRARK

Pool of 140 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
186MoTif 186 HPV 06 (E6)

MESANASTSATTIDQLCKTFNLSMHTLQINCVFCKNALTTAEIYSYAYK

QLKVLFRGGYPYAACACCLEFHGKINQYRHFDYAGYATTVEEETKQDIL

DVLIRCYLCHKPLCEVEKVKHILTKARFIKLNCTWKGRCLHCWTTCME

DMLP

Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%Cancer biomarker research, T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
187MoTif 187 HPV 18 (E6)

MARFEDPTRRPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKD

LFVVYRDSIPHAACHKCIDFYSRIRELRHYSDSVYGDTLEKLTNTGLYNL

LIRCLRCQKPLNPAEKLRHLNEKRRFHNIAGHYRGQCHSCCNRARQE

RLQRRRETQV

Pool of 37 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
188MoTif 188 HPV 11 (E6)

MESKDASTSATSIDQLCKTFNLSLHTLQIQCVFCRNALTTAEIYAYAYKN

LKVVWRDNFPFAACACCLELQGKINQYRHFNYAAYAPTVEEETNEDILK

VLIRCYLCHKPLCEIEKLKHILGKARFIKLNNQWKGRCLHCWTTCMEDLLP

Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap) through Protein E6 (Swiss-Prot ID: P04019) of Human Papillomavirus (HPV).70%-90%Cancer biomarker research, T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
189MoTif 189 HPV 16 (E6)

MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVY

DFAFRDLCIVYRDGNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNK

PLCDLLIRCINCQKPLCPEEKQRHLDKKQRFHNIRGRWTGRCMSCCRSSR

TRRETQL

Pool of 37 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
190MoTif 190 HPV 16 (E7)

MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDGPAGQAE

PDRAHYNIVTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP

Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
191MoTif 191 HPV18 (E4)

MADPEVPVTTRYPLLSLLNSYSTPPHRIPAPCPWAPQRPTARRRLLHD

LDTVDSRRSSIVDLSTHFSVQLHLQATTKDGNSVVVTLRL

Pool of 20 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
192MoTif 192 HPV16 (E2)

METLCQRLNVCQDKILTHYENDSTDLRDHIDYWKHMRLECAIYYKARE

MGFKHINHQVVPTLAVSKNKALQAIELQLTLETIYNSQYSNEKWTLQDV

SLEVYLTAPTGCIKKHGYTVEVQFDGDICNTMHYTNWTHIYICEEASVTV

VEGQVDYYGLYYVHEGIRTYFVQFKDDAEKYSKNKVWEVHAGGQVILCP

TSVFSSNEVSSPEIIRQHLANHPAATHTKAVALGTEETQTTIQRPRSEPDTG

NPCHTTKLLHRDSVDSAPILTAFNSSHKGRINCNSNTTPIVHLKGDANTL

KCLRYRFKKHCTLYTAVSSTWHWTGHNVKHKSAIVTLTYDSEWQRDQF

LSQVKIPKTITVSTGFMSI

Pool of 89 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
193MoTif 193 HSV2 (R1)

MANRPAASALAGARSPSERQEPREPEVAPPGGDHVFCRKVSGVMVLSS

DPPGPAAYRISDSSFVQCGSNCSMIIDGDVARGHLRDLEGATSTGAFVAI

SNVAAGGDGRTAVVALGGTSGPSATTSVGTQTSGEFLHGNPRTPEPQGP

QAVPPPPPPPFPWGHECCARRDARGGAEKDVGAAESWSDGPSSDSET

EDSDSSDEDTGSETLSRSSSIWAAGATDDDDSDSDSRSDDSVQPDVVV

RRRWSDGPAPVAFPKPRRPGDSPGNPGLGAGTGPGSATDPRASADSDS

AAHAAAPQADVAPVLDSQPTVGTDPGYPVPLELTPENAEAVARFLGDAV

DREPALMLEYFCRCAREESKRVPPRTFGSAPRLTEDDFGLLNYALAEMRR

LCLDLPPVPPNAYTPYHLREYATRLVNGFKPLVRRSARLYRILGVLVHLRIR

TREASFEEWMRSKEVDLDFGLTERLREHEAQLMILAQALNPYDCLIHSTP

NTLVERGLQSALKYEEFYLKRFGGHYMESVFQMYTRIAGFLACRATRGM

RHIALGRQGSWWEMFKFFFHRLYDHQIVPSTPAMLNLGTRNYYTSSCY

LVNPQATTNQATLRAITGNVSAILARNGGIGLCMQAFNDASPGTASIMP

ALKVLDSLVAAHNKQSTRPTGACVYLEPWHSDVRAVLRMKGVLAGEEA

QRCDNIFSALWMPDLFFKRLIRHLDGEKNVTWSLFDRDTSMSLADFHG

EEFEKLYEHLEAMGFGETIPIQDLAYAIVRSAATTGSPFIMFKDAVNRHYIY

DTQGAAIAGSNLCTEIVHPASKRSSGVCNLGSVNLARCVSRQTFDFGRLR

DAVQACVLMVNIMIDSTLQPTPQCTRGNDNLRSMGIGMQGLHTACLK

MGLDLESAEFRDLNTHIAEVMLLAAMKTSNALCVRGARPFSHFKRSMYR

AGRFHWERFSNASPRYEGEWEMLRQSMMKHGLRNSQFIALMPTAASAQ

ISDVSEGFAPLFTNLFSKVTRDGETLRPNTLLLKELERTFGGKRLLDAMDGL

EAKQWSVAQALPCLDPAHPLRRFKTAFDYDQELLIDLCADRAPYVDHSQS

MTLYVTEKADGTLPASTLVRLLVHAYKRGLKTGMYYCKVRKATNSGVFAGD

DNIVCTSCAL

Pool of 283 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Encephalitis, Genital herpes, Infection, Oral Herpes
194MoTif 194 HPV45 (E6)

MARFDDPKQRPYKLPDLCTELNTSLQDVSIACVYCKATLERTEVYQFAFKD

LCIVYRDCIAYAACHKCIDFYSRIRELRYYSNSVYGETLEKITNTELYNLLIRCL

RCQKPLNPAEKRRHLKDKRRFHSIAGQYRGQCNTCCDQARQERLRRRRE

TQV

Pool of 37 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
195MoTif 195 HPV45 (E7)

MHGPRETLQEIVLHLEPQNELDPVDLLCYEQLSESEEENDEADGVSHAQL

PARRAEPQRHKILCVCCKCDGRIELTVESSAEDLRTLQQLFLSTL

SFVCPWCATNQ

Pool of 24 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
196MoTif 196 HPV 18 (L2)

MVSHRAARRKRASVTDLYKTCKQSGTCPPDVVPKVEGTTLADKILQWSSL

GIFLGGLGIGTGSGTGGRTGYIPLGGRSNTVVDVGPTRPPVVIEPVGPTDPS

IVTLIEDSSVVTSGAPRPTFTGTSGFDITSAGTTTPAVLDITPSSTSVSISTTNF

TNPAFSDPSIIEVPQTGEVAGNVFVGTPTSGTHGYEEIPLQTFASSGTGEEPIS

STPLPTVRRVAGPRLYSRAYQQVSVANPEFLTRPSSLITYDNPAFEPVDTTLT

FDPRSDVPDSDFMDIIRLHRPALTSRRGTVRFSRLGQRATMFTRSGTQIGAR

VHFYHDISPIAPSPEYIELQPLVSATEDNDLFDIYADDMDPAVPVPSRSTTSF

AFFKYSPTISSASSYSNVTVPLTSSWDVPVYTGPDITLPSTTSVWPIVSPTAPA

STQYIGIHGTHYYLWPLYYFIPKKRKRVPYFFADGFVAA

Pool of 113 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
197MoTif 197 HPV 52 (E7)

MRGDKATIKDYILDLQPETTDLHCYEQLGDSSDEEDTDGVDRPDGQAEQ

ATSNYYIVTYCHSCDSTLRLCIHSTATDLRTLQQMLLGTLQVVCPGCARL

Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
198MoTif 198 HPV58 (E6)

MFQDAEEKPRTLHDLCQALETSVHEIELKCVECKKTLQRSEVYDFVFADLRIV

YRDGNPFAVCKVCLRLLSKISEYRHYNYSLYGDTLEQTLKKCLNEILIRCIICQR

PLCPQEKKRHVDLNKRFHNISGRWTGRCAVCWRPRRRQTQV

Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
199MoTif 199 HPV35 (E7)

MHGEITTLQDYVLDLEPEATDLYCYEQLCDSSEEEEDTIDGPAGQAKPDTSN

YNIVTSCCKCEATLRLCVQSTHIDIRKLEDLLMGTFGIVCPGCSQRA

Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
200MoTif 200 HPV33 (E6)

MFQDTEEKPRTLHDLCQALETTIHNIELQCVECKKPLQRSEVYDFAFADLTVVY

REGNPFGICKLCLRFLSKISEYRHYNYSVYGNTLEQTVKKPLNEILIRCIICQRPLC

PQEKKRHVDLNKRFHNISGRWAGRCAACWRSRRRETAL

Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
201MoTif 201 Collection Papillomavirus5 different HPV PepMixes + 2 Controls (15mers, overlap 11)Collection of 5 peptide pools derived from scans (overlapping peptides scans, 15mers with 11 aa overlap)70%-90%Cancer biomarker research, T-cell immunityCancer, Genital malignancies, Malignant genital cancers
202MoTif 202 Marburgvirus (GP/Angola-05)

MKTTCLLISLILIQGVKTLPILEIASNIQPQNVDSVCSGTLQKTEDVHLMGFTLSG

QKVADSPLEASKRWAFRAGVPPKNVEYTEGEEAKTCYNISVTDPSGKSLLLDPP

TNIRDYPKCKTIHHIQGQNPHAQGIALHLWGAFFLYDRIASTTMYRGKVFTEGN

IAAMIVNKTVHKMIFSRQGQGYRHMNLTSTNKYWTSSNGTQTNDTGCFGTLQ

EYNSTKNQTCAPSKKPLPLPTAHPEVKLTSTSTDATKLNTTDPNSDDEDLTTSGS

GSGEQEPYTTSDAATKQGLSSTMPPTPSPQPSTPQQGGNNTNHSQGVVTEPG

KTNTTAQPSMPPHNTTTISTNNTSKHNLSTPSVPIQNATNYNTQSTAPENEQTS

APSKTTLLPTENPTTAKSTNSTKSPTTTVPNTTNKYSTSPSPTPNSTAQHLVYFRR

KRNILWREGDMFPFLDGLINAPIDFDPVPNTKTIFDESSSSGASAEEDQHASPNI

SLTLSYFPKVNENTAHSGENENDCDAELRIWSVQEDDLAAGLSWIPFFGPGIEGL

YTAGLIKNQNNLVCRLRRLANQTAKSLELLLRVTTEERTFSLINRHAIDFLLARWG

GTCKVLGPDCCIGIEDLSRNISEQIDQIKKDEQKEGTGWGLGGKWWTSDWGVL

TNLGILLLLSIAVLIALSCICRIFTKYIG

Pool of 169 peptides derived from a peptide scan (15mers with 11 aa overlap) t70%-90%T-cell immunityInfection, Marburg Disease, Marburg virus disease
203MoTif 203 Human (Melan-A/MART-1)

MPREDAHFIYGYPKKGHGHSYTTAEEAAGIGILTVILGVLLLIGCWYCRRRNGYR

ALMDKSLHVGTQCALTRRCPQEGFDHRDSKVSLQEKNCEPVVPNAPPAYEKLS

AEQSPPPYSP

Pool of 27 peptides derived from a peptide scan through Melanoma antigen recognized by T-cells 1 (MART-1) (Swiss-Prot ID: Q16655) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer, Melanoma
204MoTif 204 Human (NY-ESO-1)

MQAEGRGTGGSTGDADGPGGPGIPDGPGGNAGGPGEAGATGGRGPRGAGA

ARASGPGGGAPRGPHGGAASGLNGCCRCGARGPESRLLEFYLAMPFATPMEA

ELARRSLAQDAPPLPVPGVLLKEFTVSGNILTIRLTAADHRQLQLSISSCLQQLSLL

MWITQCFLPVFLAQPPSGQRR

Pool of 43 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap))70%-90%Cancer biomarker research, T-cell immunityCancer, Malignant genital cancers
205MoTif 205 Yellow fever (NS4B)

NELGMLEKTKEDLFGKKNLIPSSASPWSWPDLDLKPGAAWTVYVGIVTMLSPM

LHHWIKVEYGNLSLSGIAQSASVLSFMDKGIPFMKMNISVIMLLVSGWNSITVM

PLLCGIGCAMLHWSLILPGIKAQQSKLAQRRVFHGVAENPVVDGNPTVDIEEAP

EMPALYEKKLALYLLLALSLASVAMCRTPFSLAEGIVLASAALGPLIEGNTSLLWNG

PMAVSMTGVMRGNHYAFVGVMYNLWKMKTGRR

Pool of 60 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Yellow Fever
206MoTif 206 Influenza A (NP (H3N2))

MASQGTKRSYEQMETDGERQNATEIRASVGKMIDGIGRFYIQMCTELKLSDYEG

RLIQNSLTIERMVLSAFDERRNRYLEEHPSAGKDPKKTGGPIYKRVDGRWMRELV

LYDKEEIRRIWRQANNGDDATAGLTHMMIWHSNLNDTTYQRTRALVRTGMDP

RMCSLMQGSTLPRRSGAAGAAVKGIGTMVMELIRMIKRGINDRNFWRGENGR

KTRSAYERMCNILKGKFQTAAQRAMMDQVRESRNPGNAEIEDLIFSARSALILRG

SVAHKSCLPACVYGPAVSSGYNFEKEGYSLVGIDPFKLLQNSQVYSLIRPNENPAH

KSQLVWMACHSAAFEDLRLLSFIRGTKVSPRGKLSTRGVQIASNENMDNMESST

LELRSRYWAIRTRSGGNTNQQRASAGQISVQPTFSVQRNLPFEKSTVMAAFTGN

TEGRTSDMRAEIIRMMEGAKPEEVSFRGRGVFELSDEKATNPIVPSFDMSNEGSY

FFGDNAEEYDN

Pool of 122 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
207MoTif 207 SARS-CoV-2 (Spike EG.5.1)

MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTHDLFLPFFS

NVTWFHAIHVSGTNGTKRFDNPALPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQ

SLLIVNNATNVVIKVCEFQFCNDPFLDVYQKNNKSWMESEFRVYSSANNCTFEY

VSQPFLMDLEGKEGNFKNLREFVFKNIDGYFKIYSKHTPINLERDLPQGFSALEPLV

DLPIGINITRFQTLLALHRSYLTPVDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGT

ITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFHEVF

NATTFASVYAWNRKRISNCVADYSVIYNFAPFFAFKCYGVSPTKLNDLCFTNVYAD

SFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKPSGNYNYLY

RLLRKSKLKPFERDISTEIYQAGNKPCNGVAGPNCYSPLQSYGFRPTYGVGHQPYR

VVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQF

GRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVP

VAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQ

TKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTS

VDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKT

PPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDL

ICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAY

RFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQAL

NTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAE

IRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQ

EKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNC

DVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE

IDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTS

CCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

Pool of 315 (158 + 157) peptides derived from a peptide scan (Peptide Scan (15mers with 11 aa overlap) - including a few 13 - 17mers)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
208MoTif 208 Human (HILPDA)MKHVLNLYLLGVVLTLLSIFVRVMESLEGLLESPSPGTSWTTRSQLANTEPTKGLPDHPSRSMPool of 13 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityHypoxia, Metabolism
209MoTif 209 SARS-CoV-2 (VME1 B.1.1.529 / BA.1 / Omicron)

MAGSNGTITVEELKKLLEEWNLVIGFLFLTWICLLQFAYANRNRFLYIIKLIFLWLL

WPVTLTCFVLAAVYRINWITGGIAIAMACLVGLMWLSYFIASFRLFARTRSMWS

FNPETNILLNVPLHGTILTRPLLESELVIGAVILRGHLRIAGHHLGRCDIKDLPKEIT

VATSRTLSYYKLGASQRVAGDSGFAAYSRYRIGNYKLNTDHSSSSDNIALLVQ

Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
210MoTif 210 SARS-CoV-2 (Spike EG.5.1)

MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTHDLFLPF

FSNVTWFHAIHVSGTNGTKRFDNPALPFNDGVYFASTEKSNIIRGWIFGTTLDS

KTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYQKNNKSWMESEFRVYSSANN

CTFEYVSQPFLMDLEGKEGNFKNLREFVFKNIDGYFKIYSKHTPINLERDLPQGF

SALEPLVDLPIGINITRFQTLLALHRSYLTPVDSSSGWTAGAAAYYVGYLQPRTFL

LKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNI

TNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAPFFAFKCYGVSPTKL

NDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNK

LDSKPSGNYNYLYRLLRKSKLKPFERDISTEIYQAGNKPCNGVAGPNCYSPLQSY

GFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGT

GVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTS

NQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNN

SYECDIPIGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIP

TNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAV

EQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLA

DAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSG

WTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLS

STASALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQID

RLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHL

MSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHW

FVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKN

HTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWP

WYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGV

KLHYT

Pool of 315 (158 + 157) peptides derived from a peptide scan (Peptide Scan (15mers with 11 aa overlap) - including a few 13 - 17mers)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
211MoTif 211 HSV2 (gD)

MGRLTSGVGTAALLVVAVGLRVVCAKYALADPSLKMADPNRFRGKNLPVLD

QLTDPPGVKRVYHIQPSLEDPFQPPSIPITVYYAVLERACRSVLLHAPSEAPQI

VRGASDEARKHTYNLTIAWYRMGDNCAIPITVMEYTECPYNKSLGVCPIRTQ

PRWSYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKINDWTEITQFILEHRA

RASCKYALPLRIPPAACLTSKAYQQGVTVDSIGMLPRFIPENQRTVALYSLKIA

GWHGPKPPYTSTLLPPELSDTTNATQPELVPEDPEDSALLEDPAGTVSSQIPP

NWHIPSIQDVAPHHAPAAPSNPGLIIGALAGSTLAVLVIGGIAFWVRRRAQM

APKRLRLPHIRDDDAPPSHQPLFY

Pool of 96 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Encephalitis, Genital herpes, Infection, Oral Herpes
212MoTif 212 Borrelia (OspA protein) Ultrasee additional product documentationPool of 200 peptides derived from a peptide scan (Selected immunogenic peptides (15mers))70%-90%T-cell immunityInfection, Lyme disease, Sequence diversity
213MoTif 213 Influenza A (HA/Hong Kong/1/1968 (H3N2))

MKTIIALSYIFCLALGQDLPGNDNSTATLCLGHHAVPNGTLVKTITDDQIEVTN

ATELVQSSSTGKICNNPHRILDGIDCTLIDALLGDPHCDVFQNETWDLFVERS

KAFSNCYPYDVPDYASLRSLVASSGTLEFITEGFTWTGVTQNGGSNACKRGP

GSGFFSRLNWLTKSGSTYPVLNVTMPNNDNFDKLYIWGVHHPSTNQEQTS

LYVQASGRVTVSTRRSQQTIIPNIGSRPWVRGLSSRISIYWTIVKPGDVLVINS

NGNLIAPRGYFKMRTGKSSIMRSDAPIDTCISECITPNGSIPNDKPFQNVNKI

TYGACPKYVKQNTLKLATGMRNVPEKQTRGLFGAIAGFIENGWEGMIDGW

YGFRHQNSEGTGQAADLKSTQAAIDQINGKLNRVIEKTNEKFHQIEKEFSEV

EGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTRRQL

RENAEDMGNGCFKIYHKCDNACIESIRNGTYDHDVYRDEALNNRFQIKGVE

LKSGYKDWILWISFAISCFLLCVVLLGFIMWACQRGNIRCNICI

Pool of 139 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
214MoTif 214 SARS-CoV-2 (S-RBD EG.5.1)

RVQPTESIVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAP

FFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPD

DFTGCVIAWNSNKLDSKPSGNYNYLYRLLRKSKLKPFERDISTEIYQAGNKPCN

GVAGPNCYSPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLV

KNKCVNF

Pool of 53 peptides derived from a peptide scan (Peptide Scan (15mers with 11 aa overlap))70%-90%T-cell immunityCovid-19
215MoTif 215 HPV 16 (E6)

MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAF

RDLCIVYRDGNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRC

INCQKPLCPEEKQRHLDKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL

Pool of 37 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
216MoTif 216 HPV 18 (E6)

MARFEDPTRRPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDLFVVYR

DSIPHAACHKCIDFYSRIRELRHYSDSVYGDTLEKLTNTGLYNLLIRCLRCQKPLNP

AEKLRHLNEKRRFHNIAGHYRGQCHSCCNRARQERLQRRRETQV

Pool of 37 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
217MoTif 217 HPV 52 (E7)

MRGDKATIKDYILDLQPETTDLHCYEQLGDSSDEEDTDGVDRPDGQAEQATSN

YYIVTYCHSCDSTLRLCIHSTATDLRTLQQMLLGTLQVVCPGCARL

Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
218MoTif 218 HPV 16 (E7)

MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDGPAGQAEPDRAHYNI

VTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP

Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
219MoTif 219 HSV2 (R1)

MANRPAASALAGARSPSERQEPREPEVAPPGGDHVFCRKVSGVMVLSSDPPGPA

AYRISDSSFVQCGSNCSMIIDGDVARGHLRDLEGATSTGAFVAISNVAAGGDGRTA

VVALGGTSGPSATTSVGTQTSGEFLHGNPRTPEPQGPQAVPPPPPPPFPWGHECC

ARRDARGGAEKDVGAAESWSDGPSSDSETEDSDSSDEDTGSETLSRSSSIWAAGA

TDDDDSDSDSRSDDSVQPDVVVRRRWSDGPAPVAFPKPRRPGDSPGNPGLGAG

TGPGSATDPRASADSDSAAHAAAPQADVAPVLDSQPTVGTDPGYPVPLELTPENA

EAVARFLGDAVDREPALMLEYFCRCAREESKRVPPRTFGSAPRLTEDDFGLLNYALA

EMRRLCLDLPPVPPNAYTPYHLREYATRLVNGFKPLVRRSARLYRILGVLVHLRIRTRE

ASFEEWMRSKEVDLDFGLTERLREHEAQLMILAQALNPYDCLIHSTPNTLVERGLQS

ALKYEEFYLKRFGGHYMESVFQMYTRIAGFLACRATRGMRHIALGRQGSWWEMFK

FFFHRLYDHQIVPSTPAMLNLGTRNYYTSSCYLVNPQATTNQATLRAITGNVSAILAR

NGGIGLCMQAFNDASPGTASIMPALKVLDSLVAAHNKQSTRPTGACVYLEPWHSD

VRAVLRMKGVLAGEEAQRCDNIFSALWMPDLFFKRLIRHLDGEKNVTWSLFDRDT

SMSLADFHGEEFEKLYEHLEAMGFGETIPIQDLAYAIVRSAATTGSPFIMFKDAVNRH

YIYDTQGAAIAGSNLCTEIVHPASKRSSGVCNLGSVNLARCVSRQTFDFGRLRDAVQ

ACVLMVNIMIDSTLQPTPQCTRGNDNLRSMGIGMQGLHTACLKMGLDLESAEFRD

LNTHIAEVMLLAAMKTSNALCVRGARPFSHFKRSMYRAGRFHWERFSNASPRYEG

EWEMLRQSMMKHGLRNSQFIALMPTAASAQISDVSEGFAPLFTNLFSKVTRDGETL

RPNTLLLKELERTFGGKRLLDAMDGLEAKQWSVAQALPCLDPAHPLRRFKTAFDYD

QELLIDLCADRAPYVDHSQSMTLYVTEKADGTLPASTLVRLLVHAYKRGLKTGMYYC

KVRKATNSGVFAGDDNIVCTSCAL

Pool of 283 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Encephalitis, Genital herpes, Infection, Oral Herpes
220MoTif 220 HPV35 (E7)

MHGEITTLQDYVLDLEPEATDLYCYEQLCDSSEEEEDTIDGPAGQAKPDTSNYNIV

TSCCKCEATLRLCVQSTHIDIRKLEDLLMGTFGIVCPGCSQRA

Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap) through Protein E7 (Swiss-Prot ID: P27230) of Human Papillomavirus (HPV) - type 35.70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
221MoTif 221 HPV45 (E6)

MARFDDPKQRPYKLPDLCTELNTSLQDVSIACVYCKATLERTEVYQFAFKDLCIVYRD

CIAYAACHKCIDFYSRIRELRYYSNSVYGETLEKITNTELYNLLIRCLRCQKPLNPAEKRR

HLKDKRRFHSIAGQYRGQCNTCCDQARQERLRRRRETQV

Pool of 37 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
222MoTif 222 HPV45 (E7)

MHGPRETLQEIVLHLEPQNELDPVDLLCYEQLSESEEENDEADGVSHAQLPARRAEP

QRHKILCVCCKCDGRIELTVESSAEDLRTLQQLFLSTLSFVCPWCATNQ

Pool of 24 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
223MoTif 223 HPV45 (E7)

MHGPRETLQEIVLHLEPQNELDPVDLLCYEQLSESEEENDEADGVSHAQLPARRAEP

QRHKILCVCCKCDGRIELTVESSAEDLRTLQQLFLSTLSFVCPWCATNQ

Pool of 24 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
224MoTif 224 HPV58 (E6)

MFQDAEEKPRTLHDLCQALETSVHEIELKCVECKKTLQRSEVYDFVFADLRIVYRDGNP

FAVCKVCLRLLSKISEYRHYNYSLYGDTLEQTLKKCLNEILIRCIICQRPLCPQEKKRHVDL

NKRFHNISGRWTGRCAVCWRPRRRQTQV

Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
225MoTif 225 HPV16 (E2)

METLCQRLNVCQDKILTHYENDSTDLRDHIDYWKHMRLECAIYYKAREMGFKHINHQ

VVPTLAVSKNKALQAIELQLTLETIYNSQYSNEKWTLQDVSLEVYLTAPTGCIKKHGYTVE

VQFDGDICNTMHYTNWTHIYICEEASVTVVEGQVDYYGLYYVHEGIRTYFVQFKDDAE

KYSKNKVWEVHAGGQVILCPTSVFSSNEVSSPEIIRQHLANHPAATHTKAVALGTEETQ

TTIQRPRSEPDTGNPCHTTKLLHRDSVDSAPILTAFNSSHKGRINCNSNTTPIVHLKGDA

NTLKCLRYRFKKHCTLYTAVSSTWHWTGHNVKHKSAIVTLTYDSEWQRDQFLSQVKIP

KTITVSTGFMSI

Pool of 89 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
226MoTif 226 HPV18 (E4)

MADPEVPVTTRYPLLSLLNSYSTPPHRIPAPCPWAPQRPTARRRLLHDLDTVDSRRSSI

VDLSTHFSVQLHLQATTKDGNSVVVTLRL

Pool of 20 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
227MoTif 227 HPV 06 (E6)

MESANASTSATTIDQLCKTFNLSMHTLQINCVFCKNALTTAEIYSYAYKQLKVLFRGGYPY

AACACCLEFHGKINQYRHFDYAGYATTVEEETKQDILDVLIRCYLCHKPLCEVEKVKHILTK

ARFIKLNCTWKGRCLHCWTTCMEDMLP

Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%Cancer biomarker research, T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
228MoTif 228 HPV 11 (E6)

MESKDASTSATSIDQLCKTFNLSLHTLQIQCVFCRNALTTAEIYAYAYKNLKVVWRDNFPF

AACACCLELQGKINQYRHFNYAAYAPTVEEETNEDILKVLIRCYLCHKPLCEIEKLKHILGKA

RFIKLNNQWKGRCLHCWTTCMEDLLP

Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%Cancer biomarker research, T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
229MoTif 229 HPV33 (E6)

MFQDTEEKPRTLHDLCQALETTIHNIELQCVECKKPLQRSEVYDFAFADLTVVYREGNPFG

ICKLCLRFLSKISEYRHYNYSVYGNTLEQTVKKPLNEILIRCIICQRPLCPQEKKRHVDLNKRF

HNISGRWAGRCAACWRSRRRETAL

Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Genital malignancies, Infection, Malignant genital cancers
230MoTif 230 Borrelia (OspA protein) Ultrasee additional product documentationPool of 200 peptides derived from a peptide scan (Selected immunogenic peptides (15mers))70%-90%T-cell immunityInfection, Lyme disease, Sequence diversity
231MoTif 231 Human (HMHA1)

MFSRKKRELMKTPSISKKNRAGSPSPQPSGELPRKDGADAVFPGPSLEPPAGSSGVKATG

TLKRPTSLSRHASAAGFPLSGAASWTLGRSHRSPLTAASPGELPTEGAGPDVVEDISHLLA

DVARFAEGLEKLKECVLRDDLLEARRPRAHECLGEALRVMHQIISKYPLLNTVETLTAAGTL

IAKVKAFHYESNNDLEKQEFEKALETIAVAFSSTVSEFLMGEVDSSTLLAVPPGDSSQSMES

LYGPGSEGTPPSLEDCDAGCLPAEEVDVLLQRCEGGVDAALLYAKNMAKYMKDLISYLEKR

TTLEMEFAKGLQKIAHNCRQSVMQEPHMPLLSIYSLALEQDLEFGHSMVQAVGTLQTQTF

MQPLTLRRLEHEKRRKEIKEAWHRAQRKLQEAESNLRKAKQGYVQRCEDHDKARFLVAK

AEEEQAGSAPGAGSTATKTLDKRRRLEEEAKNKAEEAMATYRTCVADAKTQKQELEDTKV

TALRQIQEVIRQSDQTIKSATISYYQMMHMQTAPLPVHFQMLCESSKLYDPGQQYASHVR

QLQRDQEPDVHYDFEPHVSANAWSPVMRARKSSFNVSDVARPEAAGSPPEEGGCTEGT

PAKDHRAGRGHQVHKSWPLSISDSDSGLDPGPGAGDFKKFERTSSSGTMSSTEELVDPD

GGAGASAFEQADLNGMTPELPVAVPSGPFRHEGLSKAARTHRLRKLRTPAKCRECNSYV

YFQGAECEECCLACHKKCLETLAIQCGHKKLQGRLQLFGQDFSHAARSAPDGVPFIVKKC

VCEIERRALRTKGIYRVNGVKTRVEKLCQAFENGKELVELSQASPHDISNVLKLYLRQLPEPL

ISFRLYHELVGLAKDSLKAEAEAKAASRGRQDGSESEAVAVALAGRLRELLRDLPPENRASL

QYLLRHLRRIVEVEQDNKMTPGNLGIVFGPTLLRPRPTEATVSLSSLVDYPHQARVIETLIV

HYGLVFEEEPEETPGGQDESSNQRAEVVVQVPYLEAGEAVVYPLQEAAADGCRESRVVS

NDSDSDLEEASELLSSSEASALGHLSFLEQQQSEASLEVASGSHSGSEEQLEATAREDGDG

DEDGPAQQLSGFNTNQSNNVLQAPLPPMRLRGGRMTLGSCRERQPEFV

Pool of 282 peptides derived from a peptide scan through Minor histocompatibility protein HA-1 (Swiss-Prot ID: Q92619) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer
232MoTif 232 EBV (BMRF1)

METTQTLRFKTKALAVLSKCYDHAQTHLKGGVLQVNLLSVNYGGPRLAAVANAGTAGLIS

FEVSPDAVAEWQNHQSPEEAPAAVSFRNLAYGRTCVLGKELFGSAVEQASLQFYKRPQG

GSRPEFVKLTMEYDDKVSKSHHTCALMPYMPPASDRLRNEQMIGQVLLMPKTASSLQK

WARQQGSGGVKVTLNPDLYVTTYTSGEACLTLDYKPLSVGPYEAFTGPVAKAQDVGAVE

AHVVCSVAADSLAAALSLCRIPAVSVPILRFYRSGIIAVVAGLLTSAGDLPLDLSVILFNHAS

EEAAASTASEPEDKSPRVQPLGTGLQQRPRHTVSPSPSPPPPPRTPTWESPARPETPSPAIP

SHSSNTALERPLAVQLARKRTSSEARQKQKHPKKVKQAFNPLI

Pool of 99 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityAutoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma
233MoTif 233 EBV (EBNA3a)

MDKDRPGPPALDDNMEEEVPSTSVVQEQVSAGDWENVLIELSDSSSEKEAEDAHLEPAQ

KGTKRKRVDHDAGGSAPARPMLPPQPDLPGREAILRRFPLDLRTLLQAIGAAATRIDTRAID

QFFGSQISNTEMYIMYAMAIRQAIRDRRRNPASRRDQAKWRLQTLAAGWPMGYQAYSS

WMYSYTDHQTTPTFVHLQATLGCTGGRRCHVTFSAGTFKLPRCTPGDRQWLYVQSSVGN

IVQSCNPRYSIFFDYMAIHRSLTKIWEEVLTPDQRVSFMEFLGFLQRTDLSYIKSFVSDALGTT

SIQTPWIDDNPSTETAQAWNAGFLRGRAYGIDLLRTEGEHVEGATGETREESEDTESDGDD

EDLPCIVSRGGPKVKRPPIFIRRLHRLLLMRAGKRTEQGKEVLEKARGSTYGTPRPPVPKPRP

EVPQSDETATSHGSAQVPEPPTIHLAAQGMAYPLHEQHGMAPCPVAQAPPTPLPPVSPG

DQLPGVFSDGRVACAPVPAPAGPIVRPWEPSLTQAAGQAFAPVRPQHMPVEPVPVPTVA

LERPVYPKPVRPAPPKIAMQGPGETSGIRRARERWRPAPWTPNPPRSPSQMSVRDRLARL

RAEAQVKQASVEVQPPQLTQVSPQQPMEGPLVPEQQMFPGAPFSQVADVVRAPGVPAM

QPQYFDLPLIQPISQGAPVAPLRASMGPVPPVPATQPQYFDIPLTEPINQGASAAHFLPQQP

MEGPLVPEQWMFPGAALSQSVRPGVAQSQYFDLPLTQPINHGAPAAHFLHQPPMEGPW

VPEQWMFQGAPPSQGTDVVQHQLDALGYTLHGLNHPGVPVSPAVNQYHLSQAAFGLPI

DEDESGEGSDTSEPCEALDLSIHGRPCPQAPEWPVQEEGGQDATEVLDLSIHGRPRPRTPE

WPVQGEGGQNVTGPETRRVVVSAVVHMCQDDEFPDLQDPPDEA

Pool of 234 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityAutoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma
234MoTif 234 EBV (EBNA3b)

MKKAWLSRAQQADAGGASGSEDPPDYGDQGNVQQVGSDPISPAIGPFELSAASEDDPQ

SGPVEENLDAAAREEEEPDEQEHNGGDDPLEVHTRQPRFVDVNPTQAPVIQLVHAVYDS

MLQSDLRSLGSLFLEQNLNIEEFIWMCMTVRHRCQAIRQKPLPIDKQRRWKLLSPYRTWR

MGYRTQTLNVNSFETGGDKVHPLLVTATLGCEEGLRHAITYSAGIVQLPRMSDQNQKIETA

FLMARRARSLSAERYTLFFDLVSSGNTLYAIWIGLGTRNRVAFVEFVGWLCKKDHTHIREWF

RQCTGRPSPSKPWMRAHPVAVPYDDPLTSEETDLAYARGLAMSIEAARLPDDPIIVEDDDE

SEEIEDKCDKDEEESGTEDVTSIPQTLPHSPTVYGRPSVFYRKPDTKSTKKCRAIVTDLSIIKVIE

DEHRKKKTARTEQPRAKPDSPAPTVVLRRPPTQKVTGPAGSLSVQAQLEPWQPLSWPHET

RVILHGPPTQGDQAHGSMLDLLEKDDQHMEQQVMATLLPPEPHQPRSGRRAPCVYTAD

LDIESDEPATSEPVLDQLLPAPGLGPLAIQPLTSPTTSQLRSSAPSHAQTPWPVTHPSQTPGG

PTTQSLAPETEAPRQWPMPLRPIPLHPLRMQPISFNPAVRPTPHQPPQVEPTFYQSTWVKP

PQQYQPQMGHIPYQPRPTGHSTMLRPQWAPTTMQPPPRAPTPMPPPQGPPTAMQRPQ

GAPTPMPPPQGPPTAMQRPRGAPTPMPPPQGPPTAMQLSPRALTGQKGPAKHILRQLLTG

GVKSGRPSLKFKAALERQAAAGLRPSPGSGTGAKIVQAPVFYPPVLQPIQVMWQVGSSKAV

AASTVTQAPTEYTGERRLGGPMSPTDIPPSKRVKKKAYPERKTPHGGPSHSSTVMWENVSQ

GQQQTLECGGTDKQERNMLGMGDIAVSSPSSSETSNDE

Pool of 234 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityAutoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma
235MoTif 235 EBV (LMP1)

MEHDLERGPPGPRRPPRGPPLSSSLGLALLLLLLALLFWLYIVMSDWTGGALLVLYSFALMLII

IILIIFIFRRDLLCPLGALCILLLMITLLLIALWNLHGQALFLGIVLFIFGCLLVLGIWIYLLEMLWRL

GATIWQLLAFFLAFFLDLILLIIALYLQQNWWTLLVDLLWLLLFLAILIWMYYHGQRHSDEHH

HDDSLPHPQQATDDSGHESDSNSNEGRHHLLVSGAGDGPPLCSQNLGAPGGGPDNGPQ

DPDNTDDNGPQDPDNTDDNGPHDPLPQDPDNTDDNGPQDPDNTDDNGPHDPLPHSP

SDSAGNDGGPPQLTEEVENKGGDQGPPLMTDGGGGHSHDSGHGGGDPHLPTLLLGSSGS

GGDDDDPHGPVQLSYYD

Pool of 94 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityAutoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma
236MoTif 236 EBV (LMP2)

MGSLEMVPMGAGPPSPGGDPDGYDGGNNSQYPSASGSSGNTPTPPNDEERESNEEPPPP

YEDPYWGNGDRHSDYQPLGTQDQSLYLGLQHDGNDGLPPPPYSPRDDSSQHIYEEAGRGS

MNPVCLPVIVAPYLFWLAAIAASCFTASVSTVVTATGLALSLLLLAAVASSYAAAQRKLLTPVT

VLTAVVTFFAICLTWRIEDPPFNSLLFALLAAAGGLQGIYVLVMLVLLILAYRRRWRRLTVCGGI

MFLACVLVLIVDAVLQLSPLLGAVTVVSMTLLLLAFVLWLSSPGGLGTLGAALLTLAAALALLA

SLILGTLNLTTMFLLMLLWTLVVLLICSSCSSCPLSKILLARLFLYALALLLLASALIAGGSILQTNF

KSLSSTEFIPNLFCMLLLIVAGILFILAILTEWGSGNRTYGPVFMCLGGLLTMVAGAVWLTVMS

NTLLSAWILTAGFLIFLIGFALFGVIRCCRYCCYYCLTLESEERPPTPYRNTV

Pool of 122 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityAutoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma
237MoTif 237 HCMVA (UL32)

MSLQFIGLQRRDVVALVNFLRHLTQKPDVDLEAHPKILKKCGEKRLHRRTVLFNELMLWLGYY

RELRFHNPDLSSVLEEFEVRCVAVARRGYTYPFGDRGKARDHLAVLDRTEFDTDVRHDAEIVE

RALVSAVILAKMSVRETLVTAIGQTEPIAFVHLKDTEVQRIEENLEGVRRNMFCVKPLDLNLDR

HANTALVNAVNKLVYTGRLIMNVRRSWEELERKCLARIQERCKLLVKELRMCLSFDSNYCRNI

LKHAVENGDSADTLLELLIEDFDIYVDSFPQSAHTFLGARSPSLEFDDDANLLSLGGGSAFSSV

PKKHVPTQPLDGWSWIASPWKGHKPFRFEAHGSLAPAAEAHAARSAAVGYYDEEEKRRERQ

KRVDDEVVQREKQQLKAWEERQQNLQQRQQQPPPPARKPSASRRLFGSSADEDDDDDDD

EKNIFTPIKKPGTSGKGAASGGGVSSIFSGLLSSGSQKPTSGPLNIPQQQQRHAAFSLVSPQVT

KASPGRVRRDSAWDVRPLTETRGDLFSGDEDSDSSDGYPPNRQDPRFTDTLVDITDTETSAK

PPVTTAYKFEQPTLTFGAGVNVPAGAGAAILTPTPVNPSTAPAPAPTPTFAGTQTPVNGNSPW

APTAPLPGDMNPANWPRERAWALKNPHLAYNPFRMPTTSTASQNTVSTTPRRPSTPRAAV

TQTASRDAADEVWALRDQTAESPVEDSEEEDDDSSDTGSVVSLGHTTPSSDYNNDVISPPSQ

TPEQSTPSRIRKAKLSSPMTTTSTSQKPVLGKRVATPHASARAQTVTSTPVQGRLEKQVSGTP

STVPATLLQPQPASSKTTSSRNVTSGAGTSSASSARQPSASASVLSPTEDDVVSPATSPLSMLS

SASPSPAKSAPPSPVKGRGSRVGVPSLKPTLGGKAVVGRPPSVPVSGSAPGRLSGSSRAASTT

PTYPAVTTVYPPSSTAKSSVSNAPPVASPSILKPGASAALQSRRSTGTAAVGSPVKSTTGMKTV

AFDLSSPQKSGTGPQPGSAGMGGAKTPSDAVQNILQKIEKIKNTEE

Pool of 260 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections
238MoTif 238 HCMVA (UL40)

MNKFSNTRIGFTCAVMAPRTLILTVGLLCMRIRSLLCSPAETTVTTAAVTSAHGPLCPLVFQGW

AYAVYHQGDMALMTLDVYCCRQTSNNTVVAFSHHPADNTLLIEVGNNTRRHVDGISCQDH

FRAQHQDCPAQTVHVRGVNESAFGLTHLQSCCLNEHSQLSERVAYHLKLRPATFGLETWAMY

TVGILALGSFSSFYSQIARSLGVLPNDHHYALKKA

Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections
239MoTif 239 HCMVA (UL55)

MESRIWCLVVCVNLCIVCLGAAVSSSSTSHATSSTHNGSHTSRTTSAQTRSVYSQHVTSSEAVS

HRANETIYNTTLKYGDVVGVNTTKYPYRVCSMAQGTDLIRFERNIICTSMKPINEDLDEGIMVV

YKRNIVAHTFKVRVYQKVLTFRRSYAYIYTTYLLGSNTEYVAPPMWEIHHINKFAQCYSSYSRVIG

GTVFVAYHRDSYENKTMQLIPDDYSNTHSTRYVTVKDQWHSRGSTWLYRETCNLNCMLTITT

ARSKYPYHFFATSTGDVVYISPFYNGTNRNASYFGENADKFFIFPNYTIVSDFGRPNAAPETHRL

VAFLERADSVISWDIQDEKNVTCQLTFWEASERTIRSEAEDSYHFSSAKMTATFLSKKQEVNMS

DSALDCVRDEAINKLQQIFNTSYNQTYEKYGNVSVFETSGGLVVFWQGIKQKSLVELERLANRS

SLNITHRTRRSTSDNNTTHLSSMESVHNLVYAQLQFTYDTLRGYINRALAQIAEAWCVDQRRT

LEVFKELSKINPSAILSAIYNKPIAARFMGDVLGLASCVTINQTSVKVLRDMNVKESPGRCYSRP

VVIFNFANSSYVQYGQLGEDNEILLGNHRTEECQLPSLKIFIAGNSAYEYVDYLFKRMIDLSSISTV

DSMIALDIDPLENTDFRVLELYSQKELRSSNVFDLEEIMREFNSYKQRVKYVEDKVVDPLPPYLK

GLDDLMSGLGAAGKAVGVAIGAVGGAVASVVEGVATFLKNPFGAFTIILVAIAVVIITYLIYTRQR

RLCTQPLQNLFPYLVSADGTTVTSGSTKDTSLQAPPSYEESVYNSGRKGPGPPSSDASTAAPPY

TNEQAYQMLLALARLDAEQRAQQNGTDSLDGQTGTQDKGQKPNLLDRLRHRKNGYRHLKD

SDEEENV

Pool of 224 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections
240MoTif 240 HCV (Capsid Protein) Ultrasee additional product documentationPool of 140 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityHepatitis, Infection, Sequence diversity
241MoTif 241 Tai Forest Ebolavirus (NP)

MESRAHKAWMTHTASGFETDYHKILTAGLSVQQGIVRQRVIQVHQVTNLEEICQLIIQAFEAGV

DFQESADSFLLMLCLHHAYQGDYKQFLESNAVKYLEGHGFRFEVRKKEGVKRLEELLPAASSGK

SIRRTLAAMPEEETTEANAGQFLSFASLFLPKLVVGEKACLEKVQRQIQVHSEQGLIQYPTAWQ

SVGHMMVIFRLMRTNFLIKFLLIHQGMHMVAGHDANDAVIANSVAQARFSGLLIVKTVLDHI

LQKTEHGVRLHPLARTAKVKNEVNSFKAALSSLAQHGEYAPFARLLNLSGVNNLEHGLFPQLS

AIALGVATAHGSTLAGVNVGEQYQQLREAATEAEKQLQKYAESRELDHLGLDDQEKKILKDFH

QKKNEISFQQTTAMVTLRKERLAKLTEAITSTSLLKTGKQYDDDNDIPFPGPINDNENSEQQDD

DPTDSQDTTIPDIIVDPDDGRYNNYGDYPSETANAPEDLVLFDLEDGDEDDHRPSSSSENNNK

HSLTGTDSNKTSNWNRNPTNMPKKDSTQNNDNPAQRAQEYARDNIQDTPTPHRALTPISEE

TGSNGHNEDDIDSIPPLESDEENNTETTITTTKNTTAPPAPVYRSNSEKEPLPQEKSQKQPNQV

SGSENTDNKPHSEQSVEEMYRHILQTQGPFDAILYYYMMTEEPIVFSTSDGKEYVYPDSLEGEH

PPWLSEKEALNEDNRFITMDDQQFYWPVMNHRNKFMAILQHHK

Pool of 182 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityEbola, Infection
242MoTif 242 HCMVA (UL48)_ 2 subpools

MKVTQASCHQGDIARFGARAGNQCVCNGIMFLHALHLGGTSAVLQTEALDAIMEEGARLD

ARLERELQKKLPAGGRLPVYRLGDEVPRRLESRFGRTVHALSRPFNGTTETCDLDGYMCPGIF

DFLRYAHAKPRPTYVLVTVNSLARAVVFTEDHMLVFDPHSSAECHNAAVYHCEGLHQVLMV

LTGFGVQLSPAFYYEALFLYMLDVATVPEAEIAARLVSTYRDRDIDLTGVVRESADTAATTTTAA

PSLPPLPDPIVDPGCPPGVAPSIPVYDPSSSPKKTPEKRRKDLSGSKHGGKKKPPSTTSKTLATA

SSSPSAIAAASSSSAVPPSYSCGEGALPALGRYQQLVDEVEQELKALTLPPLPANTSAWTLHAA

GTESGANAATATAPSFDEAFLTDRLQQLIIHAVNQRSCLRRPCGPQSAAQQAVRAYLGLSKKL

DAFLLNWLHHGLDLQRMHDYLSHKTTKGTYSTLDRALLEKMQVVFDPYGRQHGPALIAWVE

EMLRYVESKPTNELSQRLQRFVTKRPMPVSDSFVCLRPVDFQRLTQVIEQRRRVLQRQREEYH

GVYEHLAGLITSIDIHDLDASDLNRREILKALQPLDDNAKQELFRLGNAKMLELQMDLDRLSTQ

LLTRVHNHILNGFLPVEDLKQMERVVEQVLRLFYDLRDLKLCDGSYEEGFVVIREQLSYLMTGT

VRDNVPLLQEILQLRHAYQQATQQNEGRLTQIHDLLHVIETLVRDPGSRGSALTLALVQEQLAQ

LEALGGLQLPEVQQRLQNAQLALSRLYEEEEETQRFLDGLSYDDPPNEQTIKRHPQLREMLRRD

EQTRLRLINAVLSMFHTLVMRLARDESPRPTFFDAVSLLLQQLPPDSHEREDLRAANATYAQM

VKKLEQIEKAGTGASEKRFQALRELVYFFRNHEYFFQHMVGRLGVGPQVTELYERYQHEMEEQ

HLERLEREWQEEAGKLTVTSVEDVQRVLARAPSHRVMHQMQQTLTTKMQDFLDKEKRKQEE

QQRQLLDGYQKKVQQDLQRVVDAVKGEMLSTIPHQPLEATLELLLGLDQRAQPLLDKFNQDL

LSALQQLSKKLDGRINECLHGVLTGDVERRCHPHREAAMQTQASLNHLDQILGPQLLIHETQQ

ALQHAVHQAQFIEKCQQGDPTTAITGSEFEGDFARYRSSQQKMEEQLQETRQQMTETSERLDR

SLRQDPGSSSVTRVPEKPFKGQELAGRITPPPADFQQPVFKTLLDQQADAARKALSDEADLLN

QKVQTQLRQRDEQLSTAQNLWTDLVTRHKMSGGLDVTTPDAKALMEKPLETLRELLGKATQQ

LPYLSAERTVRWMLAFLEEALAQITADPTHPHHGSRTHYRNLQQQAVESAVTLAHQIEQNAAC

ENFIAQHQEATANGASTPRVDMVQAVEAVWQRLEPGRVAGGAARHQKVQELLQRLGQTLGD

LELQETLATEYFALLHGIQTFSYGLDFRSQLEKIRDLRTRFAELAKRRGTRLSNEGVLPNPRKPQAT

TSLGAFTRGLNALERHVQLGHQYLLNKLNGSSLVYRLEDIPSVLPATHETDPALIMRDRLRRLCFA

RHHDTFLEVVDVFGMRQIVTQAGEPIHLVTDYGNVAFKYLALRDDGRPLAWRRRCSGGGLKN

VVTTRYKAITVAVAVCQTLRTFWPQISQYDLRPYLTQHQSHTHPAETHTLHNLKLFCYLVSTAWH

QRIDTQQELTAADRVGSGEGGDVGEQRPGRGTVLRLSLQEFCVLIAALYPEYIYTVLKYPVQMSL

PSLTAHLHQDVIHAVVNNTHKMPPDHLPEQVKAFCITPTQWPAMQLNKLFWENKLVQQLCQ

VGPQKSTPPLGKLWLYAMATLVFPQDMLQCLWLELKPQYAETYASVSELVQTLFQIFTQQCEMV

TEGYTQPQLPTGEPVLQMIRVPRQDTTTTDTNTTTEPGLLDVFIQTETALDYALGSWLFGIPVCLG

VHVADLLKGQRILVARHLEYTSRDRDFLRIQRSRDLNLSQLLQDTWTETPLEHCWLQAQIRRLR

DYLRFPTRLEFIPLVIYNAQDHTVVRVLRPPSTFEQDHSRLVLDEAFPTFPLYDQDDNSSADNIAA

SGAAPTPPVPFNRVPVNIQFLRENPPPIARVQQPPRRHRHRAAAAADDDGQIDHVQDDTSRT

ADSALVSTAFGGSVFQENRLGETPLCRDELVAVAPGAASTSFASPPITVLTQNVLSALEILRLVRLD

LRQLAQSVQDTIQHMRFLYLL

Pool of 562 (281 + 281) peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections
243MoTif 243 Human Adenovirus 5 (Penton Protein)

MRRAAMYEEGPPPSYESVVSAAPVAAALGSPFDAPLDPPFVPPRYLRPTGGRNSIRYSELAP

LFDTTRVYLVDNKSTDVASLNYQNDHSNFLTTVIQNNDYSPGEASTQTINLDDRSHWGGD

LKTILHTNMPNVNEFMFTNKFKARVMVSRLPTKDNQVELKYEWVEFTLPEGNYSETMTIDL

MNNAIVEHYLKVGRQNGVLESDIGVKFDTRNFRLGFDPVTGLVMPGVYTNEAFHPDIILLPG

CGVDFTHSRLSNLLGIRKRQPFQEGFRITYDDLEGGNIPALLDVDAYQASLKDDTEQGGGGA

GGSNSSGSGAEENSNAAAAAMQPVEDMNDHAIRGDTFATRAEEKRAEAEAAAEAAAPAA

QPEVEKPQKKPVIKPLTEDSKKRSYNLISNDSTFTQYRSWYLAYNYGDPQTGIRSWTLLCTPD

VTCGSEQVYWSLPDMMQDPVTFRSTRQISNFPVVGAELLPVHSKSFYNDQAVYSQLIRQFT

SLTHVFNRFPENQILARPPAPTITTVSENVPALTDHGTLPLRNSIGGVQRVTITDARRRTCPYV

YKALGIVSPRVLSSRTF

Pool of 140 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Gene therapy, Infection, Respiratory infection
244MoTif 244 HRSVB (Major surface glycoprotein G)

MSKHKNQRTARTLEKTWDTLNHLIVISSCLYRLNLKSIAQIALSVLAMIISTSLIIAAIIFIISANH

KVTLTTVTVQTIKNHTEKNITTYLTQVPPERVSSSKQPTTTSPIHTNSATTSPNTKSETHHTTA

QTKGRTTTSTQTNKPSTKPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQLCKSICKTIPSNKP

KKKPTIKPTNKPTTKTTNKRDPKTPAKTTKKETTTNPTKKPTLTTTERDTSTSQSTVLDTTTLEH

TIQQQSLHSTTPENTPNSTQTPTASEPSTSNSTQNTQSHA

Pool of 72 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%Cancer biomarker research, T-cell immunityBronchiolitis, Infection, Respiratory infection
245MoTif 245 Aspergillus fumigatus (Glucanosyltransferase gel1)

MKASAVTAALAVGASTVLAAPSIKARDDVTPITVKGNAFFKGAERFYIRGVDYQPGGSSDL

ADPIADADGCKRDIAKFKELGLNTIRVYSVDNSKNHDECMNALADAGIYLVLDVNTPKYSI

NRAKPKESYNDVYLQYIFATVDAFAGYKNTLAFFSGNEVINDGPSSSAAPYVKAVTRDLRQ

YIRSRKYREIPVGYSAADIDTNRLQMAQYMNCGSDDERSDFFAFNDYSWCDPSSFKTSGW

DQKVKNFTGYGLPLFLSEYGCNTNKRQFQEVSSLYSTDMTGVYSGGLVYEYSQEASNYGLV

EISGNNVKELPDFDALKTAFEKTSNPSGDGNYNKTGGANPCPAKDAPNWDVDNDALPAIP

EPAKKYMTEGAGKGPGFAGPGSQDRGTQSTATAEPGSGSATGSSSSGTSTSSKGAAAGLTVP

SLTMAPVVVGAVTLLSTVFGAGLVLL

Pool of 111 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityAllergy, Infection, Respiratory infection
246MoTif 246 EBV (GP350/GP340)

MEAALLVCQYTIQSLIHLTGEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQLDL

DFGQLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINVTTGEEQQVSLE

SVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLDVTLPLS

LPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVPSGGILTSTSP

VATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQSNIVFSDEIPASQDM

PTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTETDFKCKWTLTSGTPSG

CENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVIFSKAPESTTTSPTLNTTGFADP

NTTTGLPSSTHVPTNLTAPASTGPTVSTADVTSPTPAGTTSGASPVTPSPSPWDNGTESKAPD

MTSSTSPVTTPTPNATSPTPAVTTPTPNATSPTPAVTTPTPNATSPTLGKTSPTSAVTTPTPNAT

SPTLGKTSPTSAVTTPTPNATSPTLGKTSPTSAVTTPTPNATGPTVGETSPQANATNHTLGGTS

PTPVVTSQPKNATSAVTTGQHNITSSSTSSMSLRPSSNPETLSPSTSDNSTSHMPLLTSAHPTG

GENITQVTPASISTHHVSTSSPAPRPGTTSQASGPGNSSTSTKPGEVNVTKGTPPQNATSPQA

PSGQKTAVPTVTSTGGKANSTTGGKHTTGHGARTSTEPTTDYGGDSTTPRPRYNATTYLPPST

SSKLRPRWTFTSPPVTTAQATVPVPPTSQPRFSNLSMLVLQWASLAVLTLLLLLVMADCAFRR

NLSTSHTYTTPPYDDAETYV

Pool of 224 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityAutoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma
247MoTif 247 Influenza A (MP1 /California (H1N1))

MSLLTEVETYVLSIIPSGPLKAEIAQRLESVFAGKNTDLEALMEWLKTRPILSPLTKGILGFVFTLTV

PSERGLQRRRFVQNALNGNGDPNNMDRAVKLYKKLKREITFHGAKEVSLSYSTGALASCMGL

IYNRMGTVTTEAAFGLVCATCEQIADSQHRSHRQMATTTNPLIRHENRMVLASTTAKAMEQ

MAGSSEQAAEAMEVANQTRQMVHAMRTIGTHPSSSAGLKDDLLENLQAYQKRMGVQMQRFK

Pool of 61 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
248MoTif 248 Lassa virus (Pre-glycoprotein complex)

MGQIVTFFQEVPHVIEEVMNIVLIALSVLAVLKGLYNFATCGLVGLVTFLLLCGRSCTTSLYKGVYEL

QTLELNMETLNMTMPLSCTKNNSHHYIMVGNETGLELTLTNTSIINHKFCNLSDAHKKNLYDHA

LMSIISTFHLSIPNFNQYEAMSCDFNGGKISVQYNLSHSYAGDAANHCGTVANGVLQTFMRMA

WGGSYIALDSGRGNWDCIMTSYQYLIIQNTTWEDHCQFSRPSPIGYLGLLSQRTRDIYISRRLLGT

FTWTLSDSEGKDTPGGYCLTRWMLIEAELKCFGNTAVAKCNEKHDEEFCDMLRLFDFNKQAIQRL

KAEAQMSIQLINKAVNALINDQLIMKNHLRDIMGIPYCNYSKYWYLNHTTTGRTSLPKCWLVSN

GSYLNETHFSDDIEQQADNMITEMLQKEYMERQGKTPLGLVDLFVFSTSFYLISIFLHLVKIPTHRH

IVGKSCPKPHRLNHMGICSCGLYKQPGVPVKWKR

Pool of 120 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFever, Hemorrhagic fever, Infection, Lassa fever
249MoTif 249 Human Adenovirus 26 (Penton Protein)

MRRAVVSSSPPPSYESVMAQATLEVPFVPPRYMAPTEGRNSIRYSELAPQYDTTRVYLVDNKSA

DIASLNYQNDHSNFLTTVVQNNDFTPAEASTQTINFDERSRWGGDLKTILHTNMPNVNEYMFT

SKFKARVMVSRKHPEGVVETDLSQDKLEYEWFEFTLPEGNFSETMTIDLMNNAILENYLQVGRQ

NGVLESDIGVKFDSRNFKLGWDPVTKLVMPGVYTYEAFHPDVVLLPGCGVDFTESRLSNLLGIRK

KQPFQEGFRIMYEDLEGGNIPALLDVPKYLESKKKVEDETKNAAAATADTTTRGDTFATPAQETAA

DKKVEVLPIEKDESGRSYNLIQGTHDTLYRSWYLSYTYGDPEKGVQSWTLLTTPDVTCGAEQVYW

SLPDLMQDPVTFRSTQQVSNYPVVGAELMPFRAKSFYNDLAVYSQLIRSYTSLTHVFNRFPDNQI

LCRPPAPTITTVSENVPALTDHGTLPLRSSIRGVQRVTVTDARRRTCPYVYKALGIVAPRVLSSRTF

Pool of 127 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Gene therapy, Infection
250MoTif 250 Vaccinia virus (MVA093L)

MAAVKTPVIVVPVIDRPPSETFPNVHEHINDQKFDDVKDNEVMPEKRNVVVVKDDPDHYKDY

AFIQWTGGNIRNDDKYTHFFSGFCNTMCTEETKRNIARHLALWDSNFFTELENKKVEYVVIVEN

DNVIEDITFLRPVLKAMHDKKIDILQMREIITGNKVKTELVMDKNHAIFTYTGGYDVSLSAYIIRVT

TALNIVDEIIKSGGLSSGFYFEIARIENEMKINRQILDNAAKYVEHDPRLVAEYRFENMKPNFWSR

IGTAAAKRYPGVMYAFTTPLISFFGLFDINVIGLIVILFIMFMLIFNVKSKLLWFLTGTFVTAFI

Pool of 79 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Small Pox, Small Pox Vaccine
251MoTif 251 Vaccinia virus (MVA105L)

MPQQLSPINIETKKAISNARLKPLDIHYNESKPTTIQNTGKLVRINFKGGYISGGFLPNEYVLSSLR

IYWGKEDDYGSNHLIDVYKYSGEINLVHWNKKKYSSYEEAKKHDDGLIIISIFLQVSDHKNVYFQ

KIVNQLDSIRSTNTSAPFDSVFYLDNLLPSKLDYFTYLGTTINHSADAVWIIFPTPINIHSDQLSKF

RTLLSSSNHDGKPHYITENYRNPYKLNDDTQVYYSGEIIRAATTSPARENYFMRWLSDLRETCFS

YYQKYIEGNKTFAIIAIVFVFILTAILFFMSQRYSREKQN

Pool of 74 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Small Pox, Small Pox Vaccine
252MoTif 252 Vaccinia virus (MVA189R)

MKPKVNNIGNTPLHNYVSQYDITLIPHPQPIKKWKLKPSISINGYRSTFTMAFPCAQFRPCHC

HATKDSLNTVADVRHCLTEYILWVSHRWTHRESAGSLYRLLISFRTDATELFGGELKDSLPWRSL

NDSMKTAEELRAIIGLCTQSAIVSGRVFNDKYIDILLMLRKILNENDYLTLLDHIRTAKY

Pool of 45 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Small Pox, Small Pox Vaccine
253MoTif 253 AAV6 (Capsid protein VP1)

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGL

DKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQ

AKKRVLEPFGLVEEGAKTAPGKKRPVEQSPQEPDSSSGIGKTGQQPAKKRLNFGQTGDSESVPD

PQPLGEPPATPAAVGPTTMASGGGAPMADNNEGADGVGNASGNWHCDSTWLGDRVITTST

RTWALPTYNNHLYKQISSASTGASNDNHYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNW

GFRPKRLNFKLFNIQVKEVTTNDGVTTIANNLTSTVQVFSDSEYQLPYVLGSAHQGCLPPFPAD

VFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFTFSYTFEDVPFHSSYAHSQSLDR

LMNPLIDQYLYYLNRTQNQSGSAQNKDLLFSRGSPAGMSVQPKNWLPGPCYRQQRVSKTKT

DNNNSNFTWTGASKYNLNGRESIINPGTAMASHKDDKDKFFPMSGVMIFGKESAGASNTAL

DNVMITDEEEIKATNPVATERFGTVAVNLQSSSTDPATGDVHVMGALPGMVWQDRDVYLQG

PIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPPAEFSATKFASFITQYSTGQVSV

EIEWELQKENSKRWNPEVQYTSNYAKSANVDFTVDNNGLYTEPRPIGTRYLTRPL

Pool of 182 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityGene therapy, Infection
254MoTif 254 SARS-CoV-2 (S-RBD C.37 / Lambda)

RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGV

SPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKV

GGNYNYQYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYSPLQSYGFQPTNGVGYQPY

RVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF

Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap))70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
255MoTif 255 Human (KRAS)

MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEE

YSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTV

DTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM

Pool of 45 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Leukemia
256MoTif 256 SARS-CoV-2 (S-RBD HK.3 + JG.3)

RVQPTESIVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAPFFAFKCYGV

SPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKP

SGNYNYLYRFLRKSKLKPFERDISTEIYQAGNKPCNGVAGPNCYSPLQSYGFRPTYGVGHQPY

RVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF

Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
257MoTif 257 Pan-SARS-CoV-2 Selectsee additional product documentationVirus-specific pool of 103 peptides (defined HLA class I & II-restricted T-cell epitopes)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
258MoTif 258 Influenza A (HA /Brisbane (H1N1))

MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENSHNGKLCLLKG

IAPLQLGNCSVAGWILGNPECELLISKESWSYIVEKPNPENGTCYPGHFADYEELREQLSSVSSF

ERFEIFPKESSWPNHTVTGVSASCSHNGESSFYRNLLWLTGKNGLYPNLSKSYANNKEKEVLV

LWGVHHPPNIGDQKALYHTENAYVSVVSSHYSRKFTPEIAKRPKVRDQEGRINYYWTLLEPG

DTIIFEANGNLIAPRYAFALSRGFGSGIINSNAPMDKCDAKCQTPQGAINSSLPFQNVHPVTIG

ECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGY

AADQKSTQNAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRMENLNKKVDDGFIDIWTYN

AELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTY

DYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI

Pool of 139 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
259MoTif 259 Influenza A (NP/AnnArbor (H2N2)

MASQGTKRSYEQMETDGERQNANEIRASVGKMIGGIGRFYIQMCTELKLSDYEGRLIQNSL

TIERMVLSAFDERRNKYLEEHPSAGKDPKKTGGPIYKRVDGKWMRELVLYDKEEIRRIWRQA

NNGDDATAGLTHMMIWHSNLNDTTYQRTRALVRTGMDPRMCSLMQGSTLPRRSGAAGA

AVKGVGTMVMELIRMIKRGINDRNFWRGENGRKTRNAYERMCNILKGKFQTAAQRAMMD

QVRESRNPGNAEIEDLIFLARSALILRGSVAHKSCLPACVYGPAVASGYDFEKEGYSLVGIDPFK

LLQNSQVYSLIRPNENPAHKSQLVWMACNSAAFEDLRVSSFIRGTKVIPRGKLSTRGVQIASN

ENMDTMGSSTLELRSRYWAIRTRSGGNTNQQRASAGQISVQPTFSVQRNLPFDKPTIMAAF

TGNAEGRTSDMRAEIIRMMEGAKPEEVSFQGRGVFELSDEKATNPIVPSFDMSNEGSYFFGD

NAEEYDN

Pool of 122 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
260MoTif 260 Vaccinia virus (MVA093L)

MAAVKTPVIVVPVIDRPPSETFPNVHEHINDQKFDDVKDNEVMPEKRNVVVVKDDPDHY

KDYAFIQWTGGNIRNDDKYTHFFSGFCNTMCTEETKRNIARHLALWDSNFFTELENKKVEYV

VIVENDNVIEDITFLRPVLKAMHDKKIDILQMREIITGNKVKTELVMDKNHAIFTYTGGYDVSL

SAYIIRVTTALNIVDEIIKSGGLSSGFYFEIARIENEMKINRQILDNAAKYVEHDPRLVAEYRFEN

MKPNFWSRIGTAAAKRYPGVMYAFTTPLISFFGLFDINVIGLIVILFIMFMLIFNVKSKLLWFLT

GTFVTAFI

Pool of 79 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Small Pox, Small Pox Vaccine
261MoTif 261 Vaccinia virus (MVA093L)

MAAVKTPVIVVPVIDRPPSETFPNVHEHINDQKFDDVKDNEVMPEKRNVVVVKDDPDHY

KDYAFIQWTGGNIRNDDKYTHFFSGFCNTMCTEETKRNIARHLALWDSNFFTELENKKVEY

VVIVENDNVIEDITFLRPVLKAMHDKKIDILQMREIITGNKVKTELVMDKNHAIFTYTGGYDV

SLSAYIIRVTTALNIVDEIIKSGGLSSGFYFEIARIENEMKINRQILDNAAKYVEHDPRLVAEYRF

ENMKPNFWSRIGTAAAKRYPGVMYAFTTPLISFFGLFDINVIGLIVILFIMFMLIFNVKSKLLW

FLTGTFVTAFI

Pool of 79 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Small Pox, Small Pox Vaccine
262MoTif 262 Vaccinia virus (MVA105L)

MPQQLSPINIETKKAISNARLKPLDIHYNESKPTTIQNTGKLVRINFKGGYISGGFLPNEYVL

SSLRIYWGKEDDYGSNHLIDVYKYSGEINLVHWNKKKYSSYEEAKKHDDGLIIISIFLQVSDH

KNVYFQKIVNQLDSIRSTNTSAPFDSVFYLDNLLPSKLDYFTYLGTTINHSADAVWIIFPTPIN

IHSDQLSKFRTLLSSSNHDGKPHYITENYRNPYKLNDDTQVYYSGEIIRAATTSPARENYFMR

WLSDLRETCFSYYQKYIEGNKTFAIIAIVFVFILTAILFFMSQRYSREKQN

Pool of 74 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Small Pox, Small Pox Vaccine
263MoTif 263 Vaccinia virus (MVA189R)

MKPKVNNIGNTPLHNYVSQYDITLIPHPQPIKKWKLKPSISINGYRSTFTMAFPCAQFRPC

HCHATKDSLNTVADVRHCLTEYILWVSHRWTHRESAGSLYRLLISFRTDATELFGGELKDSLP

WRSLNDSMKTAEELRAIIGLCTQSAIVSGRVFNDKYIDILLMLRKILNENDYLTLLDHIRTAKY

Pool of 45 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Small Pox, Small Pox Vaccine
264MoTif 264 AAV6 (Capsid protein VP1)

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNG

LDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRA

VFQAKKRVLEPFGLVEEGAKTAPGKKRPVEQSPQEPDSSSGIGKTGQQPAKKRLNFGQTGDS

ESVPDPQPLGEPPATPAAVGPTTMASGGGAPMADNNEGADGVGNASGNWHCDSTWLG

DRVITTSTRTWALPTYNNHLYKQISSASTGASNDNHYFGYSTPWGYFDFNRFHCHFSPRD

WQRLINNNWGFRPKRLNFKLFNIQVKEVTTNDGVTTIANNLTSTVQVFSDSEYQLPYVLGS

AHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFTFSYTFED

VPFHSSYAHSQSLDRLMNPLIDQYLYYLNRTQNQSGSAQNKDLLFSRGSPAGMSVQPKN

WLPGPCYRQQRVSKTKTDNNNSNFTWTGASKYNLNGRESIINPGTAMASHKDDKDKFFP

MSGVMIFGKESAGASNTALDNVMITDEEEIKATNPVATERFGTVAVNLQSSSTDPATGDVH

VMGALPGMVWQDRDVYLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPA

NPPAEFSATKFASFITQYSTGQVSVEIEWELQKENSKRWNPEVQYTSNYAKSANVDFTVDN

NGLYTEPRPIGTRYLTRPL

Pool of 182 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityGene therapy, Infection
265MoTif 265 SARS-CoV-2 (S-RBD C.37 / Lambda)

RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCY

GVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNL

DSKVGGNYNYQYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYSPLQSYGFQPTNG

VGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF

Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap))70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
266MoTif 266 Human (KRAS)

MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSA

MRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQ

AQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM

Pool of 45 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Leukemia
267MoTif 267 SARS-CoV-2 (S-RBD HK.3 + JG.3)

RVQPTESIVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAPFFAFKCYGVSP

TKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKPSGN

YNYLYRFLRKSKLKPFERDISTEIYQAGNKPCNGVAGPNCYSPLQSYGFRPTYGVGHQPYRVVVL

SFELLHAPATVCGPKKSTNLVKNKCVNF

Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
268MoTif 268 Pan-SARS-CoV-2 Selectsee additional product documentationVirus-specific pool of 103 peptides (defined HLA class I & II-restricted T-cell epitopes)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
269MoTif 269 Influenza A (HA /Brisbane (H1N1))

MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENSHNGKLCLLKGIA

PLQLGNCSVAGWILGNPECELLISKESWSYIVEKPNPENGTCYPGHFADYEELREQLSSVSSFERF

EIFPKESSWPNHTVTGVSASCSHNGESSFYRNLLWLTGKNGLYPNLSKSYANNKEKEVLVLWGV

HHPPNIGDQKALYHTENAYVSVVSSHYSRKFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEA

NGNLIAPRYAFALSRGFGSGIINSNAPMDKCDAKCQTPQGAINSSLPFQNVHPVTIGECPKYVR

SAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQ

NAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRMENLNKKVDDGFIDIWTYNAELLVLLENER

TLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLN

REKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI

Pool of 139 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
270MoTif 270 Influenza A (NP/AnnArbor (H2N2)

MASQGTKRSYEQMETDGERQNANEIRASVGKMIGGIGRFYIQMCTELKLSDYEGRLIQNSLTIE

RMVLSAFDERRNKYLEEHPSAGKDPKKTGGPIYKRVDGKWMRELVLYDKEEIRRIWRQANNGD

DATAGLTHMMIWHSNLNDTTYQRTRALVRTGMDPRMCSLMQGSTLPRRSGAAGAAVKGVGT

MVMELIRMIKRGINDRNFWRGENGRKTRNAYERMCNILKGKFQTAAQRAMMDQVRESRNPG

NAEIEDLIFLARSALILRGSVAHKSCLPACVYGPAVASGYDFEKEGYSLVGIDPFKLLQNSQVYSLIR

PNENPAHKSQLVWMACNSAAFEDLRVSSFIRGTKVIPRGKLSTRGVQIASNENMDTMGSSTLEL

RSRYWAIRTRSGGNTNQQRASAGQISVQPTFSVQRNLPFDKPTIMAAFTGNAEGRTSDMRAEII

RMMEGAKPEEVSFQGRGVFELSDEKATNPIVPSFDMSNEGSYFFGDNAEEYDN

Pool of 122 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
271MoTif 271 Zaire Ebola (GP/Mayinga-76)

MGVTGILQLPRDRFKRTSFFLWVIILFQRTFSIPLGVIHNSTLQVSDVDKLVCRDKLSSTNQLRSVG

LNLEGNGVATDVPSATKRWGFRSGVPPKVVNYEAGEWAENCYNLEIKKPDGSECLPAAPDGIRG

FPRCRYVHKVSGTGPCAGDFAFHKEGAFFLYDRLASTVIYRGTTFAEGVVAFLILPQAKKDFFSSHP

LREPVNATEDPSSGYYSTTIRYQATGFGTNETEYLFEVDNLTYVQLESRFTPQFLLQLNETIYTSGKR

SNTTGKLIWKVNPEIDTTIGEWAFWETKKNLTRKIRSEELSFTVVSNGAKNISGQSPARTSSDPGT

NTTTEDHKIMASENSSAMVQVHSQGREAAVSHLTTLATISTSPQSLTTKPGPDNSTHNTPVYKL

DISEATQVEQHHRRTDNDSTASDTPSATTAAGPPKAENTNTSKSTDFLDPATTTSPQNHSETAGN

NNTHHQDTGEESASSGKLGLITNTIAGVAGLITGGRRTRREAIVNAQPKCNPNLHYWTTQDEGA

AIGLAWIPYFGPAAEGIYIEGLMHNQDGLICGLRQLANETTQALQLFLRATTELRTFSILNRKAIDFL

LQRWGGTCHILGPDCCIEPHDWTKNITDKIDQIIHDFVDKTLPDQGDNDNWWTGWRQWIPAG

IGVTGVIIAVIALFCICKFVF

Pool of 167 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityEbola, Ebola fever, Infection
272MoTif 272 Sudan Ebolavirus (GP/Uganda-00)

MGGLSLLQLPRDKFRKSSFFVWVIILFQKAFSMPLGVVTNSTLEVTEIDQLVCKDHLASTDQLKS

VGLNLEGSGVSTDIPSATKRWGFRSGVPPKVVSYEAGEWAENCYNLEIKKPDGSECLPPPPDGVR

GFPRCRYVHKAQGTGPCPGDYAFHKDGAFFLYDRLASTVIYRGVNFAEGVIAFLILAKPKETFLQSP

PIREAVNYTENTSSYYATSYLEYEIENFGAQHSTTLFKIDNNTFVRLDRPHTPQFLFQLNDTIHLHQ

QLSNTTGRLIWTLDANINADIGEWAFWENKKNLSEQLRGEELSFEALSLNETEDDDAASSRITKG

RISDRATRKYSDLVPKNSPGMVPLHIPEGETTLPSQNSTEGRRVGVNTQETITETAATIIGTNGNH

MQISTIGIRPSSSQIPSSSPTTAPSPEAQTPTTHTSGPSVMATEEPTTPPGSSPGPTTEAPTLTTPEN

ITTAVKTVLPQESTSNGLITSTVTGILGSLGLRKRSRRQTNTKATGKCNPNLHYWTAQEQHNAAG

IAWIPYFGPGAEGIYTEGLMHNQNALVCGLRQLANETTQALQLFLRATTELRTYTILNRKAIDFLLR

RWGGTCRILGPDCCIEPHDWTKNITDKINQIIHDFIDNPLPNQDNDDNWWTGWRQWIPAGIG

ITGIIIAIIALLCVCKLLC

Pool of 167 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityEbola, Infection
273MoTif 273 Human (hSTAR-ECD)

MKTLLLDLALWSLLFQPGWLSFSSQVSQNCHNGSYEISVLMMGNSAFAEPLKNLEDAVNEGLEI

VRGRLQNAGLNVTVNATFMYSDGLIHNSGDCRSSTCEGLDLLRKISNAQRMGCVLIGPSCTYST

FQMYLDTELSYPMISAGSFGLSCDYKETLTRLMSPARKLMYFLVNFWKTNDLPFKTYSWSTSYVY

KNGTETEDCFWYLNALEASVSYFSHELGFKVVLRQDKEFQDILMDHNRKSNVIIMCGGPEFLYKL

KGDRAVAEDIVIILVDLFNDQYFEDNVTAPDYMKNVLVLTLSPGNSLLNSSFSRNLSPTKRDFALA

YLNGILLFGHMLKIFLENGENITTPKFAHAFRNLTFEGYDGPVTLDDWGDVDSTMVLLYTSVDTK

KYKVLLTYDTHVNKTYPVDMSPTFTWKNSKLPNDITGRGP

Pool of 105 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%Cancer biomarker research, T-cell immunityDiarrhea
274MoTif 274 Influenza A (MP1/AnnArbor (H2N2)

MSLLTEVETYVLSIIPSGPLKAEIAQRLEDVFAGKNTDLEALMEWLKTRPILSPLTKGILGFVFTLTV

PSERGLQRRRFVQNALNGNGDPNNMDRAVKLYRKLKREITFHGAKEIALSYSAGALASCMGLI

YNRMGAVTTEVVLGLVCATCEQIADSQHRSHRQMVTTTNPLIRHENRMVLASTTAKAMEQM

AGSSEQAAEAMEVASQARQMVQAMRVIGTHPSSSAGLKNDLLENLQAYQKRMGVQMQRFK

Pool of 61 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
275MoTif 275 Influenza A (MP2/AnnArbor (H2N2)

MSLLTEVETPIRNEWGCRCNDSSDPLVVAASIIGILHLILWILDHLFFKCIYRFFKHGLKRGPSTEG

VPESMREEYRKEQQSAVDADDSHFVSIELE

Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
276MoTif276 Human (Kir4.1)

MTSVAKVYYSQTTQTESRPLMGPGIRRRRVLTKDGRSNVRMEHIADKRFLYLKDLWTTFIDMQ

WRYKLLLFSATFAGTWFLFGVVWYLVAVAHGDLLELDPPANHTPCVVQVHTLTGAFLFSLESQTT

IGYGFRYISEECPLAIVLLIAQLVLTTILEIFITGTFLAKIARPKKRAETIRFSQHAVVASHNGKPCLMIR

VANMRKSLLIGCQVTGKLLQTHQTKEGENIRLNQVNVTFQVDTASDSPFLILPLTFYHVVDETSPL

KDLPLRSGEGDFELVLILSGTVESTSATCQVRTSYLPEEILWGYEFTPAISLSASGKYIADFSLFDQVV

KVASPSGLRDSTVRYGDPEKLKLEESLREQAEKEGSALSVRISNV

Pool of 92 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunitySESAME syndrome
277MoTif 277 Zaire Ebola (Virion Spike Glycoprotein)

MGVTGILQLPRDRFKRTSFFLWVIILFQRTFSIPLGVIHNSTLQVSDVDKLVCRDKLSSTNQLRSVG

LNLEGNGVATDVPSVTKRWGFRSGVPPKVVNYEAGEWAENCYNLEIKKPDGSECLPAAPDGIRG

FPRCRYVHKVSGTGPCAGDFAFHKEGAFFLYDRLASTVIYRGTTFAEGVVAFLILPQAKKDFFSSHP

LREPVNATEDPSSGYYSTTIRYQATGFGTNETEYLFEVDNLTYVQLESRFTPQFLLQLNETIYASGKR

SNTTGKLIWKVNPEIDTTIGEWAFWETKKNLTRKIRSEELSFTAVSNGPKNISGQSPARTSSDPETN

TTNEDHKIMASENSSAMVQVHSQGRKAAVSHLTTLATISTSPQPPTTKTGPDNSTHNTPVYKLDI

SEATQVGQHHRRADNDSTASDTPPATTAAGPLKAENTNTSKSADSLDLATTTSPQNYSETAGNN

NTHHQDTGEESASSGKLGLITNTIAGVAGLITGGRRTRREVIVNAQPKCNPNLHYWTTQDEGAAI

GLAWIPYFGPAAEGIYTEGLMHNQDGLICGLRQLANETTQALQLFLRATTELRTFSILNRKAIDFLL

QRWGGTCHILGPDCCIEPHDWTKNITDKIDQIIHDFVDKTLPDQGDNDNWWTGWRQWIPAGI

GVTGVIIAVIALFCICKFVF

Pool of 167 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityEbola, Ebola fever, Infection
278MoTif 278 Human (Prostate-specific antigen PSA)

MWVPVVFLTLSVTWIGAAPLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHPQWVLT

AAHCIRNKSVILLGRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSHDLMLLRL

SEPAELTDAVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVISNDVCAQVHPQK

VTKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALPERPSLYTKVVHYRKWIK

DTIVANP

Pool of 63 peptides derived from a peptide scan through Prostate-specific antigen (Swiss-Prot ID: P07288) of Human.70%-90%Cancer biomarker research, T-cell immunityCancer, Prostate cancer
279MoTif 279 Nipah Virus (Fusion Glycoprotein F0)

MVVILDKRCYCNLLILILMISECSVGILHYEKLSKIGLVKGVTRKYKIKSNPLTKDIVIKMIPNVSNM

SQCTGSVMENYKTRLNGILTPIKGALEIYKNNTHDLVGDVRLAGVIMAGVAIGIATAAQITAGVAL

YEAMKNADNINKLKSSIESTNEAVVKLQETAEKTVYVLTALQDYINTNLVPTIDKISCKQTELSLDL

ALSKYLSDLLFVFGPNLQDPVSNSMTIQAISQAFGGNYETLLRTLGYATEDFDDLLESDSITGQIIY

VDLSSYYIIVRVYFPILTEIQQAYIQELLPVSFNNDNSEWISIVPNFILVRNTLISNIEIGFCLITKRSVI

CNQDYATPMTNNMRECLTGSTEKCPRELVVSSHVPRFALSNGVLFANCISVTCQCQTTGRAISQ

SGEQTLLMIDNTTCPTAVLGNVIISLGKYLGSVNYNSEGIAIGPPVFTDKVDISSQISSMNQSLQQ

SKDYIKEAQRLLDTVNPSLISMLSMIILYVLSIASLCIGLITFISFIIVEKKRNTYSRLEDRRVRPTSSGD

LYYIGT

Pool of 134 peptides derived from a peptide scan (15mers with 11aa overlap)70%-90%T-cell immunityEncephalitis, Fever, Infection
280MoTif 280 SARS-CoV-2 (S-RBD EG.5.1)

RVQPTESIVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAPFFAFKCYGVSP

TKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKPSGN

YNYLYRLLRKSKLKPFERDISTEIYQAGNKPCNGVAGPNCYSPLQSYGFRPTYGVGHQPYRVVVL

SFELLHAPATVCGPKKSTNLVKNKCVNF

Pool of 53 peptides derived from a peptide scan (Peptide Scan (15mers with 11 aa overlap))70%-90%T-cell immunityCovid-19
281MoTif 281 Chimpanzee Adenovirus Y25 (Penton Protein)

MMRRAYPEGPPPSYESVMQQAMAAAAAMQPPLEAPYVPPRYLAPTEGRNSIRYSELAPLYDT

TRLYLVDNKSADIASLNYQNDHSNFLTTVVQNNDFTPTEASTQTINFDERSRWGGQLKTIMHTN

MPNVNEFMYSNKFKARVMVSRKTPNGVTVTDGSQDILEYEWVEFELPEGNFSVTMTIDLMNN

AIIDNYLAVGRQNGVLESDIGVKFDTRNFRLGWDPVTELVMPGVYTNEAFHPDIVLLPGCGVDFT

ESRLSNLLGIRKRQPFQEGFQIMYEDLEGGNIPALLDVDAYEKSKEESAAAATAAVATASTEVRGDN

FASPAAVAAAEAAETESKIVIQPVEKDSKDRSYNVLPDKINTAYRSWYLAYNYGDPEKGVRSWTLL

TTSDVTCGVEQVYWSLPDMMQDPVTFRSTRQVSNYPVVGAELLPVYSKSFFNEQAVYSQQLRA

FTSLTHVFNRFPENQILVRPPAPTITTVSENVPALTDHGTLPLRSSIRGVQRVTVTDARRRTCPYVYK

ALGIVAPRVLSSRTF

Pool of 131 peptides derived from a peptide scan (15mers with 11 aa overlap) 70%-90%T-cell immunityCancer, Gene therapy, Infection
282MoTif 282 Chimpanzee Adenovirus Y25 (Hexon Protein)

MATPSMLPQWAYMHIAGQDASEYLSPGLVQFARATDTYFSLGNKFRNPTVAPTHDVTTDRSQR

LTLRFVPVDREDNTYSYKVRYTLAVGDNRVLDMASTYFDIRGVLDRGPSFKPYSGTAYNSLAPKGA

PNSSQWEQKKAGNGDTMETHTFGVAPMGGENITIDGLQIGTDATADQDKPIYADKTFQPEPQVG

EENWQETESFYGGRALKKDTSMKPCYGSYARPTNVKGGQAKLKVGADGVPTKEFDIDLAFFDTPG

GTVNGQDEYKADIVMYTENTYLETPDTHVVYKPGKDDASSEINLVQQSMPNRPNYIGFRDNFIGL

MYYNSTGNMGVLAGQASQLNAVVDLQDRNTELSYQLLLDSLGDRTRYFSMWNQAVDSYDPDV

RIIENHGVEDELPNYCFPLDGSGTNAAYQGVKVKNGNDGDVESEWENDDTVAARNQLCKGNIFA

MEINLQANLWRSFLYSNVALYLPDSYKYTPANITLPTNTNTYDYMNGRVVPPSLVDAYINIGARWS

LDPMDNVNPFNHHRNAGLRYRSMLLGNGRYVPFHIQVPQKFFAIKSLLLLPGSYTYEWNFRKDV

NMILQSSLGNDLRTDGASISFTSINLYATFFPMAHNTASTLEAMLRNDTNDQSFNDYLSAANMLY

PIPANATNVPISIPSRNWAAFRGWSFTRLKTKETPSLGSGFDPYFVYSGSIPYLDGTFYLNHTFKKVS

ITFDSSVSWPGNDRLLTPNEFEIKRTVDGEGYNVAQCNMTKDWFLVQMLAHYNIGYQGFYVPEG

YKDRMYSFFRNFQPMSRQVVDEVNYKDYQAVTLAYQHNNSGFVGYLAPTMRQGQPYPANYPY

PLIGKSAVTSVTQKKFLCDRVMWRIPFSSNFMSMGALTDLGQNMLYANSAHALDMNFEVDPMD

ESTLLYVVFEVFDVVRVHQPHRGVIEAVYLRTPFSAGNATT

Pool of 233 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Gene therapy, Infection
283MoTif 283 Influenza A (NA/Turkey/1/2005(H5N1))

MNPNQKIITIGSICMVIGIVSLMLQIGNMISIWVSHSIQTGNQCQAEPISNTKFLTEKAVASVTLAG

NSSLCPISGWAVYSKDNSIRIGSRGDVFVIREPFISCSHLECRTFFLTQGALLNDKHSNGTVKDRSP

HRTLMSCPVGEAPSPYNSRFESVAWSASACHDGTSWLTIGISGPDNGAVAVLKYNGIITDTIKSW

RNNILRTQESECACVNGSCFTVMTDGPSSGQASYKIFKMEKGKVVKSVELDAPNYHYEECSCYPD

AGEITCVCRDNWHGSNRPWVSFNQNLEYQIGYICSGVFGDNPRPNDGTGSCGPVFSNGAYGVK

GFSFKYGNGVWIGRTKSTNSRSGFEMIWDPNGWTGTDSSFSVKQDIVAITDWSGYSGSFVQHPE

LTGLDCIRPCFWVELIRGRPKESTIWTSGSSISFCGVNSDTVSWSWPDGAELPFTIDK

Pool of 110 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
284MoTif 284 SARS-CoV-2 (S-RBD HK.3 + JG.3)

RVQPTESIVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAPFFAFKCYGVSPT

KLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKPSGNYN

YLYRFLRKSKLKPFERDISTEIYQAGNKPCNGVAGPNCYSPLQSYGFRPTYGVGHQPYRVVVLSFELL

HAPATVCGPKKSTNLVKNKCVNF

Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
285MoTif 285 SARS-CoV-2 (Spike B.1.351 / Beta)

MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHA

IHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQF

CNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDG

YFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHRSYLTPGDSSSGWTAGAAAYYVGYLQ

PRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEV

FNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVR

QIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQA

GSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF

NFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVA

VLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQT

QTNSPRRARSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGD

STECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSK

RSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITS

GWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQD

VVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIR

ASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG

KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELD

KYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIA

GLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

Peptide scan through the entire Spike glycoprotein of SARS-CoV-2 Lineage B.1.351, South Africa covering the following mutations: D0080A, D0215G, L0242-, A0243-, L0244-, K0417N, E0484K, N0501Y, D614G, A0701V.70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
286MoTif 286 Pan-SARS-CoV-2 Selectsee additional product documentationVirus-specific pool of 103 peptides (defined HLA class I & II-restricted T-cell epitopes) from selected proteins - from SARS-CoV-2- of SARS-CoV-2 (Severe Acute Respiratory Syndrome-Related Coronavirus 2) for T cell assays (e.g. ELISPOT).70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
287MoTif 287 Influenza A (HA/Puerto Rico/8/1934 H1N1)

MKANLLVLLCALAAADADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPL

QLGKCNIAGWLLGNPECDPLLPVRSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEIFPKES

SWPNHNTNGVTAACSHEGKSSFYRNLLWLTEKEGSYPKLKNSYVNKKGKEVLVLWGIHHPPNSKEQ

QNLYQNENAYVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYAF

ALSRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPKYVRSAKLRMVTGLRNIPSIQ

SRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQFT

AVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAK

EIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKVDGVKLESMGIYQILAIYSTVASSLVLLV

SLGAISFWMCSNGSLQCRICI

Pool of 139 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
288MoTif 288 Influenza A (NP/Puerto Rico/8/1934 H1N1)/Pool of 122 peptides derived from a peptide scan (15mers with 1 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza, Respiratory infection
289MoTif 289 SARS-CoV-2 (S-RBD B.1.429 / Epsilon)

RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKL

NDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYR

LFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNF

Peptide scan through Spike glycoprotein - Receptor binding domain of SARS-CoV-2 Lineage B.1.429, LA, CAL covering the following mutation: L0452R for T cell assays (e.g. ELISPOT).70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
290MoTif 290 Human (HLA classI Ig-like C1 type domain)

PKTHMTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVP

SGEEQRYTCHVQHEGLPKPLT

Control Pool of 19 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityControl
291MoTif 291 SARS-CoV-2 (S-RBD B.1.617.1 / Kappa)

RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKL

NDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRY

RLFRKSNLKPFERDISTEIYQAGSTPCNGVQGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAP

ATVCGPKKSTNLVKNKCVNF

Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap))70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
292MoTif 292 Human (TCRgamma alternate reading frame protein TARP)MQMFPPSPLFFFLQLLKQSSRRLEHTFVFLRNFSLMLLRYIGKKRRATRFWDPRRGTPPool of 12 peptides derived from a peptide scan through TCRgamma alternate reading frame protein (Swiss-Prot ID: A2JGV3) of Human.70%-90%Cancer biomarker research, T-cell immunityBreast cancer, Cancer, Prostate cancer
293MoTif 293 Influenza A (HA/H3N2/Darwin/2021)

MKTIIALSNILCLVFAQKIPGNDNSTATLCLGHHAVPNGTIVKTITNDRIEVTNATELVQNSSIGEICDS

PHQILDGGNCTLIDALLGDPQCDGFQNKEWDLFVERSRANSNCYPYDVPDYASLRSLVASSGTLEFK

NESFNWTGVKQNGTSSACIRGSSSSFFSRLNWLTSLNNIYPAQNVTMPNKEQFDKLYIWGVHHPNT

DKNQISLFAQSSGRITVSTKRSQQAVIPNIGSRPRIRGIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKI

RSGKSSIMRSDAPIGKCKSECITPNGSIPNDKPFQNVNRITYGACPRYVKQSTLKLATGMRNVPEKQT

RGIFGAIAGFIENGWEGMVDGWYGFRHQNSEGRGQAADLKSTQAAIDQINGKLNRLIGKTNEKFHQ

IEKEFSEVEGRVQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTKKQLRENAEDMG

NGCFKIYHKCDNACIGSIRNETYDHNVYRDEALNNRFQIKGVELKSGYKDWILWISFAMSCFLLCIALL

GFIMWACQKGNIRCNICI

Pool of 139 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza
294MoTif 294 Pan-SARS-CoV-2 Select w/o Ssee additional product documentationVirus-specific pool of 73 peptides (defined HLA class I & II-restricted T-cell epitopes)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
295MoTif 295 SARS-CoV-2 (S-RBD BA.2.75.2)

RVQPTESIVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPTKL

NDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYR

LFRKSKLKPFERDISTEIYQAGNKPCNGVAGSNCYFPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPAT

VCGPKKSTNLVKNKCVNF

Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap))70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
296MoTif 296 West Nile Virus (Capsid Protein) Ultrasee additional product documentationPool of 150 peptides derived from a peptide scan (Defined T-cell epitopes (15mers))70%-90%T-cell immunityEncephalitis, Fever, Infection, Meningitis, Sequence diversity, West nile fever
297MoTif 297 Yellow Fever Virus (Capsid Protein) Ultrasee additional product documentationPool of 138 peptides derived from a peptide scan (Defined T-cell epitopes (15mers)) through Capsid protein of Yellow Fever Virus (YFV).70%-90%T-cell immunityFever, Hemorrhagic fever, Infection, Liver failure, Sequence diversity, Yellow Fever
298MoTif 298 Influenza B (HA/H0N0/Phuket/2013)

MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIPLTTTPTKSYFANLKGTRTRGKLC

PDCLNCTDLDVALGRPMCVGTTPSAKASILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEKIRLSTQ

NVIDAEKAPGGPYRLGTSGSCPNATSKIGFFATMAWAVPKDNYKNATNPLTVEVPYICTEGEDQITVW

GFHSDDKTQMKSLYGDSNPQKFTSSANGVTTHYVSQIGDFPDQTEDGGLPQSGRIVVDYMMQKPG

KTGTIVYQRGVLLPQKVWCASGRSKVIKGSLPLIGEADCLHEEYGGLNKSKPYYTGKHAKAIGNCPIWV

KTPLKLANGTKYRPPAKLLKERGFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAI

NKITKNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEHLL

ALERKLKKMLGPSAVDIGNGCFETKHKCNQTCLDRIAAGTFNAGEFSLPTFDSLNITAASLNDDGLDN

HTILLYYSTAASSLAVTLMLAIFIVYMVSRDNVSCSICL

Pool of 144 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityFlu-like disease, Infection, Influenza
299MoTif 299 Crimean-Congo hem. fever virus (Nucleoprotein / IbAr10200)

MENKIEVNNKDEMNRWFEEFKKGNGLVDTFTNSYSFCESVPNLDRFVFQMASATDDAQKDSIYASA

LVEATKFCAPIYECAWVSSTGIVKKGLEWFEKNAGTIKSWDESYTELKVDVPKIEQLTGYQQAALKWRK

DIGFRVNANTAALSNKVLAEYKVPGEIVMSVKEMLSDMIRRRNLILNRGGDENPRGPVSHEHVDWC

REFVKGKYIMAFNPPWGDINKSGRSGIALVATGLAKLAETEGKGIFDEAKKTVEALNGYLDKHKDEVD

RASADSMITNLLKHIAKAQELYKNSSALRAQSAQIDTAFSSYYWLYKAGVTPETFPTVSQFLFELGKQP

RGTKKMKKALLSTPMKWGKKLYELFADDSFQQNRIYMHPAVLTAGRISEMGVCFGTIPVANPDDAA

QGSGHTKSILNLRTNTETNNPCAKTIVKLFEVQKTGFNIQDMDIVASEHLLHQSLVGKQSPFQNAYN

VKGNATSANII

Pool of 118 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap))70%-90%T-cell immunityEbola fever, Infection
300MoTif 300 St. Louis Encephalitis Virus (Capsid Protein) Ultrasee additional product documentationPool of 66 peptides derived from a peptide scan (Defined T-cell epitopes (15mers))70%-90%T-cell immunityEncephalitis, Fever, Infection, Sequence diversity
301MoTif 301 Collection Melanoma

7 different TAA PepMixes + 2 Controls (15mers, overlap 11):,Human (MAGEA1),Huma

 (MAGEA3),Human (MAGEA4),Human (Melan-A/MART-1),Human (Melanocyte protein

Pmel 17 gp100),Human (Tyrosinase),Human (Tyrosinase-related protein 2),CEF Pool 

(extended),Human (Actin)

Collection of 7 peptide pools derived from scans (overlapping peptides scans, 15mers with 11 aa overlap)70%-90%Cancer biomarker research, T-cell immunityCancer, Melanoma
302MoTif 302 Tick-borne Encephalitis Virus (Capsid Protein) Ultrasee additional product documentationPool of 150 peptides derived from a peptide scan (Defined T-cell epitopes (15mers))70%-90%T-cell immunityEncephalitis, Infection, Meningitis, Sequence diversity
303MoTif 303 Collection SARS-CoV-2 Spike Mutations

9 different SARS-CoV-2 PepMixes: SARS-CoV-2 (Spike / B.1.1.7 / Alpha) SARS-CoV-2 (Spik

 / B.1.351 / Beta) SARS-CoV-2 (Spike / P.1 / Gamma) SARS-CoV-2 (Spike / B.1.617.2 / Delta)

 SARS-CoV-2 (Spike / B.1.429 / Epsilon) SARS-CoV-2 (Spike / B.1.617.1 / Kappa) SARS-CoV-

2 (Spike / C.37 / Lambda) SARS-CoV-2 (Spike / BA.1 / Omicron) SARS-CoV-2 (Spike / BA.2

/ Omicron)

Collection of 9 peptide pools (overlapping peptides scans, 15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
304MoTif 304 Collection SARS-CoV-2 S-RBD Mutations

9 different SARS-CoV-2 PepMixes: SARS-CoV-2 (S-RBD / B.1.1.7 / Alpha) SARS-CoV-2

 (S-RBD / B.1.351 / Beta) SARS-CoV-2 (S-RBD / P.1 / Gamma) SARS-CoV-2 

(S-RBD / B.1.617.2 / Delta) SARS-CoV-2 (S-RBD / B.1.429 / Epsilon) SARS-CoV-2 (S-RBD

/ B.1.617.1 / Kappa) SARS-CoV-2 (S-RBD / C.37 / Lambda) SARS-CoV-2 (S-RBD / BA.1 /

Omicron) SARS-CoV-2 (S-RBD / BA.2 / Omicron)

Collection of 9 peptide pools (overlapping peptides scans, 15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19
305MoTif 305 Human (KRAS)

MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSA

MRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQA

QDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM

Pool of 45 peptides derived from a peptide scan (15mers with 11 aa overlap) through GTPase KRas (Swiss-Prot ID: P01116) of Human.70%-90%T-cell immunityCancer, Leukemia
306MoTif 306 Collection Prostate Cancer

7 different TAA PepMixes + 2 Controls (15mers, overlap 11):,Human (CEA),Huma(Metalloreductase

STEAP1),Human (Myc protein),Human (PAP),Human (Prostate-specific antigen PSA),Human

(TCRgamma alternate reading frame protein TARP),Human (WT1/WT33),CEF Pool (extended),

Human (Actin)

Collection of 7 peptide pools derived from scans (overlapping peptides scans, 15mers with 11 aa overlap) through 7 tumor associated antigens (prostate cancer markers: CEA, Metalloreductase STEAP1, Myc protein, PAP, PSA, TARP, WT1/WT33) of Homo sapiens plus 2 control pools (CEF Pool (extended) and Actin)70%-90%Cancer biomarker research, T-cell immunityCancer, Prostate cancer
307MoTif 307 Crimean-Congo hem. fever virus (M Polyprotein / IbAr10200)

MHISLMYAILCLQLCGLGETHGSHNETRHNKTDTMTTPGDNPSSEPPVSTALSITLDPSTVTPTTPASGLE

GSGEVYTSPPITTGSLPLSETTPELPVTTGTDTLSAGDVDPSTQTAGGTSAPTVRTSLPNSPSTPSTPQDTH

HPVRNLLSVTSPGPDETSTPSGTGKESSATSSPHPVSNRPPTPPATAQGPTENDSHNATEHPESLTQSATP

GLMTSPTQIVHPQSATPITVQDTHPSPTNRSKRNLKMEIILTLSQGLKKYYGKILRLLQLTLEEDTEGLLEWC

KRNLGLDCDDTFFQKRIEEFFITGEGHFNEVLQFRTPGTLSTTESTPAGLPTAEPFKSYFAKGFLSIDSGYYSA

KCYSGTSNSGLQLINITRHSTRIVDTPGPKITNLKTINCINLKASIFKEHREVEINVLLPQVAVNLSNCHVVIK

SHVCDYSLDIDGAVRLPHIYHEGVFIPGTYKIVIDKKNKLNDRCTLFTDCVIKGREVRKGQSVLRQYKTEIRI

GKASTGSRRLLSEEPSDDCISRTQLLRTETAEIHGDNYGGPGDKITICNGSTIVDQRLGSELGCYTINRVRSF

KLCENSATGKNCEIDSVPVKCRQGYCLRITQEGRGHVKLSRGSEVVLDACDTSCEIMIPKGTGDILVDCSG

GQQHFLKDNLIDLGCPKIPLLGKMAIYICRMSNHPKTTMAFLFWFSFGYVITCILCKAIFYLLIIVGTLGKRLK

QYRELKPQTCTICETTPVNAIDAEMHDLNCSYNICPYCASRLTSDGLARHVIQCPKRKEKVEETELYLNLER

IPWVVRKLLQVSESTGVALKRSSWLIVLLVLFTVSLSPVQSAPIGQGKTIEAYRAREGYTSICLFVLGSILFIVS

CLMKGLVDSVGNSFFPGLSICKTCSISSINGFEIESHKCYCSLFCCPYCRHCSTDKEIHKLHLSICKKRKKGSN

VMLAVCKLMCFRATMEVSNRALFIRSIINTTFVLCILILAVCVVSTSAVEMENLPAGTWEREEDLTNFCHQE

CQVTETECLCPYEALVLRKPLFLDSTAKGMKNLLNSTSLETSLSIEAPWGAINVQSTYKPTVSTANIALSWS

SVEHRGNKILVSGRSESIMKLEERTGISWDLGVEDASESKLLTVSVMDLSQMYSPVFEYLSGDRQVGEWP

KATCTGDCPERCGCTSSTCLHKEWPHSRNWRCNPTWCWGVGTGCTCCGLDVKDLFTDYMFVKWKVE

YIKTEAIVCVELTSQERQCSLIEAGTRFNLGPVTITLSEPRNIQQKLPPEIITLHPRIEEGFFDLMHVQKVLSAS

TVCKLQSCTHGVPGDLQVYHIGNLLKGDKVNGHLIHKIEPHFNTSWMSWDGCDLDYYCNMGDWPSC

TYTGVTQHNHASFVNLLNIETDYTKNFHFHSKRVTAHGDTPQLDLKARPTYGAGEITVLVEVADMELHT

KKIEISGLKFASLACTGCYACSSGISCKVRIHVDEPDELTVHVKSDDPDVVAASSSLMARKLEFGTDSTFKA

FSAMPKTSLCFYIVEREHCKSCSEEDTKKCVNTKLEQPQSILIEHKGTIIGKQNSTCTAKASCWLESVKSFFY

GLKNMLSGIFGNVFMGIFLFLAPFILLILFFMFGWRILFCFKCCRRTRGLFKYRHLKDDEETGYRRIIEKLNN

KKGKNKLLDGERLADRRIAELFSTKTHIG

Pool of 419 (vial 1: Pep 1-210, vial 2: 211-419) peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityDiarrhea, Hemorrhagic fever, Infection, Liver failure
308MoTif 308 eGFP

MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQ

CFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGH

KLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSAL

SKDPNEKRDHMVLLEFVTAAGITLGMDELYK

Pool of 57 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityControl
309MoTif 309 Rabies virus (Glycoprotein)

MVPQVLLFAPLLVFPLCFGKFPIYTIPDKLGPWSPIDLHHLSCPNNLVVEDEGCTNLSGFSYMELKVGYIS

AIKVNGFTCTGVVTEAETYTNFVGYVTTTFKRKHFRPTPDACRAAYNWKMAGDPRYEESLHNPYPDYH

WLRTVKTTKESLVIISPSVTDLDPYDKSLHSRVFPGGNCSGITVSSTYCSTNHDYTIWMPENLRLGTSCDI

FTHSRGKRASKGDKTCGFVDERGLYKSLKGACKLKLCGVLGLRLMDGTWVAMQTSDETKWCPPGQLVN

LHDFRSDEIEHLVEEELVKKREECLDALESIMTTKSVSFRRLSHLRKLVPGFGKAYTIFNKTLMEADAHYKSV

QTWNEIIPSKGCLRVGERCHPHVNGVFFNGIILGSDGHVLIPEMQSSLLQQHMELLESSVIPLMHPLADP

STVFKDGDEVEDFVEVHLPDVHKQVSGVDLGLPKWGKYVLMIAGALIALMLIIFLMTCCRRVNRPESTQS

NLGGTGRNVSVPSQSGKVISSWESYKSGGETRL

Pool of 129 peptides derived from a peptide scan (15mers with 11aa overlap)70%-90%T-cell immunityEncephalitis, Infection
310MoTif 310 Pan-CMV Selectsee additional product documentationVirus-specific pool of 99 peptides (defined HLA class I & II-restricted T-cell epitopes)70%-90%T-cell immunityControl, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections
311MoTif 311 Pan-EBV Selectsee additional product documentationVirus-specific pool of 135 peptides (defined HLA class I & II-restricted T-cell epitopes)70%-90%T-cell immunityAutoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma
312MoTif 312 Human (N-glycanase 1)

MAAAALGSSSGSASPAVAELCQNTPETFLEASKLLLTYADNILRNPNDEKYRSIRIGNTAFSTRLLPVRGAV

ECLFEMGFEEGETHLIFPKKASVEQLQKIRDLIAIERSSRLDGSNKSHKVKSSQQPAASTQLPTTPSSNPSGL

NQHTRNRQGQSSDPPSASTVAADSAILEVLQSNIQHVLVYENPALQEKALACIPVQELKRKSQEKLSRAR

KLDKGINISDEDFLLLELLHWFKEEFFHWVNNVLCSKCGGQTRSRDRSLLPSDDELKWGAKEVEDHYCDA

CQFSNRFPRYNNPEKLLETRCGRCGEWANCFTLCCRAVGFEARYVWDYTDHVWTEVYSPSQQRWLHCD

ACEDVCDKPLLYEIGWGKKLSYVIAFSKDEVVDVTWRYSCKHEEVIARRTKVKEALLRDTINGLNKQRQLFL

SENRRKELLQRIIVELVEFISPKTPKPGELGGRISGSVAWRVARGEMGLQRKETLFIPCENEKISKQLHLCYNIV

KDRYVRVSNNNQTISGWENGVWKMESIFRKVETDWHMVYLARKEGSSFAYISWKFECGSVGLKVDSISIR

TSSQTFQTGTVEWKLRSDTAQVELTGDNSLHSYADFSGATEVILEAELSRGDGDVAWQHTQLFRQSLNDH

EENCLEIIIKFSDL

Pool of 161 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityMicrocephaly
313MoTif 313 SARS-CoV-2 (NCAP B1.1.529 / BA.1 / Omicron)

MSDNGPQNQRNALRITFGGPSDSTGSNQNGGARSKQRRPQGLPNNTASWFTALTQHGKEDLKFPRGQ

GVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAGLPYGANKDGIIWVATEGALN

TPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSKRTSPARMA

GNGGDAALALLLLDRLNQLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGP

EQTQGNFGDQELIRQGTDYKHWPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKD

QVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA

Pool of 102 peptides derived from a peptide scan (15mers with 11 aa overlap - (incl. 5x 14mers))70%-90%T-cell immunityCovid-19, Infection, Respiratory infection
314MoTif 314 Human (CFTR)

MQRSPLEKASVVSKLFFSWTRPILRKGYRQRLELSDIYQIPSVDSADNLSEKLEREWDRELASKKNPKLINA

LRRCFFWRFMFYGIFLYLGEVTKAVQPLLLGRIIASYDPDNKEERSIAIYLGIGLCLLFIVRTLLLHPAIFGLHHIG

MQMRIAMFSLIYKKTLKLSSRVLDKISIGQLVSLLSNNLNKFDEGLALAHFVWIAPLQVALLMGLIWELLQA

SAFCGLGFLIVLALFQAGLGRMMMKYRDQRAGKISERLVITSEMIENIQSVKAYCWEEAMEKMIENLRQTE

LKLTRKAAYVRYFNSSAFFFSGFFVVFLSVLPYALIKGIILRKIFTTISFCIVLRMAVTRQFPWAVQTWYDSLGA

INKIQDFLQKQEYKTLEYNLTTTEVVMENVTAFWEEGFGELFEKAKQNNNNRKTSNGDDSLFFSNFSLLGT

PVLKDINFKIERGQLLAVAGSTGAGKTSLLMVIMGELEPSEGKIKHSGRISFCSQFSWIMPGTIKENIIFGVSY

DEYRYRSVIKACQLEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYKDADLYLLDSPFGYLDVLTEKEIF

ESCVCKLMANKTRILVTSKMEHLKKADKILILHEGSSYFYGTFSELQNLQPDFSSKLMGCDSFDQFSAERRN

SILTETLHRFSLEGDAPVSWTETKKQSFKQTGEFGEKRKNSILNPINSIRKFSIVQKTPLQMNGIEEDSDEPLER

RLSLVPDSEQGEAILPRISVISTGPTLQARRRQSVLNLMTHSVNQGQNIHRKTTASTRKVSLAPQANLTELDI

YSRRLSQETGLEISEEINEEDLKECFFDDMESIPAVTTWNTYLRYITVHKSLIFVLIWCLVIFLAEVAASLVVLWL

LGNTPLQDKGNSTHSRNNSYAVIITSTSSYYVFYIYVGVADTLLAMGFFRGLPLVHTLITVSKILHHKMLHSVL

QAPMSTLNTLKAGGILNRFSKDIAILDDLLPLTIFDFIQLLLIVIGAIAVVAVLQPYIFVATVPVIVAFIMLRAYFLQ

TSQQLKQLESEGRSPIFTHLVTSLKGLWTLRAFGRQPYFETLFHKALNLHTANWFLYLSTLRWFQMRIEMIFV

IFFIAVTFISILTTGEGEGRVGIILTLAMNIMSTLQWAVNSSIDVDSLMRSVSRVFKFIDMPTEGKPTKSTKPYK

NGQLSKVMIIENSHVKKDDIWPSGGQMTVKDLTAKYTEGGNAILENISFSISPGQRVGLLGRTGSGKSTLLS

AFLRLLNTEGEIQIDGVSWDSITLQQWRKAFGVIPQKVFIFSGTFRKNLDPYEQWSDQEIWKVADEVGLRSV

IEQFPGKLDFVLVDGGCVLSHGHKQLMCLARSVLSKAKILLLDEPSAHLDPVTYQIIRRTLKQAFADCTVILCE

HRIEAMLECQQFLVIEENKVRQYDSIQKLLNERSLFRQAISPSDRVKLFPHRNSSKCKSKPQIAALKEETEEEV

QDTRL

Pool of 368 (vial 1: Pep 1-184, vial 2: 185-368) peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCystic Fibrosis, Epithelium, Respiratory infection
315MoTif 315 HSV2 (gB)

MRGGGLICALVVGALVAAVASAAPAAPAAPRASGGVAATVAANGGPASRPPPVPSPATTKARKRKTKKPP

KRPEATPPPDANATVAAGHATLRAHLREIKVENADAQFYVCPPPTGATVVQFEQPRRCPTRPEGQNYTEGI

AVVFKENIAPYKFKATMYYKDVTVSQVWFGHRYSQFMGIFEDRAPVPFEEVIDKINAKGVCRSTAKYVRNN

METTAFHRDDHETDMELKPAKVATRTSRGWHTTDLKYNPSRVEAFHRYGTTVNCIVEEVDARSVYPYDEF

VLATGDFVYMSPFYGYREGSHTEHTSYAADRFKQVDGFYARDLTTKARATSPTTRNLLTTPKFTVAWDWVP

KRPAVCTMTKWQEVDEMLRAEYGGSFRFSSDAISTTFTTNLTQYSLSRVDLGDCIGRDAREAIDRMFARKYN

ATHIKVGQPQYYLATGGFLIAYQPLLSNTLAELYVREYMREQDRKPRNATPAPLREAPSANASVERIKTTSSIEF

ARLQFTYNHIQRHVNDMLGRIAVAWCELQNHELTLWNEARKLNPNAIASATVGRRVSARMLGDVMAVST

CVPVAPDNVIVQNSMRVSSRPGTCYSRPLVSFRYEDQGPLIEGQLGENNELRLTRDALEPCTVGHRRYFIFGG

GYVYFEEYAYSHQLSRADVTTVSTFIDLNITMLEDHEFVPLEVYTRHEIKDSGLLDYTEVQRRNQLHDLRFADI

DTVIRADANAAMFAGLCAFFEGMGDLGRAVGKVVMGVVGGVVSAVSGVSSFMSNPFGALAVGLLVLAGL

VAAFFAFRYVLQLQRNPMKALYPLTTKELKTSDPGGVGGEGEEGAEGGGFDEAKLAEAREMIRYMALVSAM

ERTEHKARKKGTSALLSSKVTNMVLRKRNKARYSPLHNEDEAGDEDEL

Pool of 224 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Encephalitis, Genital herpes, Infection, Oral Herpes
316MoTif 316 HSV2 (gC)

MALGRVGLAVGLWGLLWVGVVVVLANASPGRTITVGPRGNASNAAPSASPRNASAPRTTPTPPQPRKAT

KSKASTAKPAPPPKTGPPKTSSEPVRCNRHDPLARYGSRVQIRCRFPNSTRTESRLQIWRYATATDAEIGTAPS

LEEVMVNVSAPPGGQLVYDSAPNRTDPHVIWAEGAGPGASPRLYSVVGPLGRQRLIIEELTLETQGMYYWV

WGRTDRPSAYGTWVRVRVFRPPSLTIHPHAVLEGQPFKATCTAATYYPGNRAEFVWFEDGRRVFDPAQIHT

QTQENPDGFSTVSTVTSAAVGGQGPPRTFTCQLTWHRDSVSFSRRNASGTASVLPRPTITMEFTGDHAVCT

AGCVPEGVTFAWFLGDDSSPAEKVAVASQTSCGRPGTATIRSTLPVSYEQTEYICRLAGYPDGIPVLEHHGSH

QPPPRDPTERQVIRAVEGAGIGVAVLVAVVLAGTAVVYLTHASSVRYRRLR

Pool of 118 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Encephalitis, Genital herpes, Infection, Oral Herpes
317MoTif 317 BKV (large T antigen)

MDKVLNREESMELMDLLGLERAAWGNLPLMRKAYLKKCKEFHPDKGGDEDKMKRMNTLYKKMEQDVK

VAHQPDFGTWNSSEVPTYGTEEWESWWSSFNEKWDEDLFCHEDMFASDEEATADSQHSTPPKKKRKVED

PKDFPSDLHQFLSQAVFSNRTLACFAVYTTKEKAQILYKKLMEKYSVTFISRHMCAGHNIIFFLTPHRHRVSAI

NNFCQKLCTFSFLICKGVNKEYLLYSALTRDPYHIIEESIQGGLKEHDFNPEEPEETKQVSWKLITEYAVETKCED

VFLLLGMYLEFQYNVEECKKCQKKDQPYHFKYHEKHFANAIIFAESKNQKSICQQAVDTVLAKKRVDTLHMT

REEMLTERFNHILDKMDLIFGAHGNAVLEQYMAGVAWLHCLLPKMDSVIFDFLHCVVFNVPKRRYWLFKG

PIDSGKTTLAAGLLDLCGGKALNVNLPMERLTFELGVAIDQYMVVFEDVKGTGAESKDLPSGHGINNLDSLR

DYLDGSVKVNLEKKHLNKRTQIFPPGLVTMNEYPVPKTLQARFVRQIDFRPKIYLRKSLQNSEFLLEKRILQSG

MTLLLLLIWFRPVADFSKDIQSRIVEWKERLDSEISMYTFSRMKYNICMGKCILDITREEDSETEDSGHGSSTE

SQSQCSSQVSDTSAPDSENPHSQELHLCKGFQCFKRPKTPPPK

Pool of 170 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Merkel cell carcinoma, Nephritis, interstitial
318MoTif 318 BKV (capsid protein VP1)

MAPTKRKGECPGAAPKKPKEPVQVPKLLIKGGVEVLEVKTGVDAITEVECFLNPEMGDPDDNLRGYSQHLS

AENAFESDSPDRKMLPCYSTARIPLPNLNEDLTCGNLLMWEAVTVKTEVIGITSMLNLHAGSQKVHENGGG

KPVQGSNFHFFAVGGDPLEMQGVLMNYRTKYPQGTITPKNPTAQSQVMNTDHKAYLDKNNAYPVECWIP

DPSRNENTRYFGTYTGGENVPPVLHVTNTATTVLLDEQGVGPLCKADSLYVSAADICGLFTNSSGTQQWRG

LARYFKIRLRKRSVKNPYPISFLLSDLINRRTQKVDGQPMYGMESQVEEVRVFDGTEQLPGDPDMIRYIDRQ

GQLQTKMV

Pool of 88 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Merkel cell carcinoma, Nephritis, interstitial
319MoTif 319 SARS-CoV-2 (Spike HV.1)

MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTHDLFLPFFSNVTWFHAIHVSGTNGT

KRFDNPALPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYQKNNK

SWMESELRVYSSANNCTFEYVSQPFLMDLEGKEGNFKNLREFVFKNIDGYFKIYSKHTPINLERDLPQGFSAL

EPLVDLPIGINITRFQTLLALHRSYLTPVDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSE

TKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAP

FFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKPS

GNYNYRYRLLRKSKLKPFERDISTEIYQAGNKPCNGVAGPNCYSPLQSYGFRPTYGVGHQPYRVVVLSFELLH

APATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG

GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIP

IGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTM

YICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKR

SFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGA

GAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQALNT

LVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQ

SKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQR

NFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK

EIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKF

DEDDSEPVLKGVKLHYT

Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers)70%-90%T-cell immunityCovid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
320MoTif 320 Influenza A (NA/H3N2/Darwin/2021)

MNPNQKIITIGSVSLTISTICFFMQIAILITTVTLHFKQYEFNSPPNNQVMLCEPTIIERNITEIVYLTNTTIEKEICP

KPAEYRNWSKPQCGITGFAPFSKDNSIRLSAGGDIWVTREPYVSCDLDKCYQFALGQGTTLNNVHSNNTVRD

RTPYRTLLMNELGVPFHLGTKQVCIAWSSSSCHDGKAWLHVCITGDDKNATASFIYNGRLVDSVVSWSNDILR

TQESECVCINGTCTVVMTDGNATGKADTKILFIEEGKIVHTSKLSGSAQHVEECSCYPRYPGVRCVCRDNWKG

SNRPIIDINIKDHSIVSRYVCSGLVGDTPRKSDSSSSSHCLNPNNEKGDHGVKGWAFDDGNDVWMGRTINET

SRLGYETFKVVEGWSNPKSKLQINRQVIVDRGDRSGYSGIFSVEGKSCINRCFYVELIRGRKEETEVLWTSNSIVV

FCGTSGTYGTGSWPDGANLSLMHI

Pool of 115 peptides derived from a peptide scan (15mers with 11aa overlap)70%-90%T-cell immunityFever, Flu-like disease, Infection, Influenza
321MoTif 321 BKV (capsid protein VP2, isoform VP3)

MALELFNPDEYYDILFPGVNTFVNNIQYLDPRHWGPSLFATISQALWHVIRDDIPSITSQELQRRTERFFRDSL

ARFLEETTWTIVNAPINFYNYIQQYYSDLSPIRPSMVRQVAEREGTRVHFGHTYSIDDADSIEEVTQRMDLRNQ

QSVHSGEFIEKTIAPGGANQRTAPQWMLPLLLGLYGTVTPALEAYEDGPNQKKRRVSRGSSQKAKGTRASAKT

TNKRRSRSSRS

Pool of 56 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Merkel cell carcinoma, Nephritis, interstitial
322MoTif 322 AAV9 (Capsid Protein VP1)

MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAA

DAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL

Pool of 182 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCancer, Gene therapy, Infection
323MoTif 323 MERS-CoV (Spike Glycoprotein)

MIHSVFLLMFLLTPTESYVDVGPDSVKSACIEVDIQQTFFDKTWPRPIDVSKADGIIYPQGRTYSNITITYQGLFP

YQGDHGDMYVYSAGHATGTTPQKLFVANYSQDVKQFANGFVVRIGAAANSTGTVIISPSTSATIRKIYPAFMLGSSVGNFSDGKMGRFFNHTLVLLPDGCGTLLRAFYCILEPRSGNHCPAGNSYTSFATYHTPATDCSDGNYNRNASLNSFKEYFNLRNCTFMYTYNITEDEILEWFGITQTAQGVHLFSSRYVDLYGGNMFQFATLPVYDTIKYYSIIPHSIRSIQSDRKAWAAFYVYKLQPLTFLLDFSVDGYIRRAIDCGFNDLSQLHCSYESFDVESGVYSVSSFEAKPSGSVVEQAEGVECDFSPLLSGTPPQVYNFKRLVFTNCNYNLTKLLSLFSVNDFTCSQISPAAIASNCYSSLILDYFSYPLSMKSDLSVSSAGPISQFNYKQSFSNPTCLILATVPHNLTTITKPLKYSYINKCSRFLSDDRTEVPQLVNANQYSPCVSIVPSTVWEDGDYYRKQLSPLEGGGWLVASGSTVAMTEQLQMGFGITVQYGTDTNSVCPKLEFANDTKIASQLGNCVEYSLYGVSGRGVFQNCTAVGVRQQRFVYDAYQNLVGYYSDDGNYYCLRACVSVPVSVIYDKETKTHATLFGSVACEHISSTMSQYSRSTRSMLKRRDSTYGPLQTPVGCVLGLVNSSLFVEDCKLPLGQSLCALPDTPSTLTPRSVRSVPGEMRLASIAFNHPIQVDQLNSSYFKLSIPTNFSFGVTQEYIQTTIQKVTVDCKQYVCNGFQKCEQLLREYGQFCSKINQALHGANLRQDDSVRNLFASVKSSQSSPIIPGFGGDFNLTLLEPVSISTGSRSARSAIEDLLFDKVTIADPGYMQGYDDCMQQGPASARDLICAQYVAGYKVLPPLMDVNMEAAYTSSLLGSIAGVGWTAGLSSFAAIPFAQSIFYRLNGVGITQQVLSENQKLIANKFNQALGAMQTGFTTTNEAFHKVQDAVNNNAQALSKLASELSNTFGAISASIGDIIQRLDVLEQDAQIDRLINGRLTTLNAFVAQQLVRSESAALSAQLAKDKVNECVKAQSKRSGFCGQGTHIVSFVVNAPNGLYFMHVGYYPSNHIEVVSAYGLCDAANPTNCIAPVNGYFIKTNNTRIVDEWSYTGSSFYAPEPITSLNTKYVAPQVTYQNISTNLPPPLLGNSTGIDFQDELDEFFKNVSTSIPNFGSLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGNYTYYNKWPWYIWLGFIAGLVALALCVFFILCCTGCGTNCMGKLKCNRCCDRYEEYDLEPHKVHVH

Pool of 336 (168+168) peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCovid-19, Infection, Middle Eastern Respiratory Syndrome (MERS), Respiratory infection
324MoTif 324 M. tuberculosis (RpfA)

MSGRHRKPTTSNVSVAKIAFTGAVLGGGGIAMAAQATAATDGEWDQVARCESGGNWSINTGNGYLGGLQF

TQSTWAAHGGGEFAPSAQLASREQQIAVGERVLATQGRGAWPVCGRGLSNATPREVLPASAAMDAPLDAAAVNGEPAPLAPPPADPAPPVELAANDLPAPLGEPLPAAPADPAPPADLAPPAPADVAPPVELAVNDLPAPLGEPLPAAPADPAPPADLAPPAPADLAPPAPADLAPPAPADLAPPVELAVNDLPAPLGEPLPAAPAELAPPADLAPASADLAPPAPADLAPPAPAELAPPAPADLAPPAAVNEQTAPGDQPATAPGGPVGLATDLELPEPDPQPADAPPPGDVTEAPAETPQVSNIAYTKKLWQAIRAQDVCGNDALDSLAQPYVIG

Pool of 99 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
325MoTif 325 F. tularensis (Omp)

MFYKLNKQGRKIMKKTILGAMIAGGLMVSATTAMAGGVGFANVQDIFETSPLGKAKVTADEKKLKPQMDQL

KQNITALQEKVNAYTQEKDDVQTDDSKGDTKDAQSADKVENQDKQQAQADLEKAMKDYQNLMNQVQKM

ASDDADAFKDALTKASAQVAKEKQLDAILPAEMSLYNVDSIDVTKDVIAKMQ

Pool of 45 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Rabbit fever, Respiratory infection, Tularemia
326MoTif 326 L.monocytogenes (LLO)

MKKIMLVFITLILVSLPIAQQTEAKDASAFNKENSISSMAPPASPPASPKTPIEKKHADEIDKYIQGLDYNKNNVL

VYHGDAVTNVPPRKGYKDGNEYIVVEKKKKSINQNNADIQVVNAISSLTYPGALVKANSELVENQPDVLPVKR

DSLTLSIDLPGMTNQDNKIVVKNATKSNVNNAVNTLVERWNEKYAQAYPNVSAKIDYDDEMAYSESQLIAKFGTAFKAVNNSLNVNFGAISEGKMQEEVISFKQIYYNVNVNEPTRPSRFFGKAVTKEQLQALGVNAENPPAYISSVAYGRQVYLKLSTNSHSTKVKAAFDAAVSGKSVSGDVELTNIIKNSSFKAVIYGGSAKDEVQIIDGNLGDLRDILKKGATFNRETPGVPIAYTTNFLKDNELAVIKNNSEYIETTSKAYTDGKINIDHSGGYVAQFNISWDEVNYDPEGNEIVQHKNWSENNKSKLAHFTSSIYLPGNARNINVYAKECTGLAWEWWRTVIDDRNLPLVKNRNISIWGTTLYPKYSNKVDNPIE

Pool of 130 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Listeriosis
327MoTif 327 M. tuberculosis (ACR)

MATTLPVQRHPRSLFPEFSELFAAFPSFAGLRPTFDTRLMRLEDEMKEGRYEVRAELPGVDPDKDVDIMVRD

GQLTIKAERTEQKDFDGRSEFAYGSFVRTVSLPVGADEDDIKATYDKGILTVSVAVSEGKPTEKHIQIRSTN

Pool of 34 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%Cancer biomarker research, T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
328MoTif 328 M. tuberculosis (HBHA)

MAENSNIDDIKAPLLAALGAADLALATVNELITNLRERAEETRTDTRSRVEESRARLTKLQEDLPEQLTELREKF

TAEELRKAAEGYLEAATSRYNELVERGEAALERLRSQQSFEEVSARAEGYVDQAVELTQEALGTVASQTRAVGE

RAAKLVGIELPKKAAPAKKAAPAKKAAPAKKAAAKKAPAKKAAAKKVTQK

Pool of 47 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
329MoTif 329 S. pyogenes (CAS9)_2 subpools

MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTR

RKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKA

DLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLEN

LIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSD

AILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYK

FIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYV

GPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELT

KVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI

IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQS

GKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVK

VMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRD

MYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLI

TQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFR

KDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSN

IMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNS

DKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKK

DLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLD

EIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDA

TLIHQSITGLYETRIDLSQLGGD

Pool of 340 (170 + 170) peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityCellulitis, Gene editing, Infection
330MoTif 330 M. tuberculosis (CFP-10)

MAEMKTDAATLAQEAGNFERISGDLKTQIDQVESTAGSLQGQWRGAAGTAAQAAVVRFQEAANKQKQEL

DEISTNIRQAGVQYSRADEEQQQALSSQMGF

Pool of 23 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
331MoTif 331 M. tuberculosis (MPT64)

MRIKIFMLVTAVVLLCCSGVATAAPKTYCEELKGTDTGQACQIQMSDPAYNINISLPSYYPDQKSLENYIAQTR

DKFLSAATSSTPREAPYELNITSATYQSAIPPRGTQAVVLKVYQNAGGTHPTTTYKAFDWDQAYRKPITYDTL

WQADTDPLPVVFPIVQGELSKQTGQQVSIAPNAGLDPVNYQNFAVTNDGVIFFFNPGELLPEAAGPTQVLVP

RSAIDSMLA

Pool of 55 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
332MoTif 332 M. tuberculosis (PPE68)

MLWHAMPPELNTARLMAGAGPAPMLAAAAGWQTLSAALDAQAVELTARLNSLGEAWTGGGSDKALAAA

TPMVVWLQTASTQAKTRAMQATAQAAAYTQAMATTPSLPEIAANHITQAVLTATNFFGINTIPIALTEMDYFIR

MWNQAALAMEVYQAETAVNTLFEKLEPMASILDPGASQSTTNPIFGMPSPGSSTPVGQLPPAATQTLGQLGE

MSGPMQQLTQPLQQVTSLFSQVGGTGGGNPADEEAAQMGLLGTSPLSNHPLAGGSGPSAGAGLLRAESLPGAGGSLTRTPLMSQLIEKPVAPSVMPAAAAGSSATGGAAPVGAGAMGQGAQSGGSTRPGLVAPAPLAQEREEDDEDDWDEEDDW

Pool of 90 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
333MoTif 333 M. tuberculosis (Ag85A)

MQLVDRVRGAVTGMSRRLVVGAVGAALVSGLVGAVGGTATAGAFSRPGLPVEYLQVPSPSMGRDIKVQFQS

GGANSPALYLLDGLRAQDDFSGWDINTPAFEWYDQSGLSVVMPVGGQSSFYSDWYQPACGKAGCQTYKWE

TFLTSELPGWLQANRHVKPTGSAVVGLSMAASSALTLAIYHPQQFVYAGAMSGLLDPSQAMGPTLIGLAMGD

AGGYKASDMWGPKEDPAWQRNDPLLNVGKLIANNTRVWVYCGNGKPSDLGGNNLPAKFLEGFVRTSNIKF

QDAYNAGGGHNGVFDFPDSGTHSWEYWGAQLNAMKPDLQRALGATPNTGPAPQGA

Pool of 82 peptides derived from a peptide scan (15mers with 11 aa overlap) t70%-90%T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
334MoTif 334 P. vivax (CSP) Ultrasee additional product documentationPool of 157 peptides derived from a peptide scan (Selected immunogenic peptides (15mers))70%-90%T-cell immunityInfection, Malaria, Sequence diversity
335MoTif 335 M. tuberculosis (EspA)

MSRAFIIDPT ISAIDGLYDL LGIGIPNQGG ILYSSLEYFE KALEELAAAF PGDGWLGSAA DKYAGKNRNH VNFFQELADL DRQLISLIHD QANAVQTTRD ILEGAKKGLE FVRPVAVDLT YIPVVGHALS AAFQAPFCAG AMAVVGGALA YLVVKTLINA TQLLKLLAKL AELVAAAIAD IISDVADIIK GTLGEVWEFI TNALNGLKEL WDKLTGWVTG LFSRGWSNLE SFFAGVPGLT GATSGLSQVT GLFGAAGLSA SSGLAHADSL ASSASLPALA GIGGGSGFGG LPSLAQVHAA STRQALRPRA DGPVGAAAEQ VGGQSQLVSA QGSQGMGGPV GMGGMHPSSG ASKGTTTKKY SEGAAAGTED AERAPVEADA GGGQKVLVRN VV

Pool of 96 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
336MoTif 336 M. tuberculosis (EsxN)

MTINYQFGDVDAHGAMIRAQAASLEAEHQAIVRDVLAAGDFWGGAGSVACQEFITQLGRNFQVIYEQANAHGQKVQAAGNNMAQTDSAVGSSWA

Pool of 21 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
337MoTif 337 M. tuberculosis (RpfD)

MTPGLLTTAGAGRPRDRCARIVCTVFIETAVVATMFVALLGLSTISSKADDIDWDAIAQCESGGNWAANTGNGLYGGLQISQATWDSNGGVGSPAAASPQQQIEVADNIMKTQGPGAWPKCSSCSQGDAPLGSLTHILTFLAAETGGCSGSRDD

Pool of 36 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
338MoTif 338 M. tuberculosis (HRP1)

MTTARDIMNAGVTCVGEHETLTAAAQYMREHDIGALPICGDDDRLHGMLTDRDIVIKGLAAGLDPNTATAGELARDSIYYVDANASIQEMLNVMEEHQVRRVPVISEHRLVGIVTEADIARHLPEHAIVQFVKAICSPMALAS

Pool of 33 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%Cancer biomarker research, T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
339MoTif 339 M. tuberculosis (Rv1733c)

MIATTRDREGATMITFRLRLPCRTILRVFSRNPLVRGTDRLEAVVMLLAVTVSLLTIPFAAAAGTAVQDSRSHVYA

HQAQTRHPATATVIDHEGVIDSNTTATSAPPRTKITVPARWVVNGIERSGEVNAKPGTKSGDRVGIWVDSAGQLVDEPAPPARAIADAALAALGLWLSVAAVAGALLALTRAILIRVRNASWQHDIDSLFCTQR

Pool of 50 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%Cancer biomarker research, T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
340MoTif 340 M. tuberculosis (TB8.4)

MRLSLTALSAGVGAVAMSLTVGAGVASADPVDAVINTTCNYGQVVAALNATDPGAAAQFNASPVAQSYLRN

FLAAPPPQRAAMAAQLQAVPGAAQYIGLVESVAGSCNNY

Pool of 25 peptides derived from a peptide scan (15mers with 11 aa overlap)70%-90%T-cell immunityInfection, Opportunistic infections, Respiratory infection, Tuberculosis
341MoTif 341 P. falciparum (CSP) Ultrasee additional product documentationPool of 198 peptides derived from a peptide scan (Selected immunogenic peptides (15mers))70%-90%T-cell immunityInfection, Influenza, Malaria, Sequence diversity



Service Overview

Technical background

A peptide library is a systematic combination of a large number of different peptides. It is widely used in peptide library screening for drug discovery, target validation, epitope localization, vaccine development, and structure-activity studies. Due to the expanding interest in peptide drugs, the demand for peptide libraries by pharmaceutical companies is also increasing.

At present, peptide libraries are widely used in their related fields, such as GPCR ligand screening, drug development, nucleic acid binding, protein-protein interactions, protein function analysis, enzyme substrates or inhibitors.


Technical principle

The six commonly used peptide library construction services are as follows:

(1) Truncation peptide libraries: Used to determine the minimum range of epitopes. Truncated polypeptide matrix is generally established by systematically removing amino acids on both sides of the original polypeptide sequence to identify the least amino acid sequence associated with activity.

(2) Random Peptide Library: Random peptide library is designed to replace selected amino acid residues simultaneously and randomly with 20 natural amino acids through shotgun approach.

(3) Positional Scanning Library: positional scanning library is an important tool for optimizing the sequence of peptides. A selected region or site of a peptide is systematically replaced with other amino acids, and the optimal amino acids at this site are determined by measuring peptide activity. Libraries of this type of peptide help researchers discover specific regions that have a particular effect or activity at a particular location.

(4) Ala Scanning polypeptide Library (Alanine Scanning Library) : used to identify the influence of various points of polypeptide on biological activity. Ala is systematically and sequentially substituted for each amino acid in the peptide sequence. Peptide libraries are screened by Ala to identify the effects of a particular amino acid on the structure, function and other biological activities of the entire protein.

(5) Scrambled Library: The design of Scrambled Library is based on the internal replacement of the original polypeptide amino acid sequence. It is the most heavily mutated peptide library, and disrupted peptides are often used as negative controls to confirm that a particular sequence is key to protein function or activity. It's also a random screening tool for finding new targets.

(6) Overlapping Library: Overlapping library is a common way to screen linear or continuous epitopes. The design of this peptide library is mainly determined by two parameters: peptide length and offset number. After the protein is extracted from the N terminal and gradually moved to the C terminal, an Orphan peptide is likely to be left in the end. We suggest that one or several amino acids be transferred from the N terminal to maintain a consistent length. (as shown below)


image.png




MOTIF Technical Advantages and Successful Cases

Service features




英文特色服务2_03.png




The six peptide libraries of Motif Biotech provide a reliable and efficient platform for the screening of high-throughput drugs and the identification of protein interactions. Having a fast, high-throughput parallel peptide synthesis platform enables our customers to synthesize large quantities of high-purity peptides at a lower cost than traditional methods.

Peptide library construction service features:

Crude products: We guarantee purity greater than 40%, and there are cases of purity greater than 90%, mainly depending on the amino acid sequence, but also related to the synthesis process.

Pure products: We offer pure peptides of 70%, 75%, 80%, 85%, 90%, 95%, 98% and 99% purity respectively, which can be customized according to their own experimental needs.

Desalination and salt transfer: According to customer requirements, we can deTFA the peptide salt treatment, can also be converted to acetate.

Synthetic length: The general number of amino acids in the peptide library is between 1-30.

Delivery time: generally 2-3 weeks, the fastest 1-2 weeks.

Quality control: Qualified HPLC, MS and COA documentation is provided free of charge for each peptide.

Synthetic quantity: The monthly flux of Murdiff biopeptide library can reach 8000-10000.

After-sales service: Customers can raise objections within 1-2 weeks, we free retest, unqualified free return, 1-3 months use unqualified can provide free retest, free sample storage for 3 months.

Technical support: Peptide technical support is permanent, and customers enjoy one-on-one service from experienced technical experts.